Sentence,class,file
"73Fortheimageoffoc.usdevice,F OC.US,http://www.foc.us (accessedMar.24,2014).",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"81See eg Elokane, Safety of Frequent tDCS Use ,REDDIT TDCS, Jan. 18, 2013, http://www.reddit.com/r/ tDCS/comments/16u55u/safety offrequenttdcsuse/(accessed Mar.",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"24, 2014); Bigbacondude, tDCS Stimulation Duration/Timings Question ,REDDIT T DCS, Aug. 17, 2013, http://www.reddit.",OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"For each subsequent test, all 15 words were remembered in 2014);Livefromkoyto, HowOftenIsItSafetoUsetDCS?, REDDIT TDCS,Aug.19,2013, http://www.reddit.",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"24, 2014); Sat- isfyinghump, What’s the Most Times You Can Do Individual tDCS, REDDIT TDCS, Oct. 5, 2013, http://www.reddit.com/r/tDCS/comments/1nskpw/whats˙the mosttimesyoucandoindividual tdcs/ (accessedMar.24,2014);Mishefe, HaveWeLearnedAnythingaboutMaxDailyUsage ,REDDITTDCS,Oct.25, 2013,http://www.reddit.com/r/tDCS/comments/1p81pm/have welearnedanythingnewaboutmax dailyusage/(accessedMar.24,2014).",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"83Keneticforce, tDCSHomeBuilt:GreatResults...AlarmingNegativeSideEffects ,REDDIT TDCS,June9,2013, http://www.reddit.com/r/tDCS/comments/1fzb9c/tdcs homebuiltgreatresultsalarmingnegative/ (accessedMar.24,2014).",OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"84Lumosity, http://www.lumosity.com (accessed Mar.",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"24, 2014); Brain Workshop—A Dual N-Back Game,http://brainworkshop.sourceforge.net (accessed Mar.",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"24, 2014); Cambridge Brain Sciences, http://www.cambridgebrainsciences.com/challenge/introduction (accessedMar.24,2014).",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"86Torvaun,So,It’saFewHoursPastMyFirstMontage ,REDDITTDCS,Jul.23,2013, http://www.reddit.com/r/ tDCS/comments/1ixpdx/so itsafewhourspastmyfirstmontage/ (accessedMar.24,2014).",OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"Otherpowerusersalsoagreedthattherewereacertainnumberofusersinthecom- munitywhohavecorrectedandguidedotherusersnottomakedangerousmistakes: Weareself-regulatingcommunity.... EverybodyinReddithastoexpresssometypeof knowledgeashe/shewritesapostingandnobodyinthecommunitywillletuponyou understandingthedangersofmessingaroundwithelectroniccurrent.Thereasonthatit happens is because I believe at least in the beginning most of the tDCScommunity on Redditwerepeoplewhohadabackgroundinengineeringsuchasbuildingcircuits.These peoplewereextremelyhelpfulingivingrealadvices.Overthecourseoflastthreeyears,I haveyetseenanybodypostanythingthattDCShasdonesomerealdamage.So,Iguess it(theself-regulatingsystem)isworking.92 DIYusers’thoughtsonpotentialofficialguidelinesandgovernmentregulations Themajorityofsurveyrespondents(97outof121respondents)thoughtthatitwould behelpfultohaveanofficialguidelinefromgovernmentagencyorexperts(researchers orphysicians)fortheDIYuseoftDCS.Allofthepoweruserintervieweesclaimedthat the part that most needs guidelines from the government or experts is placement of electrodes.Theyreportedthatgettingreliablerepeatedplacementofanodesandcath- odes,andwhatmontagesshouldbeusedtotreatorimprovewhichthingsarethemost confusingpartsofpracticingDIYtDCS.Moreover,thepowerusersexpressedconcern thateventhoughDIYuserslocatetheelectrodesintherightplaceaccordingtoaspe- cific montage, whether a person is left-handed or right-handed might affect the out- comebecauseleft-handedpeople’sbrainsmaybeorganizeddifferentlyfromthoseof 91See eg OmegaRa, My DIY Unit ,REDDIT TDCS, Dec. 13, 2013, http://www.reddit.com/r/tDCS/ comments/1su22g/my diyunit/(accessedMar.24,2014);Rpxo, CheckOutMyDIY ;LM334ZDesign ,RED- DIT TDCS,Jan.2,2014, http://www.reddit.com/r/tDCS/comments/1u95m3/check outmydiylm334z design/(accessedMar.24,2014);OJandToothpaste, WillMyDIYSetupMeltMyBrain ,REDDITTDCS,Aug.",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"7,2013,http://www.reddit.com/r/tDCS/comments/1jvc5j/will mydiysetupmeltmybrain/(accessed Mar.24,2014).",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"105Syntheticbiology, http://syntheticbiology.org (accessedMar.24,2014).",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"; National Science Advisory Board for Biosecurity, Strategies to educate amateur biologists and scientists in non-life science disciplines about dual use research in the life sciences , June 2011, http://osp.od.nih.gov/ sites/default/files/resources/FinalNSABBReport-AmateurBiologist-NonlifeScientists June-2011 0.pdf (accessedMar.24,2014).",Non-OADS,/arxiv_data1/oa_pdf/5e/0f/lsv017.PMC5034380.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"2015, https://www.whitehouse.gov/sites/default/files/docs/national actionplanforcombating antibotic- resistantbacteria.pdf (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"AN INTRODUCTION TO FECAL MICROBIOTA TRANSPLANTATION FirstreportedinWesternmedicalliteraturein1958,19FMTremainedafringemedical practiceoverthenext50years.However,advancesinmolecularmicrobiologyandthe 14Food & Drug Administration, Fecal Microbiota for Transplantation: Scientific and Regulatory Issues 309, May2,2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetings Conferences/UCM352903.pdf (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"32Seres Therapeutics, Seres Health Presents Final Data for Study of SER-109 in Recurrent Clostrid- ium difficile Infection at ICAAC 2014 Conference, Sept. 10, 2014, http://serestherapeutics.com/ news/newsroom/seres healthpresentsfinaldataforstudyofser-109inrecurrent clostridium difficile infectionaticaac2014conference/ (accessedJune18,2015) 33In addition to OpenBiome, some hospitals and clinics also manage internal stool banking programs.",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"13, 2015, http://www.sacbee.com/news/local/health-and-medicine/healthy-choices/article14072969.html (acces- sedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"37See Alex Lash, With Vedanta Deal, J&J Marks Big-Pharma Milestone in the Microbiome ,X CONOMY,J a n .1 3 , 2015,http://www.xconomy.com/boston/2015/01/13/with-vedanta-deal-jj-marks-big-pharma-milestone- in-the-microbiome/ (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"First, to effectively regulate stool as a drug, regulators will need to address the challenge of characterizing active ingredients andguaranteeingsafetyandqualityinspiteofthevariabilityofstool.47TheFDAhas notyetpubliclyexplainedhowitplanstoaddressthischallenge.Second,thisoutcome 39Food & Drug Administration, Public Workshop: Fecal Microbiota for Transplantation, Announcement of May 2013 Workshop, http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetings Conferences/ucm341643.htm (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"Perhaps most obviously, the FDA has prioritized the removal of unapproved drugs from the market.69The FDA would also likely be sued for this 65Food & Drug Administration, Questions and Answers on Updated FDA Statement on Compounded Versions of Hydroxyprogesterone Caproate, 2012,http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm310215.htm (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"10, 2014, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD Results2.cfm?Index Number=421013 (accessedJune18,2015).",OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"67See eg Rebiotix, Rebiotix Announces First Ever Randomized Study of a Microbiota-Based Drug for Recurrent Clostridium difficile Infection Under an FDA IND, Dec. 16, 2014, http://www.rebiotix.com/index.php/ first-randomized-clinical-trial-microbiota-drug-clostridium-difficile-infection (accessed June 18, 2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
",MOTHERJONES, Aug. 18, 2014, http://www.motherjones.com/environment/2014/ 08/fecal-transplant-fda-openbiome-rebiotix (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"69Food & Drug Administration, Unapproved Drugs Initiative, 2014,http://www.fda.gov/Drugs/Guidance- ComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionson- UnapprovedDrugs/ucm118990.htm (accessed June 18, 2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"Kurt R. Karst, KV Lawsuit Involving Makena and Compounded 17P Concludes in Sopranos Style,F D AL AWBLOG, July 7, 2014, http://www.fdalawblog.net/fda lawbloghymanphelps/2014/07/ kv-lawsuit-involving-makena-and-compounded-17p-concludes-in-sopranos-style.html (accessed June 18, 2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"Andrew Pollack, The Hidden Price of Drugs ,NEWYORKTIMES, May 31, 2011, http://prescriptions.blogs.nytimes.com/2011/05/31/ the-hidden-price-of-drugs/ (accessedJune18,2015).Fidaxomicin,anothercommonantibiotic,coststwice asmuch.",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"Few healthy individuals wouldbedeemedeligiblefordonatingstoolforfecaltransplantation.Onlysixpercent of prospective donors to OpenBiome pass the full screening process, which includes a109-itemclinicalassessmentadministeredbyanurseorphysician,and30stooland bloodscreens.77Withalackoflong-termsafetydataonpatientoutcomespost-FMT,it is prudent to be overly cautious about screening for diseases that are potentially me- diated by the microbiome; for instance, researchers have notably linked the micro- biome to obesity,78metabolic syndrome,79and behavior.80Similarly, it is just as im- portanttocollectlongitudinalsafetydatatoidentifyanyconditionsthatmaybetrans- mittedviastoolofwhichweareunaware.81Thus,giventheknownandunknownrisks thatcomewithimproperdonorscreeningandinadequatepatientfollow-up,theease withwhichpatientsmayprepareandadministerfecaltransplantsthemselveswithout medicalsupervision,anyregulatoryoutcomethatresultsinrestrictedaccessbyeither 75See eg HomeFMT, Fecal Transplant (FMT) ,http://www.youtube.com/watch?v=xLIndT7fuGo (accessed June18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"§1271.90(a)(2)(2001);Food&DrugAdministration, DonorEligibilityFinalRuleandGuid- ance Questions and Answers, 2009,http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/ QuestionsaboutTissues/ucm102842.htm (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"§640.3 (2015); Food & Drug Administration, Keeping Blood Transfusions Safe: FDA’s Multi-Layered Protections for Donated Blood, 2013,http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/BloodSafety/ucm095522.htm (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"§640.5(2015);Food&DrugAdministration, KeepingBloodTransfusionsSafe:FDA’sMulti-Layered Protections for Donated Blood 2013,http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ BloodSafety/ucm095522.htm (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"98Food & Drug Administration, Tissue Reference Group: FY 2012 Update , 2012,http://www.fda.gov/ biologicsbloodvaccines/tissuetissueproducts/regulationoftissues/ucm152857.htm (accessed June 18, 2015).",OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"However, in a May 2013 publicmeeting,RebiotixstatedthatithadreceivedaletterfromtheFDAreachingthisinterpretation.Food &DrugAdministration, FecalMicrobiotaforTransplantation:ScientificandRegulatoryIssues 229,May2,2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ UCM352902.pdf (accessedJune18,2015).Assuch,wemusttakethisargumentseriously.",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"107Letter from the Presidents of the Infectious Disease Society of America, the American Gastroen- terological Association, the American Society for Gastrointestinal Endoscopy et al., Current Consen- sus Guidance on Donor Screening and Stool Testing for FMT, July 5, 2013, http://www.gastro.org/ research/Joint SocietyFMT˙Guidance.pdf (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"110SeeegSeresTherapeutics, AboutSeresTherapeutics ,2015,http://serestherapeutics.com/about/about seres therapeutics/ (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"111Food & Drug Administration, Tissue Reference Group: FY 2012 Update, 2012,http://www.fda.gov/ biologicsbloodvaccines/tissuetissueproducts/regulationoftissues/ucm152857.htm (accessed June 18, 2015).",OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"115Food & Drug Administration, Drug Shortage Management, 12, 2014, http://www.fda.gov/downloads/ AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/ UCM079936.pdf (accessedJune18,2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/33/lsv032.PMC5034381.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/e2/24/lsv021.PMC5034382.pdf
"KEYWORDS: aliyah, Jewish genes, Israel, citizenship, Law of Return, Cohanim MashaYakerson,likemanyofherJewish,college-agepeers,attemptedtosignupfora BirthrightIsrael1tripinthesummerof2013.2BirthrighttoldYakerson,whosefamilyis fromRussia,thattoprovethatshewasJewish,andeligibleforthetrip,shewouldneed to take a DNA test.3Birthright claimed that the test was required by the Israeli con- sulate,andfurtherthataDNAtestwouldberequiredifYakersoneverwantedtomake 1‘Taglit-Birthright Israel provides a gift of peer group, educational trips to Israel for Jewish young adults ages18to26.’Taglit-BirthrightIsrael,FAQ, http://www.birthrightisrael.com/Pages/Help-Center-Answers.",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"2Teentoldshecan’tjoinBirthrightwithoutDNAtest ,TIMES OFISRAEL,July28,2013, http://www.timesofisrael.",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"2, 2008, http://www.nytimes.com/2008/03/02/magazine/02jewishness-t.html?˙r=2& ; See also Naomi Darom,So You Think You are Jewish Enough for an Israeli Wedding?",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"Prove it ,HAARETZ, Nov. 7, 2013, http://www.haaretz.com/weekend/magazine/.premium-1.556772 (citing the Shulhan Arukh, the author- itative codification of Jewish law); Rabbi Reuven Hammer, On Proving Jewish Identity YD 268:10.2011 , COMMITTEE ON JEWISHLAW AND STANDARDS ,C J L S ,T HERABBINICAL ASSEMBLY, May 24, 2011, http://www.rabbinicalassembly.org/jewish-law/committee-jewish-law-and-standards/yoreh-deah .",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"9AsherZeiger, Russian-SpeakersWhoWanttoMakeAliyaCouldNeedDNATest ,TIMESOFISRAEL,July29,2013, http://www.timesofisrael.com/russian-speakers-who-want-to-immigrate-could-need-dna-test/ .",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"The1970amendmentwasaresponsetoacontroversialIsraeliSupremeCourtcase, Shalit v. Minister of the Interior , which permitted children of a Jewish father and non- JewishmothertoregisteraspartoftheJewish le’oumorethnicgroupinthePopulation 22AeyalGross, CourtRejectionofIsraeliNationalityHighlightsFlawsofJewishDemocracy ,HAARETZ,Oct.3,2013, http://www.haaretz.com/opinion/.premium-1.550336 ;CA8573/08Ornanetal.v.MinistryofInterior(Oct.",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"30JudyMaltz, HowaFormerNetanyahuAideisBoostingIsrael’sJewishMajority,One‘losttribe’ataTime ,HAARETZ, Feb.19,2015, http://www.haaretz.com/news/national/1.643020 .Theterm‘seedofIsrael’‘alsohasa[slightly differentand]broaderdefinitionthatappliestoanyonewithdemonstratedJewishancestrydatingbackseveral generations’.",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"39Kobi Nachshoni, Chief Rabbi: Stop Allowing Non-Jews to Make Aliyah ,Y NETNEWS, Nov. 3, 2014, http://www.ynetnews.com/articles/0,7340,L-4587242,00.html .",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"Molecular genetic tests can now be used to measure individuals’ whole genomes, and scientific researchhasbeguntodescribethegeneticbasisforacommonancestryofthewholeof theJewishpopulation.41 There are three key ways in which Jewishness has moved to the molecular realm, withgenesbeingdefinedasJewish:populationgenetics;genetictestingforbothdis- easeandJewishidentity;andhumanovaandspermdonation,asinthefieldofassisted conception.42Inthesedifferentconceptualarenas,Jewishgenesandinheritancearede- finedindifferentways,openingupawiderspaceofambiguityaroundJewishidentity anddefinition.43 Withpopulationgeneticsor‘tracingJewishhistorythroughDNA’,44thesetypesof studiesattempttotraceJewishhistorythroughgenetics,andelucidateacommonhis- toricaloriginoftheJewishpeopleinthebiblicallandofIsrael.Here,Jewishnessisde- terminedbygenomicanalysisas‘statisticalprobabilitiesthatDNAhaplotypeswillbe moreprevalent’withinidentifiedgroups.Butthepresenceofacertainhaplotypewithin anindividualisnotaguaranteethattheindividualisJewishornot.45Moreover,thehis- toricalclaimsthatareentangledwiththesescientificstudiesareheavilydebated.46 The Cohanim Modal Haplotype (CMH), the Jewish genetic marker that has re- ceived the most attention, was first publicized in the journal Naturein a study that identifiedsixdifferencesintheDNAsequenceofmaleJewsthatidentifiedas Cohens orCohanim(Jewishpriests).47Somescientiststhinkthatthe Cohanimsignaturecould represent the inheritance of over 100 generations from the founder of the patrilineal 40RichardSilverstein, Birthright,IsraeliGovernmentDemandDNATeststoProveJewishness ,TIKKUNOLAMBLOG, Aug. 4, 2013, http://www.richardsilverstein.com/2013/08/04/birthright-israeli-government-demand-dna- tests-to-prove-jewishness/ (accessedMay24,2015).",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
",ATLANTIC, March 2013, http://www.theatlantic.com/global/archive/2012/03/defining-jews-defining-a-nation-can-geneticssave- israel/254428/ .",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"50CenterforJewishGenetics, DorYeshorim ,https://www.jewishgenetics.org/dor-yeshorim (accessedApr.30, 2015).",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"54Caren Chesler, What Makes a Jewish Mother, THENEWYORKTIMES, June 3, 2013, http://well.blogs.",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"55RabbiAaronL.Mackler, MaternalIdentityandtheReligiousStatusofChildrenBorntoaSurrogateMother,YD 268:6.1997 ,COMMITTEE ON JEWISHLAW ANDSTANDARDS ,CJLS ,T HERABBINICAL ASSEMBLY,Sept.17,1997, 143,http://www.rabbinicalassembly.org/jewish-law/committee-jewish-law-and-standards/yoreh-deah .",Non-OADS,/arxiv_data1/oa_pdf/68/64/lsv027.PMC5034383.pdf
"3US National Institutes of Health, Standard Due Dates for Competing Applications ,http://grants.nih.gov/ grants/funding/submissionschedule.htm (accessedApr.20,2015).",Non-OADS,/arxiv_data1/oa_pdf/ca/68/lsv022.PMC5034384.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/ca/68/lsv022.PMC5034384.pdf
"GuidanceforInstitutionalReviewBoards,ClinicalInvestigators,andSpon- sorsExceptionfromInformedConsentRequirementsforEmergencyResearch ,http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM249673.pdf (accessedonApr.3,2015).",OADS,/arxiv_data1/oa_pdf/ca/68/lsv022.PMC5034384.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/73/51/lsv050.PMC5034385.pdf
"7U.S.FOOD&DRUGADMIN.,WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/ WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/default.htm [hereinafter ‘FDA Warning Letters’].",Non-OADS,/arxiv_data1/oa_pdf/73/51/lsv050.PMC5034385.pdf
"U.S. F OOD&DRUGADMIN., REGULATORY PROCEDURES MANUAL §§4-1, 4-2 (2015), available at http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/default.htm .",Non-OADS,/arxiv_data1/oa_pdf/73/51/lsv050.PMC5034385.pdf
"UnitedStatesv.Harkonen providesausefulexample.12Inthatcase, thegovernmentprosecutedDr.Harkonen,theCEOofadrugcompany,allegingthat 8FDA Warning Letters, supranote 7; The PEW Charitable Trusts, Fact Sheet, Persuading the Prescribers: PharmaceuticalIndustryMarketinganditsInfluenceonPhysiciansandPatients, http://www.pewtrusts.org/ en/research-and-analysis/fact-sheets/2013/11/11/persuading-the-prescribers-pharmaceutical-industry- marketing-and-its-influence-on-physicians-and-patients .",Non-OADS,/arxiv_data1/oa_pdf/73/51/lsv050.PMC5034385.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/d9/97/lsv056.PMC5034386.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/39/0a/lsv059.PMC5034387.pdf
"The study cases show that, in general, the juvenile defendants fared betterthan adult 74NicoleL.Watersetal., CriminalAppealsinStateCourts ,BureauofJusticeStatistics,Sep.2015,NCJ248874, http://www.bjs.gov/content/pub/pdf/casc.pdf (accessedNov.1,2015).",Non-OADS,/arxiv_data1/oa_pdf/39/0a/lsv059.PMC5034387.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/04/33/lsv047.PMC5034388.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/99/e1/lsv044.PMC5034389.pdf
"16TimothyCaulfield&JaneKaye, BroadConsentinBiobanking:ReflectionsonSeeminglyInsurmountableDilem- mas,10MED.LAWINT’L85(2009) 17Oxford Biobank, Consent Form, http://www.oxfordbiobank.org.uk/wp-content/uploads/2013/11/OBB- consent-form-Version-1.1–25–9–2013.pdf (accessed Sept. 14, 2015); Alzheimer’s Disease Neuroimaging Initiative, Introduction and Procedures for Accessing Data from Whole Genome Sequencing of ADNI Subjects, http://adni.loni.usc.edu/wp-content/uploads/2010/09/ADNI WGSNotice20130917.pdf (accessedSept.14,2015).",Non-OADS,/arxiv_data1/oa_pdf/99/e1/lsv044.PMC5034389.pdf
"22Apple ResearchKit, GitHub, ResearchKit Framework Best Practices, https://github.com/ResearchKit/ ResearchKit/wiki/best-practices (accessedSept.10,2015).",OADS,/arxiv_data1/oa_pdf/99/e1/lsv044.PMC5034389.pdf
"23National Institute of Health, Genetic Data Sharing, NIH Data Access Committees and Chairs , https://gds.nih.gov/04po2 1DAC.html (accessedSept.14,2015).",Non-OADS,/arxiv_data1/oa_pdf/99/e1/lsv044.PMC5034389.pdf
"27PatientCenteredOutcomeResearchInstitute(PCORI), http://www.pcori.org/ (accessedSept.14,2015).",Non-OADS,/arxiv_data1/oa_pdf/99/e1/lsv044.PMC5034389.pdf
"28FDA statement: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM125651.pdf (accessedSept.14,2015).",Non-OADS,/arxiv_data1/oa_pdf/99/e1/lsv044.PMC5034389.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/ac/86/lsv048.PMC5034390.pdf
"eds., 2008), http://www.nber.org/chapters/c5300.pdf (accessed Mar.",Non-OADS,/arxiv_data1/oa_pdf/ac/86/lsv048.PMC5034390.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"Unsurprisingly, the use of tDCS outside of research settings has not been well re- ceivedbyscientists,manyofwhombelievethathomeusersmay‘ruinit’fortheentire 1Pubmed title search for ‘transcranial direct current stimulation’ or ‘tDCS’, http://www.ncbi.nlm.nih.gov/ pubmed/?term=(%22transcranial +direct+current +stimulation%22%5BTitle%5D) +OR+tdcs%5BTitle %5D 2For a review of clinical tDCS studies, see Min-Fang Kuo, Walter Paulus & Michael A. Nitsche, Thera- peutic Effects of Non-Invasive Brain Stimulation with Direct Currents (tDCS) in Neuropsychiatric Diseases , 85NEUROIMAGE 948(2014);fortDCSinhealthypopulations,seeBrianA.Coffman,VincentP.Clark&Raja Parasuraman, BatteryPoweredThought:EnhancementofAttention,Learning,andMemoryinHealthyAdultsUs- ing Transcranial Direct Current Stimulation ,8 5NEUROIMAGE 895 (2014).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"Conference Questionnaire Results, Presented on Jan. 11, 2015 at the New York City Neuromodulation Conference, New York, Jan. 9–11, 2015; http://neuromodec.com/events/nyc-neuromodulation-conference-2015/ (accessedAug.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"9Fregnietal., supranote7at10.SeealsoSoterixMedical, http://soterixmedical.com/tdcs andJaliMedical (USdistributorforNeuroconn) http://www.jalimedical.com/neuroconn dcstimulator mc.html(accessed Sep.22,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"WhatfactorscontributedtotheriseofDIYtDCS?Theappearanceofthemovement correspondstotheincreaseinpopularityoftDCSinscientificjournals:in2011,there were over 130 peer-reviewed articles about tDCS, more than double that of the pre- viousyear.22Thefollowingyear,2012,sawthegreatestquantitativeincreaseinmen- tions of tDCS in the popular press.23In addition, DIY tDCS shares characteristics withrelatedmovementsthatwerewellestablishedby2010,suchasDIYbiologyand 18Attachingabatterytoyourhead, LONGECITY ,2007,http://www.longecity.org/forum/topic/19346-attaching- a-battery-to-your-head/ (accessedSep.22,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"19PaganKennedy, Brain-O-Matic ,BOSTONPHOENIX,Feb.7,2007, http://thephoenix.com/boston/life/33313- brain-o-matic/ (accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"20Yahoo Transcranial Direct Current Stimulation group, https://groups.yahoo.com/neo/groups/tDCStim/ info(accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"21Reddit/r/tDCS( http://www.reddit.com/r/tDCS/ )beganinApril2011.E-mailfrommoderatorofr/tDCS toAnnaWexler(Feb.17,2015),onfilewithauthor.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"Compared to other techniques that stimulate the brain with electricity, such as elec- troconvulsivetherapy(ECT),thelevelofcurrentusedintDCSisrelativelylow:most tDCSstudiesuse0.5–2mA,whereasECTutilizes500–900mA.27 The notion of a ready-to-wear consumer tDCS headset first hit the media in the springof2012,whentwoundergraduatesfromtheUniversityofMichigan,MattSorn- sonandNickWoodhams,builtaprototypeofatDCSdevicecalledtheGoFlow(‘the world’sfirsttDCSkit’)andpromisedtosellitfor$99.28Variouspressoutletspicked uponthestory,enthusiasticallydescribingtheinitiativewithheadlinessuchas‘Buya DIYBrainSuperchargerfor$100’and‘Transcranialdirectcurrentstimulationworks, andyoucantryitathome’.29Twomonthslater,inMay2012,thecompanyannounced thattheywerebeingdelayedduetoFDAconcerns,30andinearly2013theco-founders madethedecisiontoabandonplansfortheheadset.31Rumorsswirledonlinethatthe GoFlow team ‘ran into some problems’ with the FDA.32But Sornson had not been 24BothDIYBiologyandDIYtDCSembodywhathasbecomeknownasthemakerculture,whichplacesahigh valueontinkering,engineering,andcreatingthingsfromscratch.ForDIYBiology,seeeg http://diybio.org/ andALESSANDRO DELFANTI,BIOHACKERS :THEPOLITICSOFOPENSCIENCE(2013).BothDIYtDCSandthe quantifiedself-movementsharethesameunderlyinggoalofself-improvementandself-optimization;seeeg MelanieSwan, TheQuantifiedSelf:FundamentalDisruptioninBigDataScienceandBiologicalDiscovery 1BIG DATA85,87(2013).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"28GoFlow,http://www.flowstateengaged.com (accessed Mar.",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"http://web.archive.org/web/ 20120314201106/http://flowstateengaged.com/ 29Ashlee Vance, Buy a DIY Brain Supercharger for $100,BLOOMBERG BUSINESSWEEK , Mar.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"21, 2012, http://www.businessweek.com/articles/2012-03-21/buy-a-diy-brain-super-charger-for-100 (accessed Sep. 22, 2015); Christopher Mims, DIY Kit Overclocks Your Brain With Direct Current ,MITTECHNOLOGY REVIEW,Mar.8,2012, http://www.technologyreview.com/view/427177/diy-kit-overclocks-your-brain-with -direct-current/ (accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"30Go Flow Kickstarter Campaign Denied ,DIYTDCS,http://www.diytdcs.com/2012/05/goflow-kickstarter- campaign-denied/ (accessedDec.14,2013).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"32LongecityForum, http://www.longecity.org/forum/topic/57869-increased-cognition-with-9v-battery/",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"35Id.andNewsfromGoFlow!GoodandBad ,DIYTDCS,http://www.diytdcs.com/2013/06/news-from-goflow- good-and-bad/ (accessedDec.14,2013).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"36TransCranialTechnologies, http://www.trans-cranial.com/ (accessedJuly1,2014);notethatthecompany iscurrentlyconductingbusinessasTCTResearchLimited.",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"37Seewww.biocurrentkit.com ,www.tdcs-kit.com ,andwww.tDCSdevicekit.com ,accessedbetweenDec.2012 andApr.2013,archivedversionsat http://web.archive.org 38See eg http://www.amazon.com/DSS-Chattanooga-Ionto/dp/B00FC2SRMY andhttp://www.",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"39FOC.US, Transcranial Direct Current Stimulation for Gamers ,http://www.foc.us/ (accessed July 8, 2013), http://web.archive.org/web/20130708144009/http://www.foc.us./ 40S e ee gK a t eM u r p h y , Jump-Starter Kits for the Mind ,THENEWYORKTIMES, Oct. 28, 2013, http://www.nytimes.com/2013/10/29/science/jump-starter-kits-for-the-mind.html (accessed Sep. 22,2015);NickStatt, WhenWearableTechMakesYouSmarter—byZappingYourBrain ,CNET,Aug.9,2013, http://news.cnet.com/8301-11386 3-57597116-76/when-wearable-tech-makes-you-smarter-by-zapping- your-brain/ (accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"42Foc.usedgetDCSheadset, http://www.foc.us/edge-tdcs-headset (accessedJan.25,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"That is, absent a material price difference, consumers will optforthesafestandmosteffectiveproduct.AscompaniessuchasThynchavealready 43HaloNeuroscience—PressRelease (May28,2014) http://haloneuro.com/press/ (accessedJan.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"44HaloNeuroscience ,http://haloneuro.com/ (accessedJan.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"45Brad Stone, Thync Lets You Give Your Mind a Jolt ,BLOOMBERG BUSINESS, Oct. 8, 2014, http://www.bloomberg.com/bw/articles/2014-10-08/thync-raises-13-million-for-its-brain-stimulating- electrodes (accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"47The safety section of Thync’s website states: ‘Thync Vibes were safely tested on several thousand in- dividuals under a variety of conditions to optimize their performance and comfort.’ Thync—Safety, http://www.thync.com/science-and-technology (accessedJune25,2015).SeealsoTyleretal., supranote 26.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"55Id.and US Food and Drug Administration, Regulatory Controls (Medical Devices) ,http://www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ucm2005378.htm (accessedSep.22,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"882), https://www.federalregister.gov/articles/2014/06/12/2014–13756/neurological-devices- withdrawal-of-proposed-effective-date-of-requirement-for-premarket-approval-for (accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"890), https://www.federalregister.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"§360c(a)(1) and US Food and Drug Administration, Premarket Approval , http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/ PremarketSubmissions/PremarketApprovalPMA/ucm2007514.htm (accessedJan.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"Thus, if a new (‘postamendment’) device can demonstrate substantial equivalence to one of the few devices that were temporarily classified as Class III devices and haveyettobereclassified,thedevicecanbeclearedviathe510(k)process.See infranote128andrelated textforthediscussionofoneexample,aCESdevice.USFoodAndDrugAdministration, 515ProgramIni- tiative,http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/ CDRHTransparency/ucm240310.htm (accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"§321(h)) (2012); guidance to industry http://www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevice/ucm051512.htm (accessedSep.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"CONSUMERTDCSDEVICE MARKETINGLANGUAGE BrainStimulator∗ https://thebrainstimulator.net/what-is-tdcs/‘tDCSallowsyoutounlockyour brain’struepotential’ CognitiveKit∗ http://www.cognitivekit.com/‘Chargeyourmind’ tdcs-kit http://www.tdcs-kit.com/‘Poweryourmind’ ApeXTypeA∗ http://www.apexdevice.net/‘Behappier.Befocused.Besmarter’ Foc.us∗ http://www.foc.us/‘makeyoursynapsesfirefaster’, ‘overclockyourbrain’,‘takecharge’ Thync∗ http://www.thync.com‘quietyourmind’,‘boostyourworkout’ PriorMind http://www.priormind.com‘increaseyourattentionspan’ ‘tDCShasbeenwidelyusedtotreat depression ...’ TCT∗ http://www.trans-cranial.com‘whenonlythebestintDCS therapywilldo’ SuperSpecificDevices∗ http://www.superspecificdevices.com‘personaltDCSdevice’ ∗Websitecontainssomeformofamedicalorhealth-relateddisclaimer.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"However,thedraftguidancealsoprovidesasecondcriterion:theproductmustbe alow-riskdevice.Accordingtothedraftguidance,aproductis notalow-riskdeviceif ‘itinvolvesaninterventionortechnologythatmayposearisktoauser’ssafetyifdevice controlsarenotapplied’.81Thedraftguidancealsostatesthatindeterminingwhether 76Neurogaming 2014, Investing in Neurogaming: Panel Discussion , May 7, 2014, video recording at https://www.youtube.com/watch?v=fz95kEx3zx4 .",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"77See eg Muse, http://www.choosemuse.com/ ; Emotiv Insight, https://emotiv.com/insight.php ;N e u - rosky,http://neurosky.com/ ;M e l o n http://www.thinkmelon.com/ ; and FocusBand http://www.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"78USFoodAndDrugAdministration, GeneralWellness:PolicyforLowRiskDevicesDraftGuidanceforIndustry and Food and Drug Administration Staff , Jan. 20, 2015, https://www.federalregister.gov/articles/2015/ 01/20/2015-00756/general-wellness-policy-for-low-risk-devices-draft-guidance-for-industry-and-food-and -drug(accessedMar.1,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"6, 2012, http://www.fda.gov/RegulatoryInformation/Guidances/ucm209841.htm (accessedFeb.26,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"Thync Press Release, Thync Launches First WearabletoShiftYourStateofMind,ConsumerProductDeliversCalmandEnergywithinMinutes ,June2,2015, http://www.thync.com/resources/press-release/thync-launches-first-wearable-to-shift-your-state-of-mind (accessedJune12,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"91US Food and Drug Administration, Bed Rail Safety: FDA and CPSC Activities, http://www.fda.gov/ MedicalDevices/ProductsandMedicalProcedures/HomeHealthandConsumer/ConsumerProducts/ BedRailSafety/ucm362867.htm (accessedMar.20,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"110Larry D. Spears for Steven D. Niedelman, Acting Director, Office of Compliance, Food and Drug Administration, Warning Letter to Salton, Inc., July 12, 2000, http://www.casewatch.org/fdawarning/ prod/2000/salton.shtml (accessedMar.15,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"111GeorgiaC.Ravitz,CounselforSalton,Inc., Re:RejuveniqueFacialToningSystem ,toMr.WilliamF.Defibaugh, Compliance Offer, Center for Devices and Radiological Health, Aug. 11, 2000, http://media.corporate- ir.net/media files/nys/sfp/salton rejuv.pdf(accessedMar.15,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"112510(k) Summary — Rejuvenique R/circlecopyrtFacial Toning System, Aug. 8, 2001, http://www.accessdata.",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"114BenPopper, TheHaloNeuroscienceHeadbandWantstoMakeYouSmarterbyShockingYourBrain, THEVERGE, April 30, 2014, http://www.theverge.com/2014/4/30/5668086/halo-neuroscience-brain-stimulation- funding-andreessen (accessed Feb. 25, 2015); John Biggs, Halo, the Brain-Improving Wearable, Raises $1.5 Million,TECHCRUNCH, May 1, 2014, http://techcrunch.com/2014/05/01/halo-the-brain-improving- wearable-raises-1-5-million/ (accessedFeb.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"121CaliforniaDepartmentofPublicHealth, CDPHWarnsConsumersNottoUseTDCSHomeDeviceKit ,June 28,2013,http://www.cdph.ca.gov/Pages/NR13-029.aspx (accessedFeb.1,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"See eg, Section 1.2 in US Food and Drug Administration, FDA Executive Summary: Prepared for the February 10, 2012 meeting of the Neurologic Devices Panel, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/ MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM290787.pdf (accessed Sep. 22, 2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"10.85(k), http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=10.85 (accessed Jan. 25, 2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"882,https://www.federalregister.gov/articles/2014/07/03/2014-15625/medical-devices-neurological- devices-classification-of-the-transcutaneous-electrical-nerve (accessedFeb.22,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"134Federal Trade Commission, FTC Policy Statement on Deception ,http://www.ftc.gov/public-statements/ 1983/10/ftc-policy-statement-deception (accessedJan.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"18,539 (Sept. 16, 1971), http://www.fda.gov/AboutFDA/ PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm115791.htm (ac- cessedJan.20,2015).SeealsodiscussioninJamesSerafino, DevelopingStandardsforHealthClaims-TheFDA andtheFTC ,47FOOD&DRUGL.J.335,335–337(1992).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"136US Food and Drug Administration, Mobile Medical Applications: Guidance for Industry and Food and Drug AdministrationStaff (Feb.9,2015), http://www.fda.gov/downloads/MedicalDevices/ .../UCM263366.pdf (accessedFeb.22,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"137Federal Trade Commission, Press Release, Makers of Jungle Rangers Computer Game for Kids Set- tle FTC Charges that They Deceived Consumers with Baseless ‘Brain Training’ Claims , Jan. 20, 2015, http://www.ftc.gov/news-events/press-releases/2015/01/makers-jungle-rangers-computer-game-kids- settle-ftc-charges-they (accessedFeb.26,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"Forexample,thefirstnoticeofviolationissuedtoTDCSDeviceKitwasrelatedtoa staterequirement(lackoflicensingfromtheCDPH),notafederalone.Furthermore, 138Federal Trade Commission, Press Release, ‘ Acne Cure’ Mobile App Marketers Will Drop Baseless Claims Under FTC Settlements , Sept. 8, 2011, https://www.ftc.gov/news-events/press-releases/2011/ 09/acne-cure-mobile-app-marketers-will-drop-baseless-claims-under (accessed Jan. 8, 2015); and Federal Trade Commission, Press Release, FTC Cracks Down on Marketers of ‘Melanoma Detection’ Apps, Feb. 23, 2015,https://www.ftc.gov/news-events/press-releases/2015/02/ftc-cracks-down-marketers-melanoma- detection-apps (accessedMar.1,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"140US Consumer Product Safety Commission, Products Under the Jurisdiction of Other Federal Agencies , http://www.cpsc.gov/en/Regulations-Laws–Standards/Products-Outside-CPSCs-Jurisdiction/ (accessed Jan.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"141The application for FCC certification for the Foc.us devices (submitted by European Engineers Lim- ited, FCC ID: 2AAH6DLIG1) and for the Thync device (FCC ID: 2AELZ-1000) are publicly viewable via an ‘Equipment Authorization Search’ on the FCC website: https://apps.fcc.gov/oetcf/eas/reports/ GenericSearch.cfm (accessedJan.8,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"142USFoodandDrugAdministration, Radiation-EmittingProducts-CellPhones ,http://www.fda.gov/radiation- emittingproducts/radiationemittingproductsandprocedures/homebusinessandentertainment/cellphones/ default.htm (accessedJan.25,2015).",OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"147US Food and Drug Administration, Regulatory Procedures Manual, 9–2, Coverage of Personal Impor- tations,http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm179266.htm (accessedJan.10,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"148CouncilofBetterBusinessBureaus,MissionandVision, http://www.bbb.org/council/about/vision-mission- and-values/ (accessed Jan. 15, 2015); FTC Commissioner Maureen K. Ohlhausen has defined self- regulation as a ‘broad concept that includes any attempt by an industry to moderate its conduct with the intent of improving marketplace behavior for the ultimate benefit of consumers’.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"Maureen K. Ohlhausen, RemarksattheBBBSelf-RegulationConference ,June24,2014,at2, http://www.ftc.gov/system/ files/documents/public statements/410391/140624bbbself-regulation.pdf (accessedJan.10,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"149BBB Business Review, European Engineers Limited (see ‘Complaint Resolution Log’) http://www.bbb.",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"150National Advertising Division, http://www.bbb.org/council/the-national-partner-program/national- advertising-review-services/national-advertising-division/ (accessedJan.25,2015).",Non-OADS,/arxiv_data1/oa_pdf/cb/41/lsv039.PMC5034391.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/c1/bf/lsv042.PMC5034392.pdf
"country-westernperformer,DollyParton, SeeDollytheSheepCloneDiesYoung ,BBCN EWSWORLDEDITION, Feb.14,2003 http://news.bbc.co.uk/2/hi/science/nature/2764039.stm (accessedOct.1,2015).",Non-OADS,/arxiv_data1/oa_pdf/c1/bf/lsv042.PMC5034392.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/b8/da/lsv052.PMC5034393.pdf
"9See eg Sammy Almashat & Sidney Wolfe, Pharmaceutical Industry Criminal and Civil Penalties: An Update , Sept.27,2012, http://www.citizen.org/documents/2073.pdf (lastaccessedOct.30,2015)(identifying239 drugcompanysettlementstotaling$30.2billionbetween1991andJuly2012);SamuelD.Krumholz,David S. Egilman & Joseph S. Ross, Study of Neurontin Titrate to Effect, Profile of Safety (STEPS) Trial , 171 ARCH.",Non-OADS,/arxiv_data1/oa_pdf/b8/da/lsv052.PMC5034393.pdf
"See FDA , Guidance for Industry Distributing Scientific and Medical Publications on Unapproved New Uses—Recommended Practices , Feb. 2014, http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM387652.pdf (last ac- cessedOct.30,2015).",Non-OADS,/arxiv_data1/oa_pdf/b8/da/lsv052.PMC5034393.pdf
"22ACCME, Standards for Commercial Support: Standards to Ensure Independence in CME Activities ,S t a n d a r d s 1.1 & 4.3 (Feb. 2012), http://www.accme.org/requirements/accreditation-requirements-cme-providers/ standards-for-commercial-support (lastaccessedOct.30,2015).",Non-OADS,/arxiv_data1/oa_pdf/b8/da/lsv052.PMC5034393.pdf
"23PhRMA, Code on Interactions with Healthcare Professionals (2008) at 4, http://www.phrma.org/ sites/default/files/pdf/phrma marketing code2008.pdf(lastaccessedOct.30,2015).",Non-OADS,/arxiv_data1/oa_pdf/b8/da/lsv052.PMC5034393.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"10Jillian Boyce, Table 1 Charges and Cases Completed in Adult Criminal Court, Canada 2005/2006 to 2011/2012 in Adult Criminal Court Statistics, 2011/2012 ,STATISTICS CANADA (2013), http://www.statcan.gc.ca/pub/85-002-x/2013001/article/11804-eng.htm (accessedMay23,2015).",OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"11MiaDauvergne,Table1ChargesandCasesCompletedinYouthCourt,Canada21991/1992to2011/2012 inYouth Court Statistics in Canada, 2011/2012, STATISTICS CANADA,http://www.statcan.gc.ca/pub/ 85-002-x/2013001/article/11803-eng.htm .",OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"Brainimagingandelectroencephalographywereinfrequentlymentionedintheset ofcases.AsupplementarysearchofthesamedatabaseofCanadiancaselawupdatedto August,2014revealsonlytwocasesmakingreferencetofMRIorfunctionalmagnetic resonanceimaging,neitherofwhichinvolveacriminalmatter.Onecasefrom2013was a civil case involving end of life decision-making for a severely brain-injured patient and refers to the work of Dr Adrian Owen in using fMRI to detect covert awareness inpatientsthoughttobeinavegetativestateorminimallyconscious.15Theothercase hadtodowithaconstitutionalchallengetothestatutorycaponinsurancerecoveryfor minorinjuriessufferedinmotorvehicleaccidents,andcontainsadiscussionofexpert evidencerelatedtotheneuroanatomyofpost-traumaticstressdisorder.16 13Huw Williams, Repairing Shattered Lives: Brain Injury and its Implications for Criminal Justice .REPORT COMMISSIONED BY THE BARROWCADBURYTRUST(2012),http://www.barrowcadbury.org.uk/wp-content/ uploads/2012/11/Repairing-Shattered-Lives Report.pdf (accessedMay23,2015).",Non-OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"29The data collected by the Government of Canada for adult criminal court sentences in 2011–12 were used to identify the typical sentences imposed by offence type in Canada: Statistics Canada, Adult Crim- inal Court Statistics in Canada 2011/2012 .JURISTAT(2013),http://www.statcan.gc.ca/pub/85-002-x/ 2013001/article/11804/tbl/tbl05-eng.htm (accessedMay23,2015).",OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"5).Itispossiblethatthenumbersofnon-Aboriginaloffendersaffected inthiswayisactuallyhigherthanitappearsifthereisareducedtendencytolookfor thisprobleminthenon-Aboriginalpopulationsothatcasesarenotidentifiedandmen- tionedatsentencing.Unfortunately,theredonotseemtobeconfirmedstatisticsonthe prevalenceofFASDandassociatedconditionsinCanada,althougha2006Canadian governmentestimateis0.9percentofbirths,withtherate‘significantlygreaterinAbo- riginalpopulations,andinrural,remoteandnortherncommunities’.31 31Health Canada, Fetal Alcohol Spectrum Disorder: It’s Your Health (2006),http://www.hc-sc.gc.ca/ hl-vs/iyh-vsv/diseases-maladies/fasd-etcaf-eng.php (accessedMay23,2015).",Non-OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"55Canadian Bar Association, Resolution 13–12-A: Accommodating the Disability of FASD to Improve Ac- cess to Justice (Aug. 17–18, 2013), http://www.cba.org/CBA/resolutions/pdf/13-12-A-ct.pdf (accessed May 23, 2015).",Non-OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"Institute of Health Economics, Consensus Statement on Legal Issues of Fetal Alco- hol Spectrum Disorder (FASD) , Sept. 18–20, 2013 at 22, http://www.ihe.ca/publications/legal-issues-of- fasd-proceedings-from-a-consensus-development-conference-table-of-contents- (accessedMay23,2015).",Non-OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"26,2014 http://www.yukon-news.com/news/leef-pulls-fasd-bill-from-parliament/ (accessedMay23,2015).",Non-OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"57RobertGoguen(ParliamentarySecretarytotheMinisterofJustice,CPC),Hansard–145(Nov.20,2014) 17:40,http://www.parl.gc.ca/HousePublications/Publication.aspx?Pub=Hansard&Doc=145&Parl=41& Ses=2&Language=E&Mode=1 (accessedMay23,2015).",Non-OADS,/arxiv_data1/oa_pdf/3a/f2/lsv026.PMC5034394.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/39/d6/lsv029.PMC5034395.pdf
"3Seeat116, http://ec.europa.eu/health/medical-devices/files/revision docs/proposal 2012542en.pdf(last accessedMay28,2015).",Non-OADS,/arxiv_data1/oa_pdf/39/d6/lsv029.PMC5034395.pdf
"10http://ec.europa.eu/health/medical-devices/files/revision docs/revision iapart2annex1en.pdf(last ac- cessedMay28,2015).",Non-OADS,/arxiv_data1/oa_pdf/39/d6/lsv029.PMC5034395.pdf
"nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/home/groups/comms-ic/documents/ publication/con205362.pdf (lastaccessedMay28,2015),10.",Non-OADS,/arxiv_data1/oa_pdf/39/d6/lsv029.PMC5034395.pdf
"3.3Misuseofpublicresourcesandtheroleofhealthcare De Ridder, Vanneste, and Focquaert raise concerns about the misuse of resources, which assumes a position markedly different from that which we set out in our pa- per.Theyargue,persuasively,thatresourcesshouldbedirectedtothemostimportant causesandthatenhancementsmightnotbeofahighenoughprioritytowarrantuseof ourlimitedresources.Weagreethatlimitedresourcesneedtobeallocatedcarefully, butourproposaldoesnotthreatensuchallocation:thedevicesthatwouldbeprohib- itedunderourproposalareonesthatwouldcertainlynotwarrantsignificantinvestment of public resources, and our proposalleaves open how resources should be allocated 19Seehttp://www.reddit.com/r/tDCS (lastaccessedMay28,2015).",Non-OADS,/arxiv_data1/oa_pdf/39/d6/lsv029.PMC5034395.pdf
"21ForfurtherdetailsandjustificationofAnnexXVfromtheEuropeanCommissionandMHRA;seeat29,116, 171,http://ec.europa.eu/health/medical-devices/files/revision docs/proposal 2012542en.pdf(last ac- cessedMay28,2015);seeat10, http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.",Non-OADS,/arxiv_data1/oa_pdf/39/d6/lsv029.PMC5034395.pdf
"mhra.gov.uk/home/groups/comms-ic/documents/publication/con205362.pdf (last accessed May 28, 2015); see at 7, 8, http://www.ipem.ac.uk/Portals/0/Documents/Consultations/Revision%20of%20 European%20Legislation%20on%20Medical%20devices%20All%20responses%20April%202013.pdf (last accessedMay28,2015).",Non-OADS,/arxiv_data1/oa_pdf/39/d6/lsv029.PMC5034395.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/2f/64/lsv024.PMC5034396.pdf
"The defendant has been a member of a shooting club for a long time, and claims to have dreamt that she was at the shooting range, aiming at cardswithvagueimages.Followingthesestatements,aphysiologicalsleepassessment isconducted.Thepsycho-physiologistcomparesthewoman’scasetoguidelinesforde- terminingthepossibleroleofasleepdisorderinviolentbehavior.Heconcludesthatit islikelythatthedefendanthascommittedtheviolentactduringsleep.Hereportsin- teraliathatduringthefirstphaseofdeepsleep,theactivityofthefrontalcortexofthe brain is greatly reduced and that this was also the case in the defendant during sleep registration.Heexplains: The disconnection between the frontal cortex and other parts of the brain during deep sleepcanleadtoautomaticbehavior.Inthisstatethereisconsciousnessinthesensethat the individualregistershisenvironment.Butbecausethe controlling role of the frontal cortexhasbeen‘turnedoff’,thepersonisnolongerawareofhisownpositionrelativeto 21SeeegLindaVanLeijenhorst,WhyTeensTakeRisks:ANeurocognitiveAnalysisOfDevelopmentalChanges And Individual Differences In Decision-Making Under Risk (2010) (Doctoral Thesis Leiden University) https://openaccess.leidenuniv.nl/handle/1887/14615 .",Non-OADS,/arxiv_data1/oa_pdf/2f/64/lsv024.PMC5034396.pdf
"1149, 1158 (2004); David K. Randall, Dangerous Dreamers ,PSYCHOLOGY TODAY.COM (Jan.2,2013), https://www.psychologytoday.com/articles/201212/dangerous-dreamers .",Non-OADS,/arxiv_data1/oa_pdf/2f/64/lsv024.PMC5034396.pdf
"77Mark van Opijnen, On and in the Web: How the Accessibility of Judicial Decisions Can be Im- proved (2014) [PhD Thesis, University of Amsterdam (in Dutch with summary in English)] http://dare.uva.nl/record/466352 (accessedAug.1,2014).",Non-OADS,/arxiv_data1/oa_pdf/2f/64/lsv024.PMC5034396.pdf
"26, 2012, http://www.rechtspraak.nl/Uitspraken/Selectiecriteria/ (accessedAug.1,2014).",Non-OADS,/arxiv_data1/oa_pdf/2f/64/lsv024.PMC5034396.pdf
"84Den Haag: Raad voor de Rechtspraak, Projectgroep PromisII, Eindrapport Promis II: Project motiver- ingsverbeteringinstrafvonnissen ,2007,http://www.rechtspraak.nl/Organisatie/Raad-Voor-De-Rechtspraak/ Kwaliteit-van-de-Rechtspraak/Documents/Integraal-eindrapport-Promis def.pdf(accessedAug.26,2014).",Non-OADS,/arxiv_data1/oa_pdf/2f/64/lsv024.PMC5034396.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/87/77/lsv037.PMC5034398.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/1e/5f/lsv035.PMC5034399.pdf
"6Food & Drug Administration, Fecal Microbiota for Transplantation: Scientific and Regulatory Issues 309, May 2, 2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetings Conferences/UCM352903.pdf (accessedOct.12,2015).",Non-OADS,/arxiv_data1/oa_pdf/10/57/lsv046.PMC5034401.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/10/57/lsv046.PMC5034401.pdf
"2009 Jul; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm174620.htm (accessedOct.12,2015).",Non-OADS,/arxiv_data1/oa_pdf/10/57/lsv046.PMC5034401.pdf
"10Guidance for Industry: Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Man- ufacturing, and Control Information (February 2012) http://www.fda.gov/downloads/Biologics BloodVaccines/Guidance-ComplianceRegulatoryInformation/Guidances/General/UCM292704.pdf (accessedOct.12,2015).",Non-OADS,/arxiv_data1/oa_pdf/10/57/lsv046.PMC5034401.pdf
12http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/RegulationofTissues/ucm152857.,Non-OADS,/arxiv_data1/oa_pdf/10/57/lsv046.PMC5034401.pdf
"53248 (October 14, 1993); which was further developed http://www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM062601 .pdf(accessed Oct. 12, 2015) and was imported into FDA’s Guidance for Human So- matic Cell Therapy and Gene Therapy (1998) http://www.fda.gov/biologicsbloodvaccines/ guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ucm072987.htm (accessed Oct.12,2015).",Non-OADS,/arxiv_data1/oa_pdf/10/57/lsv046.PMC5034401.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/75/0c/lsv036.PMC5034402.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/f8/01/lsv049.PMC5034403.pdf
"6RobinFeldman, Federalism,FirstAmendment&Patents:TheFraudFallacy ,17COLUM.SCI.&TECH.L.REV.at 32(forthcoming,2015),availableat http://ssrn.com/abstract =2616519[discussingthedissentingopinion ofJusticeScaliaandJusticeAlitoin TevaPharmaceuticalsUSA,Inc.v.Sandoz,Inc.",Non-OADS,/arxiv_data1/oa_pdf/f8/01/lsv049.PMC5034403.pdf
"Sept. 17, 2015), available at http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/14-1854.Opinion.9-15-2015.1.PDF .",Non-OADS,/arxiv_data1/oa_pdf/f8/01/lsv049.PMC5034403.pdf
"(The U.S. Government Says It’s Impossible), Patently-O (Sept.20,2015),availableat http://patentlyo.com/patent/2015/09/government-infringe-impossible.html .",Non-OADS,/arxiv_data1/oa_pdf/f8/01/lsv049.PMC5034403.pdf
"16PaulBasken, UnderFinancialPressure,UniversitiesGivePatentBuyersaCloserLook ,CHRON.HIGHEREDUC., Oct.25,2013,availableat http://chronicle.com/article/Under-Financial-Pressure/142613/ .",Non-OADS,/arxiv_data1/oa_pdf/f8/01/lsv049.PMC5034403.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/c8/94/lsv030.PMC5034404.pdf
"3US Department of Veterans Affairs: Office of Research & Development, Million Veteran Program , http://www.research.va.gov/MVP/ (accessedApr.20,2015).",Non-OADS,/arxiv_data1/oa_pdf/c8/94/lsv030.PMC5034404.pdf
"4GoogleCloudPlatform, GoogleGenomics ,https://cloud.google.com/genomics/ (accessedApr.20,2015).",OADS,/arxiv_data1/oa_pdf/c8/94/lsv030.PMC5034404.pdf
"The long-term success of the many new research initiatives 5Apple,AppleResearchKit ,https://www.apple.com/researchkit/ (accessedApr.20,2015).",Non-OADS,/arxiv_data1/oa_pdf/c8/94/lsv030.PMC5034404.pdf
"34Global Alliance for Genomics & Health, Framework for Responsible Sharing of Genomic and Health-Related Data,http://genomicsandhealth.org/about-the-global-alliance/key-documents/framework-responsible- sharing-genomic-and-health-related-data (accessedApr.20,2015) 35Global Alliance for Genomics & Health, Global Alliance for Genomics & Health: Consent Policy , http://genomicsandhealth.org/our-work/work-products/consent-policy (accessedApr.20,2015).",Non-OADS,/arxiv_data1/oa_pdf/c8/94/lsv030.PMC5034404.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/bf/65/lsv025.PMC5034405.pdf
"2Forexample,foralistofpublicationsbymembersoftheResearchNetworkonLawandNeurosciencesee http://www.lawneuro.org/publications.php (accessedJan.5,2015).",Non-OADS,/arxiv_data1/oa_pdf/bf/65/lsv025.PMC5034405.pdf
"815, 822, http://forensic-centre.com/wp-content/ uploads/2013/07/BEOS-IN-INDIA-IT 222S-STATUS-AS-AN-AID-IN-INVESTIGATION-AND-AS- CORROBORATIVE-EVIDENCE-AS-SEEN-FROM-JUDGMENTS .pdf(accessedJan.4,2015).",Non-OADS,/arxiv_data1/oa_pdf/bf/65/lsv025.PMC5034405.pdf
"HUM.GENET519 (2010); Hank Greely, Another ‘Brain Mitigation’ Criminal Sentence from Italy ,THECEN- TER FORLAW AND THE BIOSCIENCES ,STANFORDLAWSCHOOL,Sept.3,2011, http://blogs.law.stanford.edu/ lawandbiosciences/2011/09/03/another-brain-mitigation-criminal-sentence-from-italy/ (accessed Jan. 5, 2015).",Non-OADS,/arxiv_data1/oa_pdf/bf/65/lsv025.PMC5034405.pdf
"52SeeegNoLieMRI’s,website http://noliemri.com/ (accessedJan.5,2015).",Non-OADS,/arxiv_data1/oa_pdf/bf/65/lsv025.PMC5034405.pdf
"2GeneticTesting ,GENETICHOMEREFERENCE,Sept.7,2015, http://ghr.nlm.nih.gov/handbook/testing?show= all#interpretingresults (accessedSept.13,2015).",OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"This is an Open Access arti- cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ ),whichpermitsnon-commercialreproductionanddistri- butionofthework,inanymedium,providedtheoriginalworkisnotalteredortransformedinanyway,andthat theworkisproperlycited.Forcommercialre-use,pleasecontact journals.permissions@oup.com",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"gov, U.S. D EP’THEALTHHUM.SERV, Sept. 27, 2012 [hereinafter Preventive Services ],http://www.hhs.gov/healthcare/facts/factsheets/2010/07/ preventive-services-list.html (accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"9Affordable Care Act Implementation FAQs – Set 12 ,C M S .g o v ,C TR.FORMEDICARE AND MEDICAIDSERV., https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca implementation faqs12.html (ac- cessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"12SeegenerallyU.S.PreventiveServicesTaskForce,Sept.2014, http://www.uspreventiveservicestaskforce.org/ (accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"14SeeBRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing, U.S. Preventative Services Task Force, Dec. 2013, http://www.uspreventiveservicestaskforce.org/Page/Document/Update- SummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing (stating the rec- ommendation); The Center for Consumer Information & Insurance Oversight, Centers for Medicare and Medicaid Services: Affordable Care Act Implementation FAQs - Set 12, CMS.",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"GOV,available at https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca implementation faqs12.html (inter- pretingtheUPSTFrecommendationtoapplytothetestingitself).",OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"732 rCoverageofinterventionsaftergenetictesting BRCA Made famous in recent years by the actress Angelina Jolie, BRCA1 and BRCA2 are protein-producinggenesthatrepairdamagedDNAandhelpensurethestabilityofa cell’sgeneticmaterial,which,inturn,suppressestumourgrowth.15Variationsinthese genes undermine the normal and necessary process of DNA repair, and hence, can cause genetic alterations to cells and lead to cancer.16Some of these variants to the genes can be inherited and can increase the risk of both breast and ovarian cancers in women.17According to the National Cancer Institute, BRCA variants are respon- sibleforapproximately20–25percentofhereditarybreastcancers,5–10percentofall breastcancers,andabout15percentofovariancancers.18Additionally,lifetimeriskfor developingbreastcancerisashighas90percentifawomaninheritsaharmfulBRCA1 orBRCA2variation.19 PrincewritesthatalthoughvariationstotheBRCA1andBRCA2genesareoneof themorewidelystudiedgeneticconditions,insurancecompaniesprovidevaryinglev- elsofcoverageforbothgenetictestingandrecommendedinterventions.20Theseinter- ventionsincludebreastcancerscreeningbeginningatanearlieragesincecancerslinked toBRCAmutationsoftendevelopinwomenintheir20sand30saswellasprophylactic mastectomyand/oroophorectomy.21Princegoesontostatethat,‘Insurancecoverage forgeneticservicesfollowingBRCAtesting,suchasgeneticcounseling,screening,and prophylacticsurgery,isevenlessofanassurancethaninsurancecoverageforthegenetic testitself.’22 Toexplorethispotentialproblem,weexaminedtheactualmedicalcoveragepolicies ofmajorprivateinsurancecompanies.Cigna,forinstance,offersBRCA1andBRCA2 genetictestingforindividualswithaknownfamilialmutation,personalhistoryofbreast or other cancers, or a family history of breast, ovarian, or pancreatic cancer.23Cigna does‘not’,however,coverBRCA1orBRCA2genetictestinginthegeneralpopulation, inindividualswithnopersonalhistoryofbreastorovariancancer,andindividualsunder theageof18.24Similarly,UnitedHealthcare’spolicystatesthatBRCA1andBRCA2 testingismedicallynecessary(ie,coveredunderstandardcontractualcoverageprovi- sions) for customers including, but not limited to women with a personal history of breastcancerwhowerediagnosedat45oryoungerwithorwithoutafamilyhistoryof cancer;womenwithapersonalhistoryofbreastcancerdiagnosedat50oryoungerwith oneclosebloodrelativewithbreastcancerorunknownfamilyhistory;womenwithout 15BRCA1andBRCA2:CancerRiskandGeneticTesting, NAT’LCANCERINST.,Apr.1,2015[hereinafter Cancer Risk]http://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q1 (accessedSept.",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"BRCA 1 & BRCA 2) ,CIGNAMEDICAL COVERAGE POLICY1–5, Aug. 15, 2015 [hereinafter Susceptibility to Breast and Ovarian Cancer ], https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm 0001coverageposition -criteriagenetictestingforbreastandovariancancer.pdf (accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"Such policies represent sound financial decisions for insurance companies, since ‘the strategy of prophylactic mastectomy 25GeneticTestingforHereditaryBreastand/orOvarianCancerSyndrome(HBOC ),UNITEDHEALTHCARE MEDICAL POL’Y3, Dec. 1, 2014, https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/ Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Proto- cols/Medical%20Policies/C&S/genetic testingforhereditary breastovariancancersyndrome hboc CS.pdf(accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"28BRCA Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy ,AETNA, July 21 [hereinafter BRCA Testing],2015,http://www.aetna.com/cpb/medical/data/200 299/0227.html (accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"30Prophylactic Oophorectomy or Salpingo-oophorectomy With or Without Hysterectomy ,CIGNAMEDICAL COVERAGE POLICY, Feb. 15, 2015, https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/ medical/mm 0026coveragepositioncriteria prophylactic oopherectomy.pdf (accessed Sept. 13, 2015); Prophylactic Mastectomy and Breast Reconstruction after Mastectomy ,BLUECROSSBLUESHIELD OF MASS., Sept. 1, 2015, http://www.bluecrossma.com/common/en US/medical policies/459%20Prophylactic% 20Mastectomy%20and%20Breast%20Reconstruction%20after%20Mastectomy%20prn.pdf (accessed Sept. 13,2015)(Note:BecauseBlueCrossBlueShieldcoveragevariesstatetostatenotallplansoffercoveragefor prophylacticmastectomies).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"31Prophylactic Oophorectomy or Salpingo-oophorectomy With or Without Hysterectomy ,CIGNAMEDICAL COVERAGE POLICY, Feb. 15, 2015, https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/ medical/mm 0026coveragepositioncriteria prophylactic oopherectomy.pdf (accessedSept.13,2015); Pro- phylactic Mastectomy and Breast Reconstruction after Mastectomy ,BLUECROSSBLUESHIELD OF MASS., Sept. 1, 2015, http://www.bluecrossma.com/common/en US/medical policies/459%20Prophylactic%20 Mastectomy%20and%20Breast%20Reconstruction%20after%20Mastectomy%20prn.pdf (accessedSept.13, 2015) (Note: Because Blue Cross Blue Shield coverage varies state to state not all plans offer coverage for prophylacticmastectomies).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"34CatecholaminergicPolymorphicVentricularTachycardia, GeneticsHomeReference,Dec.2009, http://ghr.nlm.",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"38Genetic Testing ,AETNA, May 6, 2015, http://www.aetna.com/cpb/medical/data/100 199/0140.html (accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"39Policy Update Bulletin ,UNITEDHEALTHCARE 4, June 2015, https://www.unitedhealthcareonline.com/ ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and% 20Resources/Policies%20and%20Protocols/Medical%20Policies/SV%20MPUBs/MMG%20Update%20 BulletinJune%202015.pdf (accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"40Wearable Cardioverter Defibrillator and Automatic External Defibrillator ,CIGNA3, Feb. 15, 2015, https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm 0431coverageposition criteriawearablecardioverter defibrillator andaed.pdf(accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"43Cardioverter-Defibrillators ,AETNA, Aug. 28, 2015, http://www.aetna.com/cpb/medical/data/500 599/ 0585.html (accessedSept.13,2015).",Non-OADS,/arxiv_data1/oa_pdf/be/54/lsv043.PMC5034406.pdf
"Obesity and overweight  fact sheet, http://www.who.int/mediacentre/factsheets/fs311/en/ (2016, accessed 22 July 2016).",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
"Paris: OECD Publishing, 2012, http://dx.doi.org/10.1787/9789264183896-26-en (accessed 22 July 2016).",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
"Overweight and obesity – BMI  statistics, http://ec.europa.eu/eurostat/statistics-explained/index.php/Overweight_and_obesity_-_BMI_statistics (accessed 22 July 2016).",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
"Mortality and Morbidity Weekly Report, Department of Health and  Human Services, Centers for Disease Control and Prevention,  Atlanta, GA, 7 October 2005, http://www.cdc.gov/mmwr/pre-view/mmwrhtml/rr5410a1.htm (2005, accessed 1 April 2016).",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
"Financial  Times, 17 March, http://www.ft.com/cms/s/0/8521da6e-ec5a-11e5-bb79-2303682345c8.html#axzz4FQGCXXew (2016, accessed 25 July 2016).",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
"Water is cool in school, http://www.educationscotland.",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
"394, http://www.who.int/mediacentre/factsheets/fs394/en/  (2015, accessed 4 April 2016).",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
"http://digitalcommons.hsc.unt.edu/ disease/31 (2013, accessed 23 July 2016).",Non-OADS,/arxiv_data1/oa_pdf/67/4e/10.1177_2050312116670406.PMC5034461.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2e/a7/main.PMC5034481.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2e/a7/main.PMC5034481.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.02.005 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/2e/a7/main.PMC5034481.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/48/b5/main.PMC5034482.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.02.006 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/48/b5/main.PMC5034482.pdf
"Received May 29, 2016 /C15Accepted June 2, 2016 /C15Available online 9 June 2016 http://dx.doi.org/10.1016/j.molmet.2016.06.001 Commentary MOLECULAR METABOLISM 5 (2016) 805 e806/C2112016 Published by Elsevier GmbH.",OADS,/arxiv_data1/oa_pdf/1e/75/main.PMC5034483.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1e/75/main.PMC5034483.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1e/75/main.PMC5034483.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
"Received June 28, 2016 /C15Revision received July 8, 2016 /C15Accepted July 10, 2016 /C15Available online 16 July 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.002 Brief communication 1042MOLECULAR METABOLISM 5 (2016) 1042 e1047/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/f9/main.PMC5034485.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/89/f4/main.PMC5034487.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.03.003 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/89/f4/main.PMC5034487.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/29/08/main.PMC5034488.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/29/08/main.PMC5034488.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.02.002 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/29/08/main.PMC5034488.pdf
BMJ Case Rep 2016. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/08/main.PMC5034488.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/88/05/main.PMC5034489.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.03.001 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/88/05/main.PMC5034489.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b9/5a/main.PMC5034490.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b9/5a/main.PMC5034490.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.02.007 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/b9/5a/main.PMC5034490.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org /licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c7/ba/main.PMC5034491.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c7/ba/main.PMC5034491.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.03.004 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/c7/ba/main.PMC5034491.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
"Received June 16, 2016 /C15Revision received July 5, 2016 /C15Accepted July 7, 2016 /C15Available online 25 July 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.001 Original Article MOLECULAR METABOLISM 5 (2016) 997 e1005/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/53/main.PMC5034492.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
"Abbreviation: AP, area postrema; bHLH, basic helix-loop-helix; BrdU, 50-bromo-2-deoxyuridine; CR, calretinin; CTR, calcitonin receptor; CVO, circumventricular organs; EphRs, ephrin receptors; ERK1/2, extracellular signal-regulated kinase 1 and 2; FDR, false discovery rate; GO, gene ontology; ME, median eminence; NeuroD, neuronal differentiation; NeuroD1, neuronal differentiation-1; NGS, next generation sequencing; NSC, neural stem cells; RAMP, receptor activity-modifying protein; Wnt, Wingless- Type MMTV Integration Site Family Received June 9, 2016 /C15Revision received June 22, 2016 /C15Accepted June 27, 2016 /C15Available online 5 July 2016 http://dx.doi.org/10.1016/j.molmet.2016.06.015 Original article 834MOLECULAR METABOLISM 5 (2016) 834 e843/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
"Intron-spanning primers were designed with IDT, Integrated DNA Technologies, ( http://eu.idtdna.",OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/cb/main.PMC5034493.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
"Received March 21, 2016 /C15Revision received May 24, 2016 /C15Accepted May 24, 2016 /C15Available online 31 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.013 Brief communication MOLECULAR METABOLISM 5 (2016) 1025 e1032 /C2112016 The Authors.",OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/80/main.PMC5034494.pdf
"TheOMI OMNO2 data used in thisanalysis are publicly available at http://disc.sci.gsfc.nasa.gov/Aura/ data-holdings/OMI, and theDOMINO product is available athttp://www.temis.nl.",OADS,/arxiv_data1/oa_pdf/61/16/JGRD-120-5670.PMC5034499.pdf
"The SCIAMACHY data were obtained from the Aura Validation Data Center,http://avdc.gsfc.nasa.gov.",OADS,/arxiv_data1/oa_pdf/61/16/JGRD-120-5670.PMC5034499.pdf
Available from: http://dsp-psd.pwgsc.gc.ca/Collection/CP32-85-2002E.pdf  b. Miller RJ.,OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://www.dpmc.gov.au/publications/docs/closing_the_gap_2014.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://flinders.edu.au/medicine/sites/health-care-management/research/mtwt/ 18.,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: https://www.nhmrc.gov.au/guidelines/publications/ind1-ind2 19.,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://dx.doi.org/10.1071/AH14060 21.,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://www.alrc.gov.au/publications/Recognition%20of%20Aboriginal%20Customary%20Laws%20%28ALRC%20Report%2031%29/29-special-aboriginal-courts- 26.,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://www.health.gov.au/internet/yourhealth/publishing.nsf/Content/report-redbook/$File/HRT_report3.pdf 27.,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://www.pc.gov.au/__data/assets/pdf_file/0013/90310/cs20090707.pdf 29.,OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://www.hreoc.gov.au/social_justice/sj_report/sjreport05/chap2.html#a-the130.,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://www.recognise.org.au/wp-content/uploads/shared/uploads/assets/3446_FaHCSIA_ICR_report_text_Bookmarked_PDF_12_Jan_v4.pdf 41.,OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
Available from: http://www.ahpra.gov.au/About-AHPRA/What-we-do/Legislation.aspxHowse and Dwyer,Non-OADS,/arxiv_data1/oa_pdf/66/ae/AZPH-40-S14.PMC5034501.pdf
"She also searched the ISRCTN registry (http://isrctn.com) and the search portal of the World Health Organization International Clinical Trials Registry Platform (ICTRP; http://apps.who.int/trialsearch/) to identify ongoing trials, GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review) Copyright © 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/01/de/CD010705.PMC5034505.pdf
Available from http://gdt.guidelinedevelopment.org/central_   prod/_  design/ GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review) Copyright © 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/01/de/CD010705.PMC5034505.pdf
http://hain-lifescience.de/uploadfiles/file/produkte/ mikrobiologie/mykobakterien/tb_   eng.pdf (accessed 23 December 2015).,Non-OADS,/arxiv_data1/oa_pdf/01/de/CD010705.PMC5034505.pdf
"Practical considerations, 2011. http://apps.who.int/iris/ GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review) Copyright © 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/01/de/CD010705.PMC5034505.pdf
http://apps.who.int/iris/ bitstream/10665/79199/1/9789241505345_   eng.pdf.,Non-OADS,/arxiv_data1/oa_pdf/01/de/CD010705.PMC5034505.pdf
Global tuberculosis report 2015. http://apps.who.int/iris/ bitstream/10665/191102/1/9789241565059_   eng.pdf?ua=1.,Non-OADS,/arxiv_data1/oa_pdf/01/de/CD010705.PMC5034505.pdf
"The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs, 2016. http://www.who.int/ tb/WHOPolicyStatementSLLPA.pdf.",Non-OADS,/arxiv_data1/oa_pdf/01/de/CD010705.PMC5034505.pdf
Box 2925 Riyadh – 11461KSA Tel: +966 1 2520088 ext 40151Fax: +966 1 2520718Email: sha@sha.org.saURL: www.sha.org.sa EDITORIAL DOI of original article: http://dx.doi.org/10.1016/j.jsha.2016.02.007 1016–7315 /C2112016 The Author.,Non-OADS,/arxiv_data1/oa_pdf/42/9a/main.PMC5034525.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/42/9a/main.PMC5034525.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.03.002 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/42/9a/main.PMC5034525.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
"Received May 11, 2016 /C15Revision received July 8, 2016 /C15Accepted July 10, 2016 /C15Available online 16 July 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.003 Original article MOLECULAR METABOLISM 5 (2016) 1015 e1024/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/37/main.PMC5034526.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9a/8b/main.PMC5034561.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2016.02.003 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/9a/8b/main.PMC5034561.pdf
"Stem Cell Reports Report A Generalized Gene-Regulatory Network Model of Stem Cell Differentiation for Predicting Lineage Speciﬁers Satoshi Okawa,1Sarah Nicklas,2Sascha Zickenrott,1Jens C. Schwamborn,2and Antonio del Sol1,* 1Computational Biology Group 2Developmental and Cellular Biology Group Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 7 Avenue des Hauts Fourneaux, 4362 Esch-sur-Alzette, Luxembourg *Correspondence: antonio.delsol@uni.lu http://dx.doi.org/10.1016/j.stemcr.2016.07.014 SUMMARY Identiﬁcation of cell-fate determinants for directing stem cell differentiation remains a challenge.",Non-OADS,/arxiv_data1/oa_pdf/57/9a/main.PMC5034562.pdf
307 This is an open access article under the CC BY -NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/9a/main.PMC5034562.pdf
This value was calculated for all pairs of TFs an- notated in AnimalTFDB ( http://www.bioguo.org/AnimalTFDB/ download/gene_list_of_Mus_musculus.txt ).,OADS,/arxiv_data1/oa_pdf/57/9a/main.PMC5034562.pdf
Each strongly connected component was then decomposed into smaller strongly connected components by ﬁrst ﬁnding the ﬁrst 300 short- est path-elementary circuits from each node using the graphkshor-testpaths.m program ( http://www.mathworks.com/matlabcentral/ ﬁleexchange/35397-k-shortest-paths-in-a-graph-represented-by-a-sparse-matrix–yen-s-algorithm-/content/graphkshortestpaths.m ).,OADS,/arxiv_data1/oa_pdf/57/9a/main.PMC5034562.pdf
SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental ExperimentalProcedures and four ﬁgures and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2016.07.014 .,Non-OADS,/arxiv_data1/oa_pdf/57/9a/main.PMC5034562.pdf
@ERSpublications COPD grades 3 and 4 are associated with underweight http://ow.ly/GGRP300QYlN Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/30/3f/00051-2015.PMC5034593.pdf
"https://www.folkhalsomyndigheten.se/publicerat-material/publikationer/Folkhalsan-i-Sverige-Arsrapport-2014/ Date last accessed: February 8, 2016.",OADS,/arxiv_data1/oa_pdf/30/3f/00051-2015.PMC5034593.pdf
@ERSpublications This article discusses advancements in clinical pulmonary medicine presented at the 2015 ERS Congress http://ow.ly/OXOI3010yN9 Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/9d/d3/00031-2016.PMC5034595.pdf
@ERSpublications Members of @ERStalk Assembly 10 discuss the best presentations on respiratory infections at #ERS2015 http://ow.ly/BVqM3018veM Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/e8/62/00049-2016.PMC5034596.pdf
"@ERSpublications The NLRP3 inflammasome is primed in stable COPD lungs, then activated during infectious exacerbation http://ow.ly/Wopi300DXcT The content of this work is ©the authors or their employers.",Non-OADS,/arxiv_data1/oa_pdf/9b/12/00002-2016.PMC5034597.pdf
@ERSpublications A short lingual frenulum left untreated at birth is associated with obstructive sleep apnoea syndrome at a later age http://ow.ly/6kMQ30163nG Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/fb/d4/00043-2016.PMC5034598.pdf
@ERSpublications Smoking in pregnancy increases asthma by interference of lung and placental function and through epigenetic changes http://ow.ly/WkbB301cyaS Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/7a/11/00042-2016.PMC5034599.pdf
@ERSpublications MDT case management approach significantly reduces hospitalisation in asthma patients with prior frequent admission http://ow.ly/7iOI3016277 The content of this work is ©the authors or their employers.,Non-OADS,/arxiv_data1/oa_pdf/c9/21/00039-2016.PMC5034600.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
"Received July 19, 2016 /C15Revision received August 8, 2016 /C15Accepted August 10, 2016 /C15Available online 18 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.007 Original article 882MOLECULAR METABOLISM 5 (2016) 882 e891/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/19/main.PMC5034606.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
"Received July 10, 2016 /C15Revision received August 6, 2016 /C15Accepted August 9, 2016 /C15Available online 16 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.005 Original article 1006MOLECULAR METABOLISM 5 (2016) 1006 e1014/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
"En- ergy expenditure was additionally analyzed by ANCOVA using a toolprovided by the Mouse Metabolic Phenotyping Core, Vanderbilt Uni- versity (MMPC, Nashville, TN) (https://www.mmpc.org/shared/ regression.aspx; December 2015).",OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/65/ac/main.PMC5034607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
"Received July 20, 2016 /C15Revision received August 2, 2016 /C15Accepted August 5, 2016 /C15Available online 11 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.003 Original Article 844MOLECULAR METABOLISM 5 (2016) 844 e857/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/85/17/main.PMC5034608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
"Received July 11, 2016 /C15Revision received July 20, 2016 /C15Accepted July 25, 2016 /C15Available online 30 July 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.008 Original article MOLECULAR METABOLISM 5 (2016) 937 e947/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1016/S0140-6736(16)30054-X .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
Cell 156(1 e2):20e44.http://dx.doi.org/10.1016/j.cell.2013.12.012 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1126/science.1156232 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/ 10.1016/j.cell.2008.09.036 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/ ncb2696 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1290/1071-2690(2000)036 <0038: OOEMCD >2.3.CO;2 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1016/ j.cell.2006.02.050 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/ 10.1016/j.cmet.2013.06.016 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1002/emmm.201100172 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1002/ 0471143030.cb1009s33 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
Current Biology 17(13):1151 e 1156. http://dx.doi.org/10.1016/j.cub.2007.05.078 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/ nbt.2377 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/ 10.1002/pmic.201200439 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1002/pmic.200900375 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/nprot.2013.092 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.2337/db11- 1753 .Original article 946MOLECULAR METABOLISM 5 (2016) 937 e947/C2112016 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/ 10.1016/j.bbalip.2016.06.010 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/ 10.1002/stem.190 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1083/jcb.200805092 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
NIH Public Access 8(1):70 e73.http://dx.doi.org/10.1038/nmeth.1541.SAINT .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/ncb3122 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/nm.3324 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1016/j.cmet.2014.05.005 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1016/j.cmet.2013.08.003 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1128/ MCB.01300-08 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/nature10137 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/nmat3960 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1038/nmat3339 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1074/jbc.272.21.13793 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
Up- regulation of Flotillin-2 is associated with melanoma progression and modu- lates expression of the thrombin receptor protease activated receptor 1. p. 7361 e9.http://dx.doi.org/10.1158/0008-5472.CAN-04-0823 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/10.1371/ journal.pone.0084393 .,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
http://dx.doi.org/ 10.1016/j.cell.2015.09.053 .,OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f9/5b/main.PMC5034610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
"Received June 17, 2016 /C15Revision received July 30, 2016 /C15Accepted August 1, 2016 /C15Available online 6 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.001 Original article 926MOLECULAR METABOLISM 5 (2016) 926 e936/C2112016 The Authors.",OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
Gene Set Enrichment Analysis ( http://www.broad.,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/0f/main.PMC5034611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
"Received July 18, 2016 /C15Accepted July 29, 2016 /C15Available online 5 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.012 Original article MOLECULAR METABOLISM 5 (2016) 869 e881/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/f5/main.PMC5034612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
"Received July 13, 2016 /C15Revision received July 26, 2016 /C15Accepted July 27, 2016 /C15Available online 4 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.010 Original article 858MOLECULAR METABOLISM 5 (2016) 858 e868/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/4d/main.PMC5034613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
"Abbreviations: ACC, acetyl-CoA carboxylase; ACLY, ATP citrate lyase; KIC, a-ketoisocaproic acid; SCOT, succinyl-CoA:3-ketoacid-CoA transferase; ZMP, 5-aminoimidazole- 4-carboxamide ribonucleotide Received July 1, 2016 /C15Revision received July 21, 2016 /C15Accepted July 27, 2016 /C15Available online 8 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.011 Original Article 980MOLECULAR METABOLISM 5 (2016) 980 e987/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/0a/main.PMC5034614.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
"Received May 29, 2016 /C15Revision received July 26, 2016 /C15Accepted July 28, 2016 /C15Available online 5 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.07.009 Original article MOLECULAR METABOLISM 5 (2016) 807 e822/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1210/ er.2006-0034 [Epub 2006/11/02].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1073/ pnas.1105929108 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Journal of Biological Chemistry 282(5):2862 e 2870. http://dx.doi.org/10.1074/jbc.M603454200 .,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1210/endo.141.9.7665 [Epub 2000/08/31].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1172/JCI12954 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/ 10.1111/j.1365-2265.2004.02056.x .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1172/JCI114857 [Epub 1990/11/01].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Diabetes Metabolism Reviews 12(1):15 e36.http://dx.doi.org/ 10.1002/(SICI)1099-0895(199603)12:1 <15::AID-DMR153 >3.0.CO;2-0 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1038/ nature06098 [Epub 2007/08/31].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1210/en.2012-2029 [Epub 2013/03/09].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1210/ en.2007-1311 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/ 10.1016/j.mce.2011.03.010 .,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1124/pr.56.1.1 [Epub 2004/03/06].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1097/ SHK.0b013e318188dfb8 [Epub 2008/10/02].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1016/ j.metabol.2009.06.031 [Epub 2009/09/22].,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Cell Metabolism 5(3):181 e 194. http://dx.doi.org/10.1016/j.cmet.2007.02.004 [Epub 2007/03/07].,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1055/s-2007-1004859 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1007/BF03347116 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Journal of Clinical Investigation 117(11):3475 e 3488. http://dx.doi.org/10.1172/JCI31743 [Epub 2007/09/22].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.2337/db09-0638 [Epub 2009/09/16].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Endocrinology 144(12):5194 e 5202. http://dx.doi.org/10.1210/en.2003-1008 [Epub 2003/09/13].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1038/ijo.2013.53 [Epub 2013/05/08].,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Journal of Clinical Endocrinology & Metabolism 90(2):1047 e 1054. http://dx.doi.org/10.1210/jc.2004-1124 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1016/j.cmet.2007.04.004 [Epub 2007/05/ 10].,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1007/s10519-005-9024-9 [Epub 2006/01/13].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Obesity (Silver Spring) 16(9):2113 e 2119. http://dx.doi.org/10.1038/oby.2008.313 [Epub 2008/06/14].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1096/fj.09-142000 [Epub 2009/10/20].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1210/en.2003-0452 [Epub 2003/10/ 11].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1016/j.peptides.2009.07.012 [Epub 2009/ 08/04].,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/ 10.1016/j.mce.2009.01.014 [Epub 2009/05/12].,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1038/sj.bjp.0707247 [Epub 2007/04/24].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Journal of Clinical Endocrinology & Metabolism 94(9):3535 e 3542. http://dx.doi.org/10.1210/jc.2009-0162 .,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1146/ annurev.biochem.76.060305.150444 [Epub 2007/03/23].,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1210/jc.2011-2886 [Epub 2012/06/ 23].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1172/JCI32661 [Epub 2009/01/17].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
http://dx.doi.org/10.1523/JNEUROSCI.,OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
Journal of Biological Chemistry 278(15):12605 e 12608. http://dx.doi.org/10.1074/jbc.C300012200 [Epub 2003/01/23].,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/04/main.PMC5034615.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
"Abbreviations: 17bE, 17b-estradiol; AICAR, aminoimidazole-4-carboxamide-1- b-D-ribofuranoside; AMPK, AMP-activated protein kinase; ARC, arcuate nucleus; BSA-17 bE, bovine serum albumin-conjugated 17 bE; CC, compound C; ER, estrogen receptor; GABA, g-aminobutyric acid; GE, glucose-excited; GI, glucose-inhibited; HRP, horse radish peroxidase; IR, input resistance; MPP, methylphenolpyrazole; NGS, non-glucose sensing; PHTPP, phenyltri ﬂuoromethylpyrazolophenol; POMC, pro-opiomelanocortin; PVDF, polyvinylidene di ﬂuoride; SF-1, steroidogenic factor; TTX, tetrodotoxin; VMH, ventromedial hypothalamus; VL-VMN, ventrolateral VMN; Vm, membrane potential; VMN, ventromedial hypothalamic nucleus Received July 14, 2016 /C15Revision received August 2, 2016 /C15Accepted August 4, 2016 /C15Available online 20 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.002 Original article MOLECULAR METABOLISM 5 (2016) 823 e833/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
SUPPLEMENTAL FIGURES Supplemental Figures related to this article can be found at http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
http://dx.doi.org/10.1016/j.brainres.2016.07.035 .,OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cf/26/main.PMC5034617.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
"Abbreviations: 2-DG, 2-deoxy- D-glucose; ACC, acetyl-CoA carboxylase; AD-AMPKDN, adenoviral alpha-1 dominant negative; AD-CRE, adenoviral control; ACCDKI, ACC double knock-in (Ser79/212 Ala); AMPK, 50-adenosine monophosphate-activated protein kinase; b1KO, AMPK b1-subunit knockout; ECAR, extracellular acidi ﬁcation rate; FBS, fetal bovine serum; mTORC1, mammalian target of rapamycin complex 1; OCR, oxygen consumption rate; PBS, phosphate buffered saline; SGLT1, sodi um-glucose transporter 1; SGLT2, sodium-glucose transporter 2 Received July 22, 2016 /C15Revision received August 14, 2016 /C15Accepted August 18, 2016 /C15Available online 26 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.014 Brief communication 1048MOLECULAR METABOLISM 5 (2016) 1048 e1056/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
"Bethesda, 2016. https://clinicaltrials.gov [accessed 05.05.16].",Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
"Stockholm, 2016. http://www.proteinatlas.org [accessed 06.05.15].",OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/7d/main.PMC5034684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
"Received August 5, 2016 /C15Revision received August 16, 2016 /C15Accepted August 18, 2016 /C15Available online 26 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.013 Original article 948MOLECULAR METABOLISM 5 (2016) 948 e958/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/j.jhealeco.2011.10.003 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1001/jamainternmed.2015.2405 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/S0140- 6736(05)67402-8 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1074/ jbc.M109.053942 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/ j.cmet.2012.01.019 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1194/jlr.M018846 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Biochimica et Biophysica Acta 1831(5):950 e 959. http://dx.doi.org/10.1016/j.bbalip.2013.02.005 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/j.cmet.2015.06.022 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Nature Cell Biology 15(6):659 e 667. http://dx.doi.org/10.1038/ncb2740 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/j.cell.2012.05.016 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1038/nm.3324 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Science 328(5982):1158 e 1161. http://dx.doi.org/10.1126/science.1186034 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
The Journal of Clinical Investigation 124(2):515 e 527. http://dx.doi.org/10.1172/JCI67353 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Diabetes 63(2):514 e 525. http://dx.doi.org/10.2337/db13-1106 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/0026-0495(95)90123-X .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/ j.molmet.2015.03.001 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1074/ jbc.M002136200 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1152/physiolgenomics.00057.2003 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/ 10.1093/bioinformatics/btp120 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1038/ nbt.1621 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1093/ nar/gkr965 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/ j.cell.2014.12.005 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Nature 520(7545):57 e62.http://dx.doi.org/10.1038/nature14344 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1194/jlr.M600287-JLR200 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Obesity(Silver Spring) 24(1):51 e59.http://dx.doi.org/10.1002/oby.21317 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1172/JCI44271 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1101/gad.177857.111 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Nature Medicine 18(6):918 e 925. http://dx.doi.org/10.1038/nm.2757 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/ 10.1016/j.bbalip.2014.06.003 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/ j.bbalip.2013.01.016 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/ 10.1016/j.cell.2015.06.025 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1038/ nature12642 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
Genes & Development 27(3):234 e250 http://dx.doi.org/10.1101/gad.211649.112 .,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1016/j.cmet.2005.10.002 .,OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
http://dx.doi.org/10.1128/MCB.00504-08 .Original article 958MOLECULAR METABOLISM 5 (2016) 948 e958/C2112016 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/9c/main.PMC5034685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
"Received July 19, 2016 /C15Revision received August 12, 2016 /C15Accepted August 16, 2016 /C15Available online 23 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.011 Original Article 918MOLECULAR METABOLISM 5 (2016) 918 e925/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
"Statistical analyses used R version 3.1.0 ( http://www.r-project.org/ ) with the R packages survival, pROC and glmnet.",OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
http://dx.doi.org/ 10.2337/db14-0228 .,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c6/a7/main.PMC5034686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
"Abbreviations: GPCR, G protein-coupled receptors; RGS, Regulators of G-protein Signaling; PTX, Bordetella pertussis toxin; SST, Somatostatin Received July 20, 2016 /C15Revision received August 12, 2016 /C15Accepted August 16, 2016 /C15Available online 26 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.010 Original article 988MOLECULAR METABOLISM 5 (2016) 988 e996/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/53/main.PMC5034687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
"Abbreviations: ANG, Angiotensin; BAT, brown adipose tissue; BB, beam break; HACT, horizontal activity; HFD, high-fat diet; HRP, handle-region peptide; KO, knock- out; ND, normal diet; OGTT, oral glucose tolerance test; PGF, perigonadal fat; PPAR- g, peroxisome proliferator-activated receptor- g; PRA, plasma renin activity; PRF, perirenal fat; (P) RR, prorenin/renin receptor; RAS, renin-angiotensin system; SE, standard error; SFC, abdominal subcutaneous fat; SM, skeletal muscle; SMG, subma ndibular gland; TG, triglycerides; V-ATPase, vacuolar proton pump H þ-ATPase; VCO 2, carbon dioxide production; VO 2, oxygen consumption; WT, wild-type Received August 3, 2016 /C15Revision received August 12, 2016 /C15Accepted August 16, 2016 /C15Available online 23 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.009 Original article MOLECULAR METABOLISM 5 (2016) 959 e969/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/ 10.1161/HYPERTENSIONAHA.112.192690 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
"http://dx.doi.org/ 10.1097/HJH.0b013e3282f624a0 , 00004872-200805000-00001 [pii].",OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1152/ ajpregu.00224.2015 ajpregu.00224.2015 [pii].,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.3389/fendo.2012.00166 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1111/j.1467-789X.2011.00942.x .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
"http://dx.doi.org/ 10.1073/pnas.0403929101 , 0403929101 [pii].",OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
"http://dx.doi.org/10.1126/science.1179802 , 327/5964/459 [pii].",OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1161/CIRCRESAHA.110.224667 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1002/oby.20844 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
"http://dx.doi.org/10.4161/adip.29674 , 2014ADIPOCYTE206R [pii].",OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.2337/db12-1089 db12-1089 [pii].,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1161/HYPER- TENSIONAHA.113.01983 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1152/ ajpendo.00307.2011 ajpendo.00307.2011 [pii].,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1016/ j.diabres.2005.10.005 .,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1016/j.arcmed.2010.07.008 .S 0 1 8 8 e 4409(10)00191-8 [pii].,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
"http://dx.doi.org/10.1097/MNH.0b013e3282f29a8b , 00041552- 200801000-00009 [pii].",OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1007/978-1-59745-245-8_15 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/ 10.1038/nm.3361 nm.3361 [pii].,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
Essays in Biochemistry 42:89 e 103. http://dx.doi.org/10.1042/bse0420089 bse0420089 [pii].,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1002/oby.21352 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1038/ ki.2010.391 ki2010391 [pii].,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1002/oby.21592 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1038/ nrm2391 nrm2391 [pii].,OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
"Hypertension 42:76 e 81. http://dx.doi.org/10.1161/01.HYP.0000078490.59735.6E , 01.HYP.00000 78490.59735.6E [pii].",Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1371/journal.pone.0067192 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.06954 .,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/f9/main.PMC5034688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
"Abbreviations: IP6K, Inositol hexakisphosphate kinase; 5-IP7, diphosphoinositol pentakisphosphate; TNP, [N2-(m-Tri ﬂuorobenzyl), N6-(p-nitrobenzyl)purine]; CD, chow-diet; HFD, high-fat diet; DIO, diet-induced obesity; T2D, type-2 diabetes; EE, energy expenditure; H&E, hematoxylin and eosin; AUC, area under curve; WAT , white adipose tissue; EWAT, epididymal adipose tissue; IWAT, inguinal adipose tissue; RWAT, retroperitoneal adipose tissue; BAT, brown adipose tissue; Q-NMR, quantita tive nuclear magnetic resonance; HPLC, high performance liquid chromatography; PCR, polymerase chain reaction; QRT-PCR, quantitative reverse transcription polymera se chain reaction; GTT, glucose tolerance test; ITT, insulin tolerance test; T308, threonine 308; S473, serine 473; S9, serine 9; VO 2, volume of oxygen consumption; RER, Respiratory exchange ratio; ALT, alanine aminotransferase; AST, aspartate transaminase; IP6K1-KO, IP6K1 knockout; GSK3, glycogen synthase kinase; PKA, protein kinas e A; UCP-1/3, uncoupling protein 1/3; Cidea, cell death activator-A; PPAR g, peroxisome proliferator-activated receptor gamma; PGC1 a, PPAR coactivator 1 alpha; PRDM16, PR domain containing 16; CPT1a, carnitine palmitoyltransferase I; SREV-TNP, short-term TNP treatment for reversal of DIO; Pro-TNP, TNP treatment for protection against DI O; Rev-TNP, long-term TNP treatment for reversal of DIO; RevT-TNP, Long-term TNP treatment for reversal of DIO at thermoneutral temperature Received July 22, 2016 /C15Revision received August 10, 2016 /C15Accepted August 15, 2016 /C15Available online 21 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.008 Original article MOLECULAR METABOLISM 5 (2016) 903 e917/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/59/38/main.PMC5034689.pdf
"1521-0111/90/4/418 –426$25.00 http://dx.doi.org/10.1124/mol.116.104125 MOLECULAR PHARMACOLOGY Mol Pharmacol 90:418 –426, October 2016 Copyright ª2016 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license.",Non-OADS,/arxiv_data1/oa_pdf/58/f5/mol.116.104125.PMC5034690.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
"Received July 17, 2016 /C15Revision received August 17, 2016 /C15Accepted August 19, 2016 /C15Available online 26 August 2016 http://dx.doi.org/10.1016/j.molmet.2016.08.012 Original article 970MOLECULAR METABOLISM 5 (2016) 970 e979/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/c1/main.PMC5034694.pdf
"1521-009X/44/10/1709 –1719$25.00 http://dx.doi.org/10.1124/dmd.116.072363 DRUGMETABOLISM AND DISPOSITION Drug Metab Dispos 44:1709 –1719, October 2016 Copyright ª2016 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license.",Non-OADS,/arxiv_data1/oa_pdf/3c/d2/dmd.116.072363.PMC5034696.pdf
Available at https://www.gov.uk/government/publications/ payment-by-results-pbr-operational-guidance-and-tariffs Lastaccessed June 2014.,Non-OADS,/arxiv_data1/oa_pdf/84/dc/DME-33-471.PMC5034744.pdf
http://info.cancerresearchuk.org/cancerstats/types/breast[accessed 24 February 2015].,Non-OADS,/arxiv_data1/oa_pdf/07/d7/BJS-102-1360.PMC5034747.pdf
http://www.comet-initiative.org [accessed 24 February 2015].,Non-OADS,/arxiv_data1/oa_pdf/07/d7/BJS-102-1360.PMC5034747.pdf
"Data From the Psychiatric Genomics Consortium For gene-based and gene-complex analyses we utilized the data from the large-scale association meta-analysis of childhood ADHD (cADHD) performed by The Psychiatric Genetics Con-sortium (PGC, http://www.med.unc.edu/pgc/downloads) as itwould have a larger power and provide more accurate estimatesthan our own discovery sample.",OADS,/arxiv_data1/oa_pdf/cc/f5/AJMG-168-423.PMC5034749.pdf
"Available online: http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf Fleiss, J. L., Tytun, A. and Ury, H. K. (1980).",Non-OADS,/arxiv_data1/oa_pdf/73/be/BIMJ-58-43.PMC5034755.pdf
Avail- able online: http://www.g-ba.de/downloads/62-492-765/VerfO_2013-06-20_und_2013-02-21.pdf.,Non-OADS,/arxiv_data1/oa_pdf/73/be/BIMJ-58-43.PMC5034755.pdf
Available online: https://www.iqwig.de/download/A11-02_Extract_of_dossier_assessment_Ticagrelor.pdf.,OADS,/arxiv_data1/oa_pdf/73/be/BIMJ-58-43.PMC5034755.pdf
Available online: https://www.iqwig.de/download/IQWiG_Methoden_Version_4-1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/73/be/BIMJ-58-43.PMC5034755.pdf
Available online: https://www.iqwig.de/download/Dokumentation_und_Wuerdigung_der_Stellungnahmen_IQWiG_ Methoden_4-1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/73/be/BIMJ-58-43.PMC5034755.pdf
Available online: http://support.sas.,Non-OADS,/arxiv_data1/oa_pdf/73/be/BIMJ-58-43.PMC5034755.pdf
Incarceration.Table 2Variables Required for the Online Prediction of Mortality FromPulmonary Embolism in Cancer (POMPE-C) Logistic Regression Equation (http://www.studymaker.com/projects/pompe/index.php) Independent Variable Patient weight (lb) Highest respiratory rate (breaths/min) SaO 2(%) Heart rate >99 beats/min Altered mental statusRespiratory distressDo not resuscitate statusUnilateral limb swelling790 Beam et al.,Non-OADS,/arxiv_data1/oa_pdf/53/e7/ACEM-22-788.PMC5034796.pdf
Available at http://who.int/mediacentre/factsheets/fs310/en/.,Non-OADS,/arxiv_data1/oa_pdf/42/96/DME-33-218.PMC5034798.pdf
Available at http://www.socialstyrelsen.se/register/halsodataregis- ter/lakemedelsregistret.,OADS,/arxiv_data1/oa_pdf/42/96/DME-33-218.PMC5034798.pdf
http://www.accessdata.fda.gov/sc ripts/cder/drugsatfda/index.,OADS,/arxiv_data1/oa_pdf/bc/5a/JCPH-55-1378.PMC5034805.pdf
http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ ucm292362.pdf.,Non-OADS,/arxiv_data1/oa_pdf/bc/5a/JCPH-55-1378.PMC5034805.pdf
"Methods of identifying first-degree relatives and family ascertainment have been previously reported (see Supplemen- tary material, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39127/abstract) (24).",Non-OADS,/arxiv_data1/oa_pdf/8b/c0/ART-67-1904.PMC5034806.pdf
"We also identified patients with other autoimmune diseases including RA, SLE, systemic sclerosis, idiopathic inflammatory myopathy, type 1 diabetes mellitus, multiplesclerosis, myasthenia gravis, psoriasis, inflammatory bowel dis-ease, and vasculitis (for full code lists, see Supplementarymaterial, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39127/abstract).",OADS,/arxiv_data1/oa_pdf/8b/c0/ART-67-1904.PMC5034806.pdf
"Occu- pations were classified into 5 categories, and income levelswere categorized into sex-specific income quintiles (for addi- tional details, see Supplementary material, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.",Non-OADS,/arxiv_data1/oa_pdf/8b/c0/ART-67-1904.PMC5034806.pdf
[41] Available: http://www.chemaxon.com.,Non-OADS,/arxiv_data1/oa_pdf/34/90/RCM-29-1473.PMC5034808.pdf
See http://www.qni.org.uk for further information.Quality care as an ethical care ©2015 The Authors Nursing Inquiry Published by John Wiley & Sons Ltd 19,Non-OADS,/arxiv_data1/oa_pdf/79/ce/NIN-23-12.PMC5034813.pdf
All calculations were made in the statistical scripting language R (http://www.R-project.org/).,OADS,/arxiv_data1/oa_pdf/be/48/EHF2-2-194.PMC5034814.pdf
"An experienced gynae-cological histopathologist, blinded to the original diagnosis in the country of origin, reviewed all cases and categorised them according to an agreed predeﬁned classiﬁcation based on amodiﬁcation of the WHO histological classiﬁcation of tumours of the uterine cervix (http://screening.iarc.fr/atlas- classifwho.php).",Non-OADS,/arxiv_data1/oa_pdf/05/97/IJC-137-2858.PMC5034816.pdf
Available at: http://globocan.iarc.fr/Pages/fact_ sheets_cancer.aspx.,Non-OADS,/arxiv_data1/oa_pdf/05/97/IJC-137-2858.PMC5034816.pdf
"Statistical analyses The software ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.- gov/ij/, 1997 –2014) was used to quantify the densities of protein bands on ﬁlm that had been exposed to immunoblots.",OADS,/arxiv_data1/oa_pdf/11/13/JNC-135-76.PMC5034817.pdf
Available at: http://www.who.int/healthinfo/ global_burden_disease/metrics_daly/en(accessed 14 November 2014).,Non-OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at: http://www.capmas.gov.eg/pdf/ Electronic%20Static%20Book2013/english/population/untitled1/pop.aspx (accessed 14 November 2014).,Non-OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at: http://www.aihw.gov.au/WorkArea/ DownloadAsset.aspx?id=6442459196(accessed 14 November 2014).,OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at: http://data.worldbank.,Non-OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at: http://www.capmas.gov.eg/pdf/news/Twzf2012.pdf (accessed 14 November 2014).,Non-OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at:http://www.dot.gov/sites/dot.gov/ﬁles/docs/VSL%20Guidance_2013.pdf (accessed 14 November 2014).29.,OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at: http://www.whitehouse.gov/sites/default/ ﬁles/omb/ inforeg/2013_cb/draft_2013_cost_ beneﬁt_report.pdf (accessed 14 November 2014).,Non-OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Available at: http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS (accessed 14November 2014).,OADS,/arxiv_data1/oa_pdf/5d/b3/APT-42-696.PMC5034818.pdf
Master Settlement Agreement 1998. http://publichealthlawcenter.org/sites/ default/files/resources/master-settlement-agreement.pdf.,Non-OADS,/arxiv_data1/oa_pdf/af/3a/LARY-125-2722.PMC5034819.pdf
"New York Times July 19, 2014. http://www.nytimes.com/2014/07/20/business/jury- awards-23-6-billion-in-florida-smoking-case.html?_r=0.",Non-OADS,/arxiv_data1/oa_pdf/af/3a/LARY-125-2722.PMC5034819.pdf
http://www.PHAIOnline.,Non-OADS,/arxiv_data1/oa_pdf/af/3a/LARY-125-2722.PMC5034819.pdf
https://www.entnet.org/sites/default/files/Expert%20Witness%20Testimony%20Policy_0.pdf.,Non-OADS,/arxiv_data1/oa_pdf/af/3a/LARY-125-2722.PMC5034819.pdf
Available from URL: https://www.merckconnect.com/januvia/overview.html.,Non-OADS,/arxiv_data1/oa_pdf/7a/7f/DOM-17-1033.PMC5034821.pdf
Participant organizations in ALICE RAP can be seenat<http://www.alicerap.eu/about-alicerap/partners.html >.,Non-OADS,/arxiv_data1/oa_pdf/19/04/ADD-110-1625.PMC5034824.pdf
Available: http://www.frac.info[1February2015].,Non-OADS,/arxiv_data1/oa_pdf/5f/22/PS-72-398.PMC5034827.pdf
Available: http://imagej.nih.gov/ij/ [1February2015].,Non-OADS,/arxiv_data1/oa_pdf/5f/22/PS-72-398.PMC5034827.pdf
Avail- able:http://www.frac.info[1February2015].,Non-OADS,/arxiv_data1/oa_pdf/5f/22/PS-72-398.PMC5034827.pdf
projects ’websites: (i) OMOP (http://omop.fnih.org and www.omop.org); (ii) Mini-Sentinel (www.mini- sentinel.org); (iii) the HMO Research Network(www.hmoresearchnetwork.org); (iv) EU-ADR (www.,Non-OADS,/arxiv_data1/oa_pdf/38/f0/PDS-24-897.PMC5034829.pdf
2010; Available at: http://www.mini-sentinel.org [14 April 2015].,Non-OADS,/arxiv_data1/oa_pdf/38/f0/PDS-24-897.PMC5034829.pdf
2013; Available at: http://www.hmoresearch- network.org [14 April 2015].,Non-OADS,/arxiv_data1/oa_pdf/38/f0/PDS-24-897.PMC5034829.pdf
2013; Available at: http://www.cnodes.ca [14 April 2015].,Non-OADS,/arxiv_data1/oa_pdf/38/f0/PDS-24-897.PMC5034829.pdf
(2008) Available at: http://euadr-project.org [14 April 2015].,Non-OADS,/arxiv_data1/oa_pdf/38/f0/PDS-24-897.PMC5034829.pdf
2009; Available at: http://www.imi-pro- tect.eu [14 April 2015].,Non-OADS,/arxiv_data1/oa_pdf/38/f0/PDS-24-897.PMC5034829.pdf
"To complete protein database, we assembled tran- scriptomic data (SRR824147) [51] obtained from DDBJ (http://trace.ddbj.nig.ac.jp/DRASearch/) by using default Trinity [52] settings.",OADS,/arxiv_data1/oa_pdf/e3/ec/PMIC-15-4145.PMC5034830.pdf
Prior to assembly preprocessing of transcriptomic data was done with FASTX Toolkit (http://hannonlab.csh1.edu/fastx_toolkit/) to remove low quality (Q <20) reads.,OADS,/arxiv_data1/oa_pdf/e3/ec/PMIC-15-4145.PMC5034830.pdf
MS/MS spectra were analyzed by MASCOT server (version 2.4) in house (http://www.matrixscience.com/) and the pro- ﬁles were compared with those annotated from T. lutea tran- scriptome database according to a recent publication [51].,OADS,/arxiv_data1/oa_pdf/e3/ec/PMIC-15-4145.PMC5034830.pdf
"In addi- tion, a BLAST (http://www.ncbi.nlm.nih.gov/) database was also used for further detailed analysis as described below.",OADS,/arxiv_data1/oa_pdf/e3/ec/PMIC-15-4145.PMC5034830.pdf
2.9 BLAST annotation We used Blast2GO (V 2.7.2) (http://www.blast2go.com/ b2ghome) for annotation of peptide sequences [54].,OADS,/arxiv_data1/oa_pdf/e3/ec/PMIC-15-4145.PMC5034830.pdf
"Moreover, those sequences were quite similar among alkenone producers which are limited only to the haptophytes in BLAST homolog search by using protein database in Ma- rine Microbial Eukaryote Transcriptome Sequencing Project (http://camera.calit2.net/mmetsp/combinedassemblies.php) (Supporting Information Table 13).",OADS,/arxiv_data1/oa_pdf/e3/ec/PMIC-15-4145.PMC5034830.pdf
Available at http://www.health .belgium.be/ﬁlestore/19089658_EN/HIV-plan_ENG.pdf (accessed 29 May 2015).,Non-OADS,/arxiv_data1/oa_pdf/87/fd/HIV-17-231.PMC5034831.pdf
"T o ensure ampliﬁcation speciﬁcity, we designed two-stage nested PCR primers for mutations in genomic regions (200 bp upstream and 200 bp downstream around the mu- tation) that have a paralogous sequence elsewhere on the genome (i.e.,/226595% sequence identity over 200 bp determined by UCSC BLAT at http://genome.ucsc.edu/cgi-bin/hgBlat).",Non-OADS,/arxiv_data1/oa_pdf/8a/ac/HUMU-36-861.PMC5034833.pdf
"For comparison, common SNPs with population allele frequency over 1% were obtained from dbSNP version 137 as neutral variants and previously known causal variants for DS were collected from the SCN1A variant database at http://www.molgen.ua.ac.be/SCN1AMutations/ [Claes et al., 2009].",OADS,/arxiv_data1/oa_pdf/8a/ac/HUMU-36-861.PMC5034833.pdf
"Protscale provided by the ExPASy server at http://web.expasy.org/protscale/ was used to calculate the possible changes to the protein three-dimensional structures induced by the amino acid alternations [Gasteiger et al., 2005].",OADS,/arxiv_data1/oa_pdf/8a/ac/HUMU-36-861.PMC5034833.pdf
Available at: http://www.fda.,Non-OADS,/arxiv_data1/oa_pdf/24/73/CNCY-123-566.PMC5034834.pdf
Available at: http://www.cap- todayonline.com/letters-november-2014/.,Non-OADS,/arxiv_data1/oa_pdf/24/73/CNCY-123-566.PMC5034834.pdf
"We have previously reported results of a cross- sectional study of airways obstruction among 7579 con-struction and trade workers employed at U.S. Department of Energy (DOE) sites and participating in the Building Trades National Medical Screening Program (BTMED)(https://www.btmed.org) [Dement et al., 2010].",OADS,/arxiv_data1/oa_pdf/22/9f/AJIM-58-1083.PMC5034836.pdf
"Visualization procedures for the manganese in vivo tracer (manganese t-maps), and the method by which t-maps obtained from P2 and P3 were warped onto the image space of P1 that is used for tractography in this study are described elsewhere [Dyrby et al., 2007] and aremade available at http://dig.drcmr.dk/downloads upon publication of this article.",OADS,/arxiv_data1/oa_pdf/0e/2c/HBM-36-4116.PMC5034837.pdf
"The seed ROIs were the same as those used by Dyrby et al., [2007](http://dig.drcmr.dk/downloads) and were manually drawn with the guidance of the three injection sites identi- ﬁed from the (warped) t-maps of the manganese tracer.",OADS,/arxiv_data1/oa_pdf/0e/2c/HBM-36-4116.PMC5034837.pdf
"An alternative approach is the tensor deﬂection method [Lazar et al., 2003] implemented in MedINRIA (Version 1.6, http://www-sop.inria.fr/asclepios/software/MedINRIA), which will be used in this study.",Non-OADS,/arxiv_data1/oa_pdf/0e/2c/HBM-36-4116.PMC5034837.pdf
"Here, we used the probtrackx procedure implemented in FSL (http://fsl.fmrib.ox.ac.uk/ fsl/fsl-4.1.9/fdt/fdt_probtrackx.html; version 4.1.9).",OADS,/arxiv_data1/oa_pdf/0e/2c/HBM-36-4116.PMC5034837.pdf
Retrieved from http://www.currentpsychiatry.com/education-center/education- center/article/challenges-in-recognition-clinical-management-and- treatment-of-bipolar-disorder-at-the-interface-of-psychiatric-medicine-and- primary-care/a3b717e8fc79bbb15d27bf9352f872f5.html.,Non-OADS,/arxiv_data1/oa_pdf/8c/91/JAAN-27-530.PMC5034840.pdf
Retrieved from http://dbsanca.org/docs/APA Bipolar Guidelines.1783155.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/91/JAAN-27-530.PMC5034840.pdf
"Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK55353/ Nierenberg, A.",Non-OADS,/arxiv_data1/oa_pdf/8c/91/JAAN-27-530.PMC5034840.pdf
Andersen Contract grant sponsor: Novo Nordisk Foundation Contract grant sponsor: Lundbeck FoundationReceived 14 January 2015; Accepted 11 May 2015Accepted manuscript online 20 May 2015; Article ﬁrst published online 30 June 2015 in Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/bit.25652/abstract).DOI 10.1002/bit.25652ARTICLE /C2232015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/e4/10/BIT-112-2373.PMC5034845.pdf
Marker positions in the genome were determined based onthe sequence tags in the B73 reference genome (AGPv2;http://www.maizesequence.org/index.html ).,OADS,/arxiv_data1/oa_pdf/22/28/JIPB-58-81.PMC5034846.pdf
"To ﬁne map qVb9-2 , new markers were developed based on the B73 reference genome v2.0 assembly (B73 RefGen_v2;http://www.maizegdb.org/ ).",OADS,/arxiv_data1/oa_pdf/22/28/JIPB-58-81.PMC5034846.pdf
Primers were designed using software Primer 3.0 (http://bioinfo.ut.ee/primer3-0.4.0/) andwere then ampli ﬁed from NIL_maize and NIL_teosinte.,OADS,/arxiv_data1/oa_pdf/22/28/JIPB-58-81.PMC5034846.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3d/00/ndt-12-2367.PMC5034902.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2367–2372Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2367OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11391 7 expanded DMPK  repeats in dizygotic twins  referred for diagnosis of autism versus absence  of expanded DMPK  repeats at screening of  330 children with autism Zuzana Musova1 Miroslava hancarova1 Marketa havlovicova1 radka Pourova1 Michal hrdlicka2 Josef Kraus3 Marie Trkova4 David stejskal4 Zdenek sedlacek1 1Department of Biology and Medical  genetics, 2Department of child  Psychiatry, 3Department of child  Neurology, charles University 2nd  Faculty of Medicine and University  hospital Motol, 4gennet, centre  for Fetal Medicine, Prague, czech  republicAbstract:  Myotonic dystrophy type 1 (DM1) belongs to the broad spectrum of genetic  disorders associated with autism spectrum disorders (ASD).",Non-OADS,/arxiv_data1/oa_pdf/3d/00/ndt-12-2367.PMC5034902.pdf
"Myotonic dystrophy type 1 (DM1) is also often listed among genetic disorders  associated with ASD.2,3 DM1 is an autosomal-dominant disorder with an estimated  prevalence of 1/8,000 and a highly variable spectrum of manifestations progressively correspondence: Zuzana Musova Department of Biology and Medical  genetics, charles University 2nd Faculty  of Medicine and University hospital  Motol, V Uvalu 84, 15006 Prague 5,  czech republic Tel +420 2 2443 3521 email zuzana.musova@fnmotol.c z Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Musova et al Running head recto: Expanded DMPK  repeats in children with autism DOI: http://dx.doi.org/10.2147/NDT.S113917",Non-OADS,/arxiv_data1/oa_pdf/3d/00/ndt-12-2367.PMC5034902.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/3d/00/ndt-12-2367.PMC5034902.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3d/00/ndt-12-2367.PMC5034902.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/df/29/copd-11-2315.PMC5034903.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2315–2319International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2315OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11310 8 Preference for different relaxation techniques by   COPD patients: comparison between six  techniques Michael e hyland,1 David  Mg halpin,2 sue Blake,3  Clare seamark,3 Margaret  Pinnuck,3 David Ward,3 Ben  Whalley,1 Colin J greaves,4  adam l hawkins,5 Dave  seamark3 1school of Psychology, University of  Plymouth, Plymouth, 2Department of  respiratory Medicine, royal Devon  and exeter hospital, exeter, 3honiton  group Practice, honiton, 4University  of exeter Medical school, exeter,   5gsK house, Brentford, UKBackground:  A review of the effectiveness of relaxation techniques for chronic obstructive  pulmonary disease patients has shown inconsistent results, but studies have varied in terms of  technique and outcome measures.",Non-OADS,/arxiv_data1/oa_pdf/df/29/copd-11-2315.PMC5034903.pdf
"Guided imagery Correspondence: David Mg halpin Department of respiratory Medicine,  royal Devon and exeter hospital,  exeter, Devon eX2 5DW, UK email d.halpin@nhs.ne t Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Hyland et al Running head recto: Preference for different relaxation techniques by COPD patients DOI: http://dx.doi.org/10.2147/COPD.S113108 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/df/29/copd-11-2315.PMC5034903.pdf
Or use: http://youtu.be/1F-KmT5qEL UVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/df/29/copd-11-2315.PMC5034903.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/df/29/copd-11-2315.PMC5034903.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/df/29/copd-11-2315.PMC5034903.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 4743–4763International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4743RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S10762 4 Demineralization–remineralization dynamics  in teeth and bone ensanya Ali Abou Neel1–3 Anas Aljabo3 Adam Strange3 Salwa Ibrahim3 Melanie Coathup4 Anne M Y oung3 Laurent Bozec3 vivek Mudera4 1Division of Biomaterials, Operative  Dentistry Department, Faculty of  Dentistry, King Abdulaziz University,   Jeddah, Saudi Arabia; 2Biomaterials  Department, Faculty of Dentistry,   Tanta University, Tanta, egypt;   3Department of Biomaterials and  Tissue engineering, UCL eastman  Dental Institute, London, UK; 4UCL  Institute of Orthopaedics and  Musculoskeletal Sciences, Royal  National Orthopaedic Hospital,   Stanmore, London, UKAbstract:  Biomineralization is a dynamic, complex, lifelong process by which living organ - isms control precipitations of inorganic nanocrystals within organic matrices to form unique  hybrid biological tissues, for example, enamel, dentin, cementum, and bone.",Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
"Enamel apatite, Correspondence: ensanya Ali Abou Neel Division of Biomaterials, Operative  Dentistry Department, Faculty of  Dentistry, King Abdulaziz University,  PO Box 80209, Jeddah 21589,  Saudi Arabia Tel +966 596820208 email eabouneel@kau.edu.s a Journal name: International Journal of Nanomedicine Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Abou Neel et al Running head recto: Demineralization–remineralization dynamics DOI: http://dx.doi.org/10.2147/IJN.S107624",Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
"Available from:  http://www.dentalcare.com/media/en-US/education/ce372/ce372.pd f.  Accessed June 23, 2016.",Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
Available from: http://www.dh.gov.uk/en/ Publicationsand   statistics /Bulletins/Chiefdentalofficersbulletin/ Browsable / DH_486075 3.,OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
"Available from: https://www.rcseng.ac.uk/fds/policy/ documents/fds-report-on-the-state-of-childrens-oral-healt h. Accessed  June 23, 2016.",Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
Available from: http://www.reuters.com/ article/us-dental-device-idUSKCN0QU21C2015082 5.,Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/04/5a/ijn-11-4743.PMC5034904.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/11/f5/opth-10-1825.PMC5034905.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1825–1828Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1825Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S11554 0 Longevity results of modified Hughes procedure  in reconstructing large lower eyelid defects adel galal Zaky hesham Mohamed Fouad  elmazar Mohamed samy abd elaziz Ophthalmology Department, Faculty  of Medicine, Menoufia University,   shebin el-Kom, Menoufia, egyptPurpose:  The purpose of this study was to evaluate the longevity results of modified Hughes  procedure in reconstructing large lower eyelid defects.",Non-OADS,/arxiv_data1/oa_pdf/11/f5/opth-10-1825.PMC5034905.pdf
"The patients who suffered from lower eyelid defects due to either Correspondence: adel galal Zaky Department of Ophthalmology, Faculty  of Medicine, Menoufia University, Yasen  abd al ghafar street, shebin el-Kom,  Menoufia 32511, Egypt Tel +20 10 0618 5456 email adelzaky12@gmail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Zaky et al Running head recto: Longevity results of modified Hughes procedure DOI: http://dx.doi.org/10.2147/OPTH.S115540",Non-OADS,/arxiv_data1/oa_pdf/11/f5/opth-10-1825.PMC5034905.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/11/f5/opth-10-1825.PMC5034905.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/11/f5/opth-10-1825.PMC5034905.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e8/f5/copd-11-2209.PMC5034906.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2209–2210International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2209Letteropen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/COPD.S11786 1 Noninvasive mechanical ventilation on the ward  for severe COPD: still unresolved question of  balance among safety and drawbacks?",Non-OADS,/arxiv_data1/oa_pdf/e8/f5/copd-11-2209.PMC5034906.pdf
"It could be relevant to know the authors’ opinion about the potential role of Correspondence: Angelo Petroianni Department of Cardiovascular and  respiratory Diseases, Policlinico  Umberto I, Sapienza University  of rome Viale del Policlinico 155,  00162 rome, Italy tel +39 06 49979062 email angelo.petroianni@uniroma1.i t Journal name: International Journal of COPD Article Designation: Letter Y ear: 2016 Volume: 11 Running head verso: Petroianni and Esquinas Running head recto: Noninvasive mechanical ventilation on the ward for severe COPD DOI: http://dx.doi.org/10.2147/COPD.S117861",Non-OADS,/arxiv_data1/oa_pdf/e8/f5/copd-11-2209.PMC5034906.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/e8/f5/copd-11-2209.PMC5034906.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/f5/copd-11-2209.PMC5034906.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3e/5a/opth-10-1803.PMC5034907.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1803–1810Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1803Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S11737 2 Corneal stromal demarcation line after collagen  cross-linking in corneal ectatic diseases: a review  of the literature Leopoldo Spadea emanuele T onti enzo Maria vingolo Department of Medico-Surgical  Sciences and Biotechnologies,   Sapienza University of Rome,   Latina,  italyAbstract:  Collagen cross-linking (CXL) is a relatively new conservative approach for  progressive corneal ectasia, which is able to strengthen corneal tissue reforming new covalent  bonds.",Non-OADS,/arxiv_data1/oa_pdf/3e/5a/opth-10-1803.PMC5034907.pdf
"It usually appears as an isolated disease, but it has been  associated with a number of ocular and systemic pathologies, including vernal disease, Correspondence: Leopoldo Spadea via Benozzo Gozzoli 34, 00142  Rome, italy Tel +39 6 519 3220 Fax +39 6 8865 7818 email leopoldo.spadea@uniroma1.i t Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Spadea et al Running head recto: Corneal stromal demarcation line after CXL DOI: http://dx.doi.org/10.2147/OPTH.S117372",Non-OADS,/arxiv_data1/oa_pdf/3e/5a/opth-10-1803.PMC5034907.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/3e/5a/opth-10-1803.PMC5034907.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3e/5a/opth-10-1803.PMC5034907.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/25/5f/ijwh-8-489.PMC5034908.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2016:8 489–496International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  489OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S11276 8 Primary dysmenorrhea magnitude, associated risk  factors, and its effect on academic performance:  evidence from female university students in ethiopia solomon Hailemeskel1 asrate Demissie2 nigussie assefa3 1Department of Midwifery, college  of Health science, Institute of  Medicine and Health science, Debre  Berhan University, Debre Berhan,   ethiopia; 2Department of nursing  and Midwifery, school of allied  Health science, college of Health  sciences, addis ababa University,   addis ababa, ethiopia; 3Department  of reproductive Health and Health  service Management, school of Public  Health, college of Health sciences,   addis ababa University, addis ababa,   ethiopiaBackground:  Primary dysmenorrhea (PD) is the most common gynecologic compliant  among adolescent females.",Non-OADS,/arxiv_data1/oa_pdf/25/5f/ijwh-8-489.PMC5034908.pdf
"Keywords:  academic performance, risk factors, dysmenorrhea, Ethiopia, adolescents, young,  higher institution Introduction Primary dysmenorrhea (PD) is pain during menstrual bleeding without organ  pathological abnormalities.1 It usually begins during adolescence.2,3 Affected females correspondence: nigussie assefa PO Box 17193, addis ababa, ethiopia Tel +251 912 142 509 email nigussie19@gmail.co m Journal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2016 Volume: 8 Running head verso: Hailemeskel et al Running head recto: PD magnitude, risk factors, and effect on academic performance DOI: http://dx.doi.org/10.2147/IJWH.S112768",Non-OADS,/arxiv_data1/oa_pdf/25/5f/ijwh-8-489.PMC5034908.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/25/5f/ijwh-8-489.PMC5034908.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/25/5f/ijwh-8-489.PMC5034908.pdf
"Available from: http://www.ijcm.or g. Accessed March 17, 2016.",Non-OADS,/arxiv_data1/oa_pdf/25/5f/ijwh-8-489.PMC5034908.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ac/dc/ndt-12-2381.PMC5034909.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2381–2386Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2381Case seriesopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11108 3 Varenicline improves motor and cognitive  symptoms in early Huntington’s disease ailsa L McGregor1,2 Jo Dysart3 Malcolm D Tingle4 Bruce r russell1,2 rob r Kydd5 Gregory Finucane2 1New Zealand’s National school  of Pharmacy, Division of Health  sciences, University of Otago,   Dunedin, New Zealand; 2Centre  for Brain research, University  of auckland, 3Liaison Psychiatry,   auckland City Hospital, 4Department  of Pharmacology and Clinical  Pharmacology, 5Department of  Psychological Medicine, University  of auckland, auckland, New ZealandAbstract:  The aim of this study was to describe the effects of varenicline, a smoking cessation  aid that acts as a nicotinic agonist, on cognitive function in patients with early clinical  Huntington’s disease (HD) who were current smokers.",Non-OADS,/arxiv_data1/oa_pdf/ac/dc/ndt-12-2381.PMC5034909.pdf
"Combined with the progressive decline in cognitive function, these behavioral  symptoms have a significant impact on disease coping, interpersonal relationships,  judgment, and the ability to live independently.7 The cognitive deficits associated with normal aging and age-related neurode - generative diseases are proposed to be caused by impairments in cholinergic neu - rotransmission, in part due to a reduction in the number of nicotinic acetylcholine  receptors (nAChRs).8,9 However, postmortem analysis of the HD brain shows no  change in the number of nAChRs, rather a significant loss of the neurotransmitter  acetylcholine, its key synthetic enzyme (choline acetyl transferase), and transporter  (vesicular acetylcholine transporter).10–13 These neurochemical changes within the  brain correlate with cognitive defects3 and support the hypothesis that dysfunctional Correspondence: ailsa L McGregor New Zealand’s National school of  Pharmacy, Division of Health sciences,  University of Otago, PO Box 56,  Dunedin 9054, New Zealand Tel +64 3 479 4235 email ailsa.mcgregor@otago.ac.n zJournal name: Neuropsychiatric Disease and Treatment Article Designation: Case Series Y ear: 2016 Volume: 12 Running head verso: McGregor et al Running head recto: Varenicline in HD DOI: http://dx.doi.org/10.2147/NDT.S111083",Non-OADS,/arxiv_data1/oa_pdf/ac/dc/ndt-12-2381.PMC5034909.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/ac/dc/ndt-12-2381.PMC5034909.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ac/dc/ndt-12-2381.PMC5034909.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9b/08/cia-11-1287.PMC5034910.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1287–1299Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1287OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11571 1 effects of combined physical and cognitive  training on fitness and neuropsychological  outcomes in healthy older adults laurence Desjardins- Crépeau1,2 nicolas Berryman2,3 sarah A Fraser4 Thien T uong Minh Vu5,6 Marie-Jeanne Kergoat2,6 Karen Zh li7 laurent Bosquet8 louis Bherer2,7 1Department of Psychology, University  of Quebec at Montreal, Montreal,   QC, Canada; 2research Center,   Institut universitaire de gériatrie de  Montréal, Montreal, QC, Canada;   3Department of sports studies,   Bishop’s University, sherbrooke, QC,   Canada; 4Interdisciplinary school  of health sciences, University  of Ottawa, Ottawa, On , Canada;   5research Center, Centre hospitalier  de l’Université de Montréal, Montreal,   QC, Canada; 6Faculty of Medicine,   Université de Montréal, Montreal, QC,   Canada; 7Department of Psychology  and P erFOrM Centre, Concordia  University, Montréal, QC, Canada;   8Faculté des sciences du sport,   Université de Poitiers, Poitiers, FrancePurpose:  Physical exercise and cognitive training have been shown to enhance cognition  among older adults.",Non-OADS,/arxiv_data1/oa_pdf/9b/08/cia-11-1287.PMC5034910.pdf
"The present study aims at examining the effects of the combination of a  physical training regimen and a cognitive training intervention on cognitive perfor - mance in healthy older individuals.Correspondence: laurence Desjardins- Crépeau Centre de recherche de l’Institut  universitaire de gériatrie de Montréal,  4565, chemin Queen-Mary, Montréal,  QC h3W 1W5, Canada Tel +1 514 340 3540 ext 4148 Fax +1 514 340 3530 email desjardins.laurence@gmail.co m Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Desjardins-Crépeau et al Running head recto: Combined physical and cognitive training in older adults DOI: http://dx.doi.org/10.2147/CIA.S115711",Non-OADS,/arxiv_data1/oa_pdf/9b/08/cia-11-1287.PMC5034910.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/9b/08/cia-11-1287.PMC5034910.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/9b/08/cia-11-1287.PMC5034910.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e3/dc/ijn-11-4777.PMC5034911.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 4777–4785International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4777OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11256 0 Functionalized immunostimulating complexes  with protein a via lipid vinyl sulfones to  deliver cancer drugs to trastuzumab-resistant  her2-overexpressing breast cancer cells Fernando rodríguez- serrano1,* Nuria Mut-salud1,* T eresa cruz-Bustos2 Mercedes gomez-samblas2 esther carrasco1 Jose Manuel garrido3 F Javier lópez-Jaramillo4 Francisco santoyo- gonzalez4 antonio Osuna2 1Institute of Biopathology and  regenerative Medicine, 2Molecular  Biochemistry and Parasitology  research group, Department of  Parasitology, Faculty of sciences,   Institute of Biotechnology, University  of granada, 3Department of  cardiovascular surgery, Virgen de  las Nieves hospital, 4Department  of Organic chemistry, Faculty of  sciences, Institute of Biotechnology,   University of granada, granada, spain *These authors contributed equally  to this workBackground:  Around 20%–30% of breast cancers overexpress the proto-oncogene human  epidermal growth receptor 2 (HER2), and they are characterized by being very invasive.",Non-OADS,/arxiv_data1/oa_pdf/e3/dc/ijn-11-4777.PMC5034911.pdf
"Currently, there exist a wide diversity of NPs, including some  of inorganic nature such as iron oxide and gold NPs.2correspondence: antonio Osuna Molecular Biochemistry and Parasitology  research group, University of granada,  Mecenas Building, campus Fuentenueva  s/N, 18071 granada, spain Tel +34 958 244 163 Fax +34 958 243 174 email aosuna@ugr.e s Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Rodríguez-Serrano et al Running head recto: ISCOMs for selective delivery of cancer drugs DOI: http://dx.doi.org/10.2147/IJN.S112560",Non-OADS,/arxiv_data1/oa_pdf/e3/dc/ijn-11-4777.PMC5034911.pdf
The  authors thank http://www.somersault1824.com/resources /  for allowing the use of its platform in the design of the  figures.,Non-OADS,/arxiv_data1/oa_pdf/e3/dc/ijn-11-4777.PMC5034911.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/e3/dc/ijn-11-4777.PMC5034911.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e3/dc/ijn-11-4777.PMC5034911.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).ClinicoEconomics and Outcomes Research 2016:8 485–493ClinicoEconomics and Outcomes Research Dovepress submit your manuscript | www.dovepress.com Dovepress  485 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEOR.S110553Economic evaluation of eribulin as second-line  treatment for metastatic breast cancer in   South Korea Gabriel Tremblay1 Unnati Majethia2 Janis L Breeze3 Ilias Kontoudis4 Jeongae Park5 1Geneconomics Inc., Lévis, Quebec,   Canada; 2Global Value and Access, Eisai  Inc., Woodcliff Lake, NJ, 3T ufts Clinical  and Translational Science Institute,   T ufts University, and Institute for Clinical Research and Health Policy Studies, T ufts Medical Center, Boston,  MA, USA;  4Global Value and Access,   Eisai Limited, Hatfield, Hertfordshire,  UK;  5Eisai Korea Inc., Gangnam-gu,   Seoul, South KoreaBackground: Metastatic breast cancer (MBC) is associated with poor prognosis, particularly  for those patients with human epidermal growth factor receptor (HER2)-negative tumor.",Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
"3Correspondence: Unnati Majethia Eisai Inc., 155 Tice Boulevard, Woodcliff Lake, NJ 07677, USATel +1 551 999 0514Fax +1 201 949 4011Email unnati_majethia@eisai.comJournal name: ClinicoEconomics and Outcomes Research Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 8Running head verso: Tremblay et alRunning head recto: Economic evaluation of eribulin for MBC in South KoreaDOI: http://dx.doi.org/10.2147/CEOR.S110553",Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
"ClinicoEconomics and Outcomes Research 2016:8submit your manuscript | www.dovepress.com Dovepress Dovepress ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinicoeconomics-and-outcomes-research-journalClinicoEconomics and Outcomes Research is an international, peer- reviewed open-access journal focusing on health technology assess-ment, pharmacoeconomics and outcomes research in the areas of   diagnosis, medical devices, and clinical, surgical and pharmacological intervention.",Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 493 Economic evaluation of eribulin for MBC in South Korea Most importantly, vinorelbine was not included in Study  301, and thus, estimates for the efficacy of vinorelbine as  second-line therapy were not available.",Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
Available from: http://seer.cancer.gov/statfacts/html/breast.html.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
mfds.go.kr: https://ezdrug.mfds.go.kr/#!CCBAA03F010.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
Available from: https://authentication.khapps.com/.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
Avail-able from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id= CP-2012-PI-02654-1&d= 2015070116114622412.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
Available from: http://www.nhic.or.kr/static/html/wbd/g/a/wbdga0101.html.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
Available from: http://www.ispor.org/peguidelines/source/Korean_PE_Guidelines_Korean_Version.pdf.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
Available from: http://www.who.int/choice/costs/ en/.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
Available from: http://www.inflation.eu/inflation-rates/south-korea/historic-inflation/cpi-inflation-south-korea.aspx.,Non-OADS,/arxiv_data1/oa_pdf/76/01/ceor-8-485.PMC5034912.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/2c/dc/ijnrd-9-235.PMC5034913.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/2c/dc/ijnrd-9-235.PMC5034913.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of Nephrology and Renovascular Disease 2016:9 235–241International Journal of Nephrology and Renovascular Disease Dovepress submit your manuscript | www.dovepress.com Dovepress 235 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJNRD.S115701 Calciphylaxis in peritoneal dialysis patients: a  single center cohort study Yanchen Zhang1 Kristin M Corapi2 Maria Luongo2  Ravi Thadhani2 Sagar U Nigwekar2 1Harvard Summer Research Program  in Kidney Medicine, Boston, MA,   USA; 2Division of Nephrology,   Massachusetts General Hospital,  Boston, MA, USABackground: Calciphylaxis is a rare but devastating condition in end-stage renal disease  (ESRD) patients.",Non-OADS,/arxiv_data1/oa_pdf/2c/dc/ijnrd-9-235.PMC5034913.pdf
"3,5–7 Cinacalcet has been reported to reduce the risk Correspondence: Sagar U Nigwekar Division of Nephrology, Massachusetts General Hospital, 165 Cambridge Street, Suite 302, Boston, MA 02114, USATel +1 617 726 7872Fax +1 617 724 1122Email snigwekar@mgh.harvard.eduJournal name: International Journal of Nephrology and Renovascular Disease Article Designation: ORIGINAL RESEARCH Y ear: 2016V olume: 9Running head verso: Zhang et alRunning head recto: Calciphylaxis in peritoneal dialysisDOI: http://dx.doi.org/10.2147/IJNRD.S115701",Non-OADS,/arxiv_data1/oa_pdf/2c/dc/ijnrd-9-235.PMC5034913.pdf
"International Journal of Nephrology and Renovascular Disease 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of Nephrology and Renovascular Disease Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journalThe International Journal of Nephrology and Renovascular Disease is   an international, peer-reviewed open access journal focusing on the  pathophysiology of the kidney and vascular supply.",Non-OADS,/arxiv_data1/oa_pdf/2c/dc/ijnrd-9-235.PMC5034913.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published   authors.Dovepress 241 Calciphylaxis in peritoneal dialysis 14.,Non-OADS,/arxiv_data1/oa_pdf/2c/dc/ijnrd-9-235.PMC5034913.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c0/b3/mder-9-331.PMC5034914.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c0/b3/mder-9-331.PMC5034914.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2016:9 331–339Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 331 REviEw open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S96167 Robotic magnetic navigation for ablation of human  arrhythmias Antoine Da Costa Jean Baptiste Guichard Cécile Roméyer-Bouchard Antoine GerbayKarl isaaz North Hospital, Cardiology  Department University of Saint Etienne Jean Monnet,  Saint Etienne Cedex 2, FranceAbstract:  Radiofrequency treatment represents the first choice of treatment for arrhythmias,  in particular complex arrhythmias and especially atrial fibrillation, due to the greater benefit/ risk ratio compared to antiarrhythmic drugs.",Non-OADS,/arxiv_data1/oa_pdf/c0/b3/mder-9-331.PMC5034914.pdf
"Two Correspondence: Antoine Da Costa North Hospital; Cardiology Department University of Saint Etienne Jean Monnet, FRANCE 42055 Saint Etienne Cedex 2, FranceTel +33 4 77 82 81 13Fax +33 4 77 82 81 64Email dakosta@orange.frJournal name: Medical Devices: Evidence and Research Article Designation: ReviewY ear: 2016V olume: 9Running head verso: Da Costa et alRunning head recto: Robotic magnetic navigation for ablation of human arrhythmiasDOI: http://dx.doi.org/10.2147/MDER.S96167",Non-OADS,/arxiv_data1/oa_pdf/c0/b3/mder-9-331.PMC5034914.pdf
"Medical Devices: Evidence and Research 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/c0/b3/mder-9-331.PMC5034914.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/36/4f/ndt-12-2363.PMC5034915.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2363–2366Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2363Case repor Topen access to scientific and medical research open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11214 5 epilepsia partialis continua present with shoulder  joint-trunk-hip joint rhythmic clonic seizure:  a case report Yudan Lv Zan Wang Fengna Chu Chang Liu Hongmei Meng Department of Neurology and  Neuroscience Center, The First  Hospital of Jilin University, ChangChun,   people’s republic of ChinaAbstract:  Epilepsia partialis continua (EPC) is a particular type of epilepsy which is distinguished  from “common epilepsy” by its characteristic semiological features.",Non-OADS,/arxiv_data1/oa_pdf/36/4f/ndt-12-2363.PMC5034915.pdf
"A family member of the patient reported that the patient had Correspondence: Hongmei Meng Department of Neurology and  Neuroscience Center, The First Hospital  of Jilin University, 71 Xinmin street,  ChangChun, people’s republic of China Tel +86 136 5436 2588 email hongmeiyp@126.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Case report Y ear: 2016 Volume: 12 Running head verso: Lv et al Running head recto: Shoulder joint-trunk-hip joint rhythmic clonic seizure DOI: http://dx.doi.org/10.2147/NDT.S112145",Non-OADS,/arxiv_data1/oa_pdf/36/4f/ndt-12-2363.PMC5034915.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/36/4f/ndt-12-2363.PMC5034915.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/36/4f/ndt-12-2363.PMC5034915.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e8/a1/dddt-10-2997.PMC5034916.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2997–3003Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2997Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S9418 8 Profile of adalimumab and its potential in the  treatment of uveitis Stephen J Balevic C Egla Rabinovich Department of Pediatric  Rheumatology, Duke University  Medical Center, Durham, NC, USAAbstract:  Uveitis refers to the presence of intraocular inflammation, and as a strict definition  compromises the iris and ciliary body anteriorly and the choroid posteriorly (the uvea).",Non-OADS,/arxiv_data1/oa_pdf/e8/a1/dddt-10-2997.PMC5034916.pdf
"The SUN criteria also further classify uveitis based on the Correspondence: C Egla Rabinovich Department of Pediatric Rheumatology,  Duke University Medical Center, 2301  erwin Road, CHC, T-level, Durham,  NC 27710, USA Tel +1 919 684 4291 Fax +1 919 684 6616 email egla.rabinovich@duke.ed u Journal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Balevic and Rabinovich Running head recto: Profile of adalimumab and its potential in the treatment of uveitis DOI: http://dx.doi.org/10.2147/DDDT.S94188",Non-OADS,/arxiv_data1/oa_pdf/e8/a1/dddt-10-2997.PMC5034916.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/e8/a1/dddt-10-2997.PMC5034916.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/a1/dddt-10-2997.PMC5034916.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/ee/84/imcrj-9-295.PMC5034917.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/ee/84/imcrj-9-295.PMC5034917.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Medical Case Reports Journal 2016:9 295–299International Medical Case Reports Journal Dovepress submit your manuscript | www.dovepress.com Dovepress 295 CASE REPORT open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IMCRJ.S115315Atypical scleromyxedema presenting with  cutaneous and cardiovascular manifestations Sue-Ann T eh¹ David A Kandiah² 1Department of Health Western  Australia, Bunbury Hospital, Bunbury,   ²School of Psychiatry and Clinical Neurosciences, Faculty of Medicine,  Dentistry and Health Sciences,  University of Western Australia,  Crawley,  WA,   AustraliaAbstract:  Scleromyxedema is part of a group of cutaneous mucinoses, characterized by a  generalized papular eruption, dermal mucin deposition, and an increase in dermal collagen.",Non-OADS,/arxiv_data1/oa_pdf/ee/84/imcrj-9-295.PMC5034917.pdf
"Correspondence: David A Kandiah School of Psychiatry and Clinical Neurosciences, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, PO Box 1293, Bondi Junction, NSW 1355, AustraliaTel +61 4488 01141Fax +61 2903 41241Email davidkandiah@doctor.comJournal name: International Medical Case Reports Journal Article Designation: CASE REPORTY ear: 2016V olume: 9Running head verso: Teh and KandiahRunning head recto: Atypical scleromyxedemaDOI: http://dx.doi.org/10.2147/IMCRJ.S115315",Non-OADS,/arxiv_data1/oa_pdf/ee/84/imcrj-9-295.PMC5034917.pdf
"International Medical Case Reports Journal 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/international-medical-case-reports-journal-journalThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/ee/84/imcrj-9-295.PMC5034917.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 299 Atypical scleromyxedema  8.,Non-OADS,/arxiv_data1/oa_pdf/ee/84/imcrj-9-295.PMC5034917.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/df/ee/ppa-10-1889.PMC5034918.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1889–1902Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1889OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10869 9 Efficacy and safety of Chinese herbal medicine  for chronic prostatitis associated with damp-heat  and blood-stasis syndromes: a meta-analysis  and literature review Zhiqiang Wang1 lei Yuan1 Y ongchuan Wang2 Baizhi Yang1 Xiaohong Dong1 Zhaowang gao3 1Department of Urology, Shouguang  hospital of Traditional chinese  Medicine, Shouguang, 2Department  of Urology, Weifang Traditional  Chinese Hospital, Weifang,   3Department of Urology, Shandong  University of Traditional Chinese  Medicine Affiliated Hospital,   Shandong, People’s Republic   of chinaObjective:  The aim of this meta-analysis and systematic review is to evaluate the safety and  efficacy of Chinese herbal medicine (CHM) for chronic prostatitis (CP) associated with damp- heat and blood-stasis syndromes.",Non-OADS,/arxiv_data1/oa_pdf/df/ee/ppa-10-1889.PMC5034918.pdf
"Keywords:  chronic prostatitis, meta-analysis, damp-heat and blood-stasis syndromes, traditional  Chinese medicine Introduction Chronic prostatitis (CP), a frequently occurring disease with a complex and  heterogeneous etiology, is characterized by high prevalence, frequent recurrence, low  cure rate, and severe impairment of quality of life.1 In many Asian countries, particularly in the People’s Republic of China, Chinese  herbal medicine (CHM) is widely used as an alternative or complement to conventional correspondence: Zhiqiang Wang Department of Urology, Shouguang  hospital of Traditional chinese  Medicine, Shouguang 262700,  People’s Republic of China Tel +86 137 9161 2182 email TcMwangzhiqiang@163.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Wang et al Running head recto: A meta-analysis of CHM for chronic prostatitis DOI: http://dx.doi.org/10.2147/PPA.S108699",Non-OADS,/arxiv_data1/oa_pdf/df/ee/ppa-10-1889.PMC5034918.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/df/ee/ppa-10-1889.PMC5034918.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/88/5f/copd-11-2269.PMC5034919.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2269–2286International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2269OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10423 8 The effect of domiciliary noninvasive ventilation  on clinical outcomes in stable and recently  hospitalized patients with COPD: a systematic  review and meta-analysis Janine Dretzke1 David Moore1 Chirag Dave2 rahul Mukherjee2 Malcolm J Price1 sue Bayliss1 Xiaoying Wu1 rachel e Jordan1 alice M T urner2,3 1Institute of applied health research,   College of Medical and Dental  sciences, University of Birmingham,   edgbaston, 2heart of england  nhs  Foundation Trust, heartlands  hospital, 3Queen elizabeth hospital  research laboratories, University  of Birmingham, edgbaston,   Birmingham, UKIntroduction:  Noninvasive ventilation (NIV) improves survival among patients with  hypercapnic respiratory failure in hospital, but evidence for its use in domiciliary settings is  limited.",Non-OADS,/arxiv_data1/oa_pdf/88/5f/copd-11-2269.PMC5034919.pdf
"Exacerbations are a key cause of increased morbidity, mortality, and poor health status, Correspondence: David Moore Institute of applied health research,  College of Medical and Dental sciences,  University of Birmingham, edgbaston,  Birmingham B15 2TT, UK Tel +44 121 414 7449 email d.j.moore@bham.ac.u k Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Dretzke et al Running head recto: Systematic review of domiciliary noninvasive ventilation in COPD DOI: http://dx.doi.org/10.2147/COPD.S104238",Non-OADS,/arxiv_data1/oa_pdf/88/5f/copd-11-2269.PMC5034919.pdf
Available from: http://www.crd.york.ac.uk/ PROSPERO/display_record.asp?ID=CRD42012003286.,Non-OADS,/arxiv_data1/oa_pdf/88/5f/copd-11-2269.PMC5034919.pdf
Available from: http://www.cochrane-handbook.org /.,OADS,/arxiv_data1/oa_pdf/88/5f/copd-11-2269.PMC5034919.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/88/5f/copd-11-2269.PMC5034919.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/88/5f/copd-11-2269.PMC5034919.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4a/4a/opth-10-1819.PMC5034920.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1819–1824Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1819Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S11607 3 short wave–automated perimetry (sW aP) versus  optical coherence tomography in early detection  of glaucoma adel galal Zaky1 ahmed Tarek Yassin2 saber hamed el sayid1 1Ophthalmology Department, Faculty  of Medicine, Menoufia University,   shebin el Kom, Menoufia, egypt;   2Ophthalmology Department,   Banha educational hospital, Banha,   el Kalyobia, egyptObjective:  To assess the role and diagnostic effectiveness of optical coherence tomography  (OCT) and short wave–automated perimetry (SWAP) to distinguish between normal, glaucoma  suspects, and surely diagnosed glaucomatous eye.",Non-OADS,/arxiv_data1/oa_pdf/4a/4a/opth-10-1819.PMC5034920.pdf
"Optical coherence tomography (OCT) is a noninvasive imaging modality that  uses low-coherence light to obtain a high-resolution cross-section of anterior and Correspondence: adel galal Zaky Department of Ophthalmology, Faculty  of Medicine, Menoufia University, Yasen  abd el ghafar street, shebein el Kom,  32511, Menoufia, Egypt Tel +20 100 618 5456 email a delzaky12@gmail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Zaky et al Running head recto: SWAP versus OCT DOI: http://dx.doi.org/10.2147/OPTH.S116073",Non-OADS,/arxiv_data1/oa_pdf/4a/4a/opth-10-1819.PMC5034920.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/4a/4a/opth-10-1819.PMC5034920.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4a/4a/opth-10-1819.PMC5034920.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/02/5d/ijwh-8-497.PMC5034921.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2016:8 497–504International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  497RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S10098 7 Managing hyperthyroidism in pregnancy: current  perspectives Stine Linding Andersen1,2 Peter Laurberg1,3,† 1Department of endocrinology,   Aalborg University Hospital,   2Department of Clinical Biochemistry,   Aalborg University Hospital,   3Department of Clinical Medicine,   Aalborg University, Aalborg, Denmark †Peter Laurberg passed away on  June 20, 2016Abstract:  Hyperthyroidism in women who are of childbearing age is predominantly of  autoimmune origin and caused by Graves’ disease.",Non-OADS,/arxiv_data1/oa_pdf/02/5d/ijwh-8-497.PMC5034921.pdf
"Keywords:  thyroid, hyperthyroidism, Graves’ disease, pregnancy, antithyroid drug, fetal  programming Introduction Hyperthyroidism is defined by abnormally high levels of thyroid hormone caused  by an increased synthesis and secretion of thyroid hormone from the thyroid gland.1  The term “thyrotoxicosis”, on the other hand, is used to describe “excess of thyroid  hormone”, and this can be due to an increased synthesis of thyroid hormone in the  thyroid gland (hyperthyroidism), but may also occur in the absence of hyperthyroidism,  eg, in patients with leakage of thyroid hormone from the thyroid gland (thyroiditis)  or in patients with excess intake of thyroid hormone.1 Careful management and control of patients suffering from hyperthyroidism are  important to prevent the possible complications related to the disease itself or to the  treatment.1–3 A special situation is hyperthyroidism in women of reproductive age who  are or may in the future become pregnant.4,5 Hyperthyroidism in pregnancy is a special  clinical situation because physiological changes related to the pregnant state challenge  the interpretation of thyroid function test and because potential complications related to Correspondence: Stine Linding Andersen Department of endocrinology,  Aalborg University Hospital, Søndre  Skovvej 15, Aalborg 9000, Denmark Tel +45 97 66 36 85 email stine.a@rn.d k Journal name: International Journal of Women’s Health Article Designation: Review Y ear: 2016 Volume: 8 Running head verso: Andersen and Laurberg Running head recto: Hyperthyroidism in pregnancy DOI: http://dx.doi.org/10.2147/IJWH.S100987",Non-OADS,/arxiv_data1/oa_pdf/02/5d/ijwh-8-497.PMC5034921.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/02/5d/ijwh-8-497.PMC5034921.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/02/5d/ijwh-8-497.PMC5034921.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a0/07/cia-11-1263.PMC5034922.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1263–1276Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1263OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11109 7 Digital life storybooks for people with dementia  living in care homes: an evaluation Ponnusamy subramaniam1 Bob Woods2 1health Psychology Programme,   University Kebangsaan Malaysia, Kuala  lumpur, Malaysia; 2Dementia services  Development Centre Wales, Bangor  University, Bangor, gwynedd, UKBackground and aim:  There is increasing interest in using information and communication  technology to help older adults with dementia to engage in reminiscence work.",Non-OADS,/arxiv_data1/oa_pdf/a0/07/cia-11-1263.PMC5034922.pdf
"This application has taken a variety of forms,  such as an interactive multimedia storytelling device,4,5 multimedia biographies,6,7  networked reminiscence systems,8 media “memory lane”,9 Y ouTube and Internet- based reminiscence work,10 personalized reminiscence photograph videos,11 networked  videophones,12 personalized multimedia systems,13 and digital life stories using life- logging entities.14 The contents of the reminiscence materials used range from general4  to highly personalized.15Correspondence: Bob Woods Dementia services Development Centre  Wales, Bangor University, Ardudwy,  holyhead road, Bangor, gwynedd  ll57 2PZ, UK Tel +44 1248 383 719 email b.woods@bangor.ac.u k Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Subramaniam and Woods Running head recto: Digital life storybooks and dementia DOI: http://dx.doi.org/10.2147/CIA.S111097",Non-OADS,/arxiv_data1/oa_pdf/a0/07/cia-11-1263.PMC5034922.pdf
"Available from: http://www.scie.org.uk/publications/ictfordementia/ index.as p. Accessed April 18, 2016.",OADS,/arxiv_data1/oa_pdf/a0/07/cia-11-1263.PMC5034922.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/a0/07/cia-11-1263.PMC5034922.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/a0/07/cia-11-1263.PMC5034922.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/eb/c0/copd-11-2305.PMC5034923.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2305–2313International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2305OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11386 8 Influence of country-level differences on COPD  prevalence shawn D aaron1 andrea s gershon2 Yuan gao1 Jenna Yang1 ga Whitmore1,3 On behalf of the Canadian  Respiratory Research  network 1Ottawa hospital research Institute,   University of Ottawa, Ottawa,   2Sunnybrook Research Institute,   University of T oronto, ON, 3Desautels  Faculty of Management, McGill  University, Montreal, QC, CanadaPurpose:  Studies suggest that COPD prevalence may vary between countries.",Non-OADS,/arxiv_data1/oa_pdf/eb/c0/copd-11-2305.PMC5034923.pdf
"Recent  improvements in the quality of studies are likely attributable to the Burden of Obstruc - tive Lung Disease (BOLD) initiative, which developed and published instructions for  a standard protocol and methodology for COPD prevalence studies.1 The quality of  COPD prevalence studies has similarly improved because the Global initiative for  chronic Obstructive Lung Disease (GOLD) provided investigators with a standard  framework for diagnosing COPD.2 Numerous COPD prevalence studies across many countries have shown that being  male, older, and a former or current smoker are consistent risk factors associated with  COPD.3,4 We subsequently refer to age, sex, smoking status, and smoking amount Correspondence: shawn D aaron The Ottawa hospital, general  Campus, 501 Smyth Road, Ottawa,  On K1h 8l6, Canada Tel +1 613 739 6636 Fax +1 613 739 6807 email saaron@ohri.c a Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Aaron et al Running head recto: Country differences and COPD prevalence DOI: http://dx.doi.org/10.2147/COPD.S113868",Non-OADS,/arxiv_data1/oa_pdf/eb/c0/copd-11-2305.PMC5034923.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/eb/c0/copd-11-2305.PMC5034923.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/eb/c0/copd-11-2305.PMC5034923.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/98/56/cia-11-1301.PMC5034924.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1301–1307Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1301OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11504 2 Efficacy and safety of tamsulosin hydrochloride  0.2 mg and combination of tamsulosin  hydrochloride 0.2 mg plus solifenacin succinate  5 mg after transurethral resection of the prostate:  a prospective, randomized controlled trial Yu Seob Shin1,* Li Tao Zhang1,* Jae Hyung Y ou1 In Sung Choi1 Chen Zhao2 Jong Kwan Park1 1Department of Urology, Chonbuk  National University and Research  Institute of Clinical Medicine of  Chonbuk National University- Biomedical Research Institute  and Medical Device Clinical Trial  Center of Chonbuk National  University, Jeonju, Republic of Korea;   2Department of Urology, Renji  Hospital, Shanghai Jiao T ong University  School of Medicine, and Shanghai  Institute of Andrology, Shanghai,   People’s Republic of China *These authors contributed equally  to this workObjective:  The objective of this study was to evaluate the safety and efficacy of tamsulosin  hydrochloride 0.2 mg (TAM) and its combination with solifenacin succinate 5 mg (SOL) after  transurethral resection of the prostate (TURP).",Non-OADS,/arxiv_data1/oa_pdf/98/56/cia-11-1301.PMC5034924.pdf
"Bladder outlet obstruction resulting  from BPH can directly lead to voiding and postvoiding LUTS.2 Additionally, LUTS  have adverse effects on health-related quality of life (QoL), including interference Correspondence: Jong Kwan Park Department of Urology, Chonbuk  National University and Research  Institute of Clinical Medicine of Chonbuk  National University-Biomedical Research  Institute and Medical Device Clinical Trial  Center of Chonbuk National University,  Geonji-Ro 20, Deokjin-Gu, Jeonju 54907,  republic of Korea Tel +82 63 250 1510 Fax +82 63 250 1564 email rain@chonbuk.ac.k r Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Shin et al Running head recto: Randomized clinical trial of tamsulosin and solifenacin after TURP DOI: http://dx.doi.org/10.2147/CIA.S115042",Non-OADS,/arxiv_data1/oa_pdf/98/56/cia-11-1301.PMC5034924.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/98/56/cia-11-1301.PMC5034924.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/98/56/cia-11-1301.PMC5034924.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1277–1286Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1277OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11192 7 Tai chi qigong as a means to improve night-time  sleep quality among older adults with cognitive  impairment: a pilot randomized controlled trial Aileen WK Chan Doris sF Yu KC Choi Diana TF lee Janet Wh sit helen Yl Chan The nethersole school of n ursing,   The Chinese University of hong Kong,   hong Kong sAr, People’s republic  of ChinaPurpose:  Age-related cognitive decline is a growing public health concern worldwide.",Non-OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
Clinical trial registration:  CUHK_CCT00448 ( https://www2.ccrb.cuhk.edu.hk/registry/ public/28 7).,Non-OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
"hong Kong sAr, People’s  republic of China Tel +852 3943 4290 Fax +852 2603 5269 email aileenchan@cuhk.edu.h k Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Chan et al Running head recto: Tai chi qigong improves night-time sleep DOI: http://dx.doi.org/10.2147/CIA.S111927",Non-OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
Available from: http://www.cdc.gov/aging/pdf/ cognitive_impairment/cogimp_poilicy_final.pd f. [Updated February  2011].,OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
Available from: http://www21.ha.org.hk/ smartpatient/en/chronicdiseases_zone/details.html?id =174.,Non-OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/bb/6e/cia-11-1277.PMC5034925.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ed/75/ppa-10-1855.PMC5034926.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1855–1868Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1855OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10867 8 Professionals’ perception on the management  of patients with dual disorders carlos roncero1,2 néstor szerman3 Antonio T erán4 carlos Pino5 José María Vázquez6 elena Velasco7 Marta garcía-Dorado7 Miguel casas1,2 1Addiction and Dual Diagnosis Unit,   ciBersAM, hospital Vall hebron,   Barcelona Public health Agency  (AsPB), Barcelona, spain; 2Department  of Psychiatry, Autonomous University  of Barcelona, Barcelona, spain;   3Outpatient Mental health clinic el  retiro, gregorio Marañón University  hospital, Madrid, spain; 4Outpatient  Drug clinic, hospital san Juan de  Dios, Palencia, spain; 5Pontevedra  city council Drug Dependence  service, galician health service  (Xunta de galicia), Pontevedra,   spain; 6Outpatient Drug clinic sants,   Barcelona Public health Agency  (AsPB), Barcelona, spain; 7Medical  Affairs Department, Janssen-cilag  s.A., Madrid, spainBackground:  There is a need to evaluate the professionals’ perception about the consequences  of the lack of therapeutic adherence in the evolution of patients with co-occurring disorders.",Non-OADS,/arxiv_data1/oa_pdf/ed/75/ppa-10-1855.PMC5034926.pdf
"DDs can occur simultaneously or, even more  importantly, sequentially throughout their life span1–4 and constitute a serious problem  for the public health.5,6 Up to 70% of individuals who have been diagnosed with a substance use disorder   (SUD) show a lifetime disorder, that is, a second psychiatric diagnosis throughout  their life,7 and 50% of the patients diagnosed with a mental disorder have a history  of substance use.8–11 In Spain, the prevalence rate of population with a mental disor - der associated with SUD ranges between 25% and 70%.12–14 This percentage varies  depending on the research methodology and, especially, the health care center where  the study was conducted.15,16 Lifetime diagnoses of any mental disorder, and particularly personality disorders  and psychotic disorders, were found to be associated with higher prevalence of transi - tion from substance use to SUDs across most categories of substances.17correspondence: carlos roncero Addiction and Dual Diagnosis Unit,  ciBersAM, hospital Vall hebron,  Barcelona Public health Agency (AsPB),   Paseo Vall d’hebron 119-129,  08035 Barcelona, spain Tel +34 93 489 4294 Fax +34 93 489 4587 email croncero@vhebron.ne t Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Roncero et al Running head recto: Management of patients with dual disorders DOI: http://dx.doi.org/10.2147/PPA.S108678",Non-OADS,/arxiv_data1/oa_pdf/ed/75/ppa-10-1855.PMC5034926.pdf
"This online survey, which was open to any profes - sional involved in dual diagnosis assistance who wanted  to participate, was made available through the institutional  websites of two scientific societies (the Spanish Society  of Dual Pathology [SEPD]; www.patologiadual.e s and the  Spanish Scientific Society for Research on Alcohol, Alco - holism and other Drug Addic  tions [Sociodrogalcohol];  http://www.socidrogalcohol.or g) and was answered  between October 1, 2013 and December 31, 2013. sample The survey was answered by 250 professionals from the  following care centers: outpatient drug clinics (47.2%),  mental health centers (25.2%), psychiatric hospitalization  Table 1  list of clinical and academic experts on DDs carlos   roncero MDAddiction and Dual Diagnosis Unit, Vall d’hebron   University hospital – Public health Agency,   Barcelona (AsPB), ciBersAM, Autonomous   University of Barcelona, Barcelona, spain néstor   szerman MDgregorio Marañón University general hospital,   Madrid, spain Antonio   Terán MDsan Juan de Dios health care center,   Palencia, spain carlos   Pino MDPontevedra city council Drug Dependence service,   galician health service (Xunta de galicia), spain José María   Vázquez MDOutpatient Drug clinic sants, AsPB, spain Miguel   casas MDAddiction and Dual Diagnosis Unit, Vall d’hebron   University hospital – AsPB, ciBersAM,   Autonomous University of Barcelona,   Barcelona, spain Abbreviation:  DD, dual disorder.",Non-OADS,/arxiv_data1/oa_pdf/ed/75/ppa-10-1855.PMC5034926.pdf
Available from:  http://www.pnsd.msssi.gob.es /.,Non-OADS,/arxiv_data1/oa_pdf/ed/75/ppa-10-1855.PMC5034926.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/ed/75/ppa-10-1855.PMC5034926.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d0/0e/opth-10-1811.PMC5034927.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1811–1817Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1811Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S11189 3 intravitreal methotrexate infusion for proliferative  vitreoretinopathy ama sadaka1 robert a sisk1–3 James M Osher1,3 Okan T oygar4 Melinda K Duncan5 Christopher D riemann1,3 1Department of Ophthalmology,   University of Cincinnati College  of Medicine, 2Department of  Opthalmology, Cincinnati Children’s  hospital Medical Center, 3Cincinnati  eye institute, Cincinnati, Oh, Usa;   4Department of Ophthalmology,   Bahcesehir University Medical Faculty,   istanbul, T urkey; 5Department of  Biological sciences, University of  Delaware, newark, De, UsaPurpose:  The purpose of this study was to evaluate intravitreal methotrexate infusion (IMI)  during pars plana vitrectomy (PPV) for retinal detachment in patients with high risk for the  development of proliferative vitreoretinopathy (PVR).",Non-OADS,/arxiv_data1/oa_pdf/d0/0e/opth-10-1811.PMC5034927.pdf
"These  mislocated RPE cells proliferate and undergo epithelial to mesenchymal transition  (EMT) into contractile myofibroblasts that produce the extracellular matrix of the  fibrocellular membrane.1 The EMT of RPE cells occur coincidently with the activa - tion of glia, immune cells, and astrocytes, which proliferate and migrate on both the  sides of the detached retina, increasing the complexity of the cellular organization of  the fibrocellular membranes.2 Anti-inflammatory drugs such as corticosteroids have been used as adjuvants to  retinal reattachment surgery to prevent PVR since preexisting ocular inflammation  is a known PVR risk factor, and inflammatory cells are found associated with peri- retinal membranes.3 However, the efficacy of anti-inflammatory treatment in improv - ing retinal reattachment rates, vitreous cell reaction, and PVR are mixed.4 Similarly, Correspondence: Christopher D riemann 1945 Cei Drive, Cincinnati,  Oh 45242, Usa Tel +1 513 984 5133 Fax +1 513 984 2390 email criemann@cincinnatieye.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Sadaka et al Running head recto: Methotrexate for proliferative vitreoretinopathy DOI: http://dx.doi.org/10.2147/OPTH.S111893",Non-OADS,/arxiv_data1/oa_pdf/d0/0e/opth-10-1811.PMC5034927.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/d0/0e/opth-10-1811.PMC5034927.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d0/0e/opth-10-1811.PMC5034927.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e0/39/ppa-10-1881.PMC5034928.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1881–1888Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1881OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10811 7 A qualitative investigation of barriers and  facilitators of rehabilitation success from the  psychosomatic inpatients’ perspective Anna levke Brütt1 Julia luise Magaard1 sylke Andreas1,2 holger schulz1 1Department of Medical Psychology,   center for Psychosocial Medicine,   University Medical center hamburg- eppendorf, hamburg, germany;   2Psychology institute, Alps-Adria- University Klagenfurt, Klagenfurt,   AustriaObjective:  Psychosomatic inpatient rehabilitation aims at promoting functioning in patients  with mental disorders.",Non-OADS,/arxiv_data1/oa_pdf/e0/39/ppa-10-1881.PMC5034928.pdf
"For example, a woman is diagnosed with recurrent major depressive disorder (health  problem, F33.3, according to ICD-10 criteria).5 Her predominant symptoms include correspondence: Anna levke Brütt Department of Medical Psychology,  centre for Psychosocial Medicine,  University Medical center hamburg- eppendorf, Martinistr 52, Building W26,  hamburg D-20246, germany Tel +49 40 741 057313 Fax +49 40 741 054940 email abruett@uke.d e Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Brütt et al Running head recto: A qualitative investigation of barriers and facilitators of rehabilitation success DOI: http://dx.doi.org/10.2147/PPA.S108117",Non-OADS,/arxiv_data1/oa_pdf/e0/39/ppa-10-1881.PMC5034928.pdf
Available from: http://www.who.int/classifications/icf/en/.,OADS,/arxiv_data1/oa_pdf/e0/39/ppa-10-1881.PMC5034928.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/e0/39/ppa-10-1881.PMC5034928.pdf
"20, http://nbn-resolving.de/urn:nbn:de:0114-fqs000220 4  24.",Non-OADS,/arxiv_data1/oa_pdf/e0/39/ppa-10-1881.PMC5034928.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5a/51/ijn-11-4765.PMC5034929.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 4765–4776International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4765OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11008 1 Multifunctional nanocomposite based on  halloysite nanotubes for efficient luminescent  bioimaging and magnetic resonance imaging Tao Zhou1 lei Jia1 Yi-Feng luo2 Jun Xu1 ru-hua chen2 Zhi-Jun ge2 Tie-liang Ma2 hong chen2 Tao-Feng Zhu2 1Department of Physics and  chemistry, henan Polytechnic  University, Jiaozuo, henan, 2The  affiliated Yixing hospital of Jiangsu  University, Yixing, Jiangsu, People’s  republic of chinaAbstract:  A novel multifunctional halloysite nanotube (HNT)-based Fe3O4@HNT-polyethyle - neimine-Tip-Eu(dibenzoylmethane)3 nanocomposite (Fe-HNT-Eu NC) with both photolumines - cent and magnetic properties was fabricated by a simple one-step hydrothermal process combined  with the coupling grafting method, which exhibited high suspension stability and excellent  photophysical behavior.",Non-OADS,/arxiv_data1/oa_pdf/5a/51/ijn-11-4765.PMC5034929.pdf
"However, these traditional fluorescent labels have limited use in  large-scale applications due to their short lifetimes, photobleaching, and potential  toxicity to cells.4,5 To address the limitations of organic dyes and quantum dots,  lanthanide complexes have been investigated as luminescent probes because of their  excellent optical properties, including sharp emission bands, high quantum yields,  long lifetime, high color purity, and large Stokes shift.6,7 Unfortunately, the application  of lanthanide complexes in biological imaging is limited by their low photochemical  stability, hydrophobicity, and potential toxicity.8 To solve these issues, luminescent  nanocomposites (NCs) have been designed by incorporating lanthanide complexes  into matrices, thus generating suitable diagnostic bioimaging probes with the intrinsic  stability of inorganic matrices and the luminescent features of trivalent lanthanide  ions.9–11 In recent years, nanoclays have attracted considerable interest as supports due  to their low cost, small size, and unusual chemically active surfaces.12,13correspondence: lei Jia Department of Physics and chemistry,  henan Polytechnic University, No 2001,  shiji street, Jiaozuo 454000, henan,  People’s republic of china Tel/fax +86 391 398 7811 email jlxj@hpu.edu.c n  Taofeng Zhu The Affiliated Yixing Hospital of Jiangsu  University, No 75, Tongzhenguan road,  Yixing 214200, Jiangsu, People’s republic  of china Tel +86 510 8792 1196 Fax +86 510 8792 1110 email staff1639@yxph.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Zhou et al Running head recto: Multifunctional nanocomposite in luminescent bioimaging and MRI DOI: http://dx.doi.org/10.2147/IJN.S110081",Non-OADS,/arxiv_data1/oa_pdf/5a/51/ijn-11-4765.PMC5034929.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/5a/51/ijn-11-4765.PMC5034929.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/51/ijn-11-4765.PMC5034929.pdf
"This is an Open Access article distributed under the terms of the Creative CommonsAttribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e5/47/jiw335.PMC5034952.pdf
"This is an Open Access article distributed under the terms of the Creative CommonsAttribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c5/1f/jiw338.PMC5034953.pdf
http://www.lixoft.eu/products/monolix/ documentation/ .,Non-OADS,/arxiv_data1/oa_pdf/c5/1f/jiw338.PMC5034953.pdf
"Guidelines on co-trimoxazole prophylaxis for HIV- related infections among children, adolescents and adults: Recommendations for apublic health approach, 2006 .http://www.who.int/hiv/pub/plhiv/ctx/en/ .A c - cessed 1 March 2016.",Non-OADS,/arxiv_data1/oa_pdf/c5/1f/jiw338.PMC5034953.pdf
"This is an Open Access article distributed under the terms of the Creative CommonsAttribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c1/5e/jiw357.PMC5034960.pdf
"Studies are significant for comparisons and use in transfu-sion practice, identifying predictors of transfusion in hospitals and de-veloping strategies to optimize prac - tice (1-3).ORIGINAL PAPER © 2016 Dzenana Begic, Ermina Mujicic,  Jozo Coric, Svjetlana Loga Zec, and Lejla Zunic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.248-251 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/e3/db/MA-70-248.PMC5034966.pdf
"Establishing the diag-CASE REPORT © 2016 Rame Miftari, Valdete Topçiu,  Adem Nura, and Valdete Haxhibeqiri This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.314-317 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/2b/fd/MA-70-314.PMC5034967.pdf
"ProBNP levels increase ORIGINAL PAPER © 2016 IIoannis Vogiatzis, Irena  Dapcevic, Antonis Datsios, Kostas Koutsambasopoulos, Argirios Gontopoulos, and Savas Grigoriadis This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.269-273 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/80/8a/MA-70-269.PMC5034970.pdf
"Acquired causes of rhabdomyolysis are: trauma and crush syndrome, surgery, extreme physical activity, influence of extreme temperatures, metabolic disorders of water and salts, vascular ischaemia, surgery, various drugs (statins, corticoste-roids, antidepressants, neuroleptics, barbiturates, benzodiazepines, salic - ylates, theophylline, aminocapronic acid) and anesthetics, alcohol abuse, cocaine abuse, neuroleptic malig-nant syndrome, seizures, toxins, in-fections or sepsis, prolonged immo-bilization,carbon monoxide (CO), endocrine disorders, malignant hyprtermia, electrical current and PROFESSIONAL PAPER © 2016 Biljana Kuzmanovska, Emilija  Cvetkovska, Igor Kuzmanovski, Nikola Jankulovski, Mirjana Shosholcheva, Adrijan Kartalov, and Tatjana Spirovskai This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.308-310 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/4b/af/MA-70-308.PMC5034971.pdf
http://www.cdc.hbi.ir 6.,Non-OADS,/arxiv_data1/oa_pdf/93/76/MSM-28-249.PMC5034975.pdf
Available from: http://www.news- medical.net/health/History-of-Tuberculosis.aspx .,Non-OADS,/arxiv_data1/oa_pdf/93/76/MSM-28-249.PMC5034975.pdf
[cited 2013]; Available from: URL: http://fhc.sums.ac.ir/ files/vagir/kargah/TB_sadra_sina%281%29.pdf [In Persian].,OADS,/arxiv_data1/oa_pdf/93/76/MSM-28-249.PMC5034975.pdf
Avail - able from: http://www.who.int/mediacentre/factsheets/fs104/en/print.html .,Non-OADS,/arxiv_data1/oa_pdf/93/76/MSM-28-249.PMC5034975.pdf
[cited 2015]; Available from: URL: http://www.who.int/ gho/tb/en/  21.,OADS,/arxiv_data1/oa_pdf/93/76/MSM-28-249.PMC5034975.pdf
[cited 2013]; Available from: URL: http://apps.who.,OADS,/arxiv_data1/oa_pdf/93/76/MSM-28-249.PMC5034975.pdf
"The characteristics of patients ORIGINAL PAPER © 2016 Nabil Naser, Alen Dzubur, Azra  Durak, Mehmed Kulic, and Nura Naser This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.274-279 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/91/5b/MA-70-274.PMC5034977.pdf
"Blood Journey Phase 6PBS http://www.pbs.org/wnet/redgold/journey/phase6_a1.html, Accessed 1th 2015.",Non-OADS,/arxiv_data1/oa_pdf/85/85/MSM-28-274.PMC5034978.pdf
"INTRODUCTION There is a need for muscle relax - ants in general anesthesia in differ - ent surgeries including cardiac sur -geries, and the type of relaxant to  be used considering their different hemodynamic effects on patients with heart disease can be of high ORIGINAL PAPER © 2016 Masoud Gharbanio, Mahmoud  Reza Mohaghegh, Forozan Yazdanian, Mehrdad Mesbah, and Ziya Totonchi This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.265-268 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/3d/d6/MA-70-265.PMC5034980.pdf
"Vascular complications of diabe- tes are classically divided into mi-ORIGINAL PAPER © 2016 Keyvan Shirzadi, Kourosh  Shahraki, Emad Yahaghi, Ali Makateb, and Keivan Khosravifard This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.280-283 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/c3/10/MA-70-280.PMC5034982.pdf
"Thir - teenth Conference on Civil Engineering students across the country;  Kerman, Shahid Bahonar University available at: http://www.civilica.",Non-OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
"Tenth National Congress on Irrigation  and Reduction of Evaporation; Kerman, Shahid Bahonar University:  available at: http://www.civilica.com/Paper-ABYARI10-ABYARI10_196.",Non-OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
http://www.irna.ir/ fa/News/81448924/;  [Accessed 2015 Jan 11].,Non-OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
http://www.nafir.net/?p=3899  [2015 jan 11].,Non-OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
http://www.asriran.com/ fa/news/;  [2011 May 16].,Non-OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
http://www.niazerooz.com/Key-News/;   [Accessed 2008 June 9].,Non-OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
http://www.tabnak.ir/pages/?cid=9106;  [Accessed 2008 April  15].,OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
"Third Specialized Conference on Environmental Engineering; Tehran University, Faculty of Environment: available at : http://www.civilica.com/Paper-  CEE03-CEE03_100.html 2009.",Non-OADS,/arxiv_data1/oa_pdf/70/b8/MSM-28-307.PMC5034983.pdf
"Despite his potential role in the occurrence and development of ORIGINAL PAPER © 2016 Aida Hamzic-Mehmedbasic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.252-255 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/c8/2a/MA-70-252.PMC5034984.pdf
ORCID ID: http://orcid.org/0000-0002-5237-443X.,OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Avail- able at: https://ejournals.bc.edu/ojs/index.php/ihe/article/view - File/7400/6597 .,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Available at: http://www.bologna-berlin2003.de/pdf/ bologna_declaration.pdf .,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Avail-able at: https://ejournals.bc.edu/ojs/index.php/ihe/article/view - File/6850/6068 6.,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Available at: http://gse.nu.edu.kz/gse/MAIN/ About/Bologna .,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
"2016 Aug; 28(4): 316-319 • Instructions for the authors Instructions for the authorsInstructions for the authors INSTRUCTIONS FOR THE AUTHORS All papers need to be sent to: Editorial board of the journal Mat Soc Med, electroni - cally over the web site http://scopemed.org/?jid=16.",Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Available at: http://www.enqa.eu/ wp-content/uploads/2013/03/010519PRAGUE_COMMUNIQUE.,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Available  at: http://www.enqa.eu/wp-content/uploads/2013/03/BerlinCom - munique1.pdf .,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Available at: http://www.ehea.info/Uploads/news/Budapest- Vienna_Declaration.pdf .,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
Available at: http://www.independent.,Non-OADS,/arxiv_data1/oa_pdf/47/a8/MSM-28-316.PMC5034985.pdf
http://www.who.int/topics/ health_education/en/ .,Non-OADS,/arxiv_data1/oa_pdf/78/d9/MSM-28-278.PMC5034986.pdf
Dostupno na: http://www.azoo.hr/index.,Non-OADS,/arxiv_data1/oa_pdf/78/d9/MSM-28-278.PMC5034986.pdf
: http://www.unesco.org/education/ tlsf/mods/theme_b/mod08.html .,Non-OADS,/arxiv_data1/oa_pdf/78/d9/MSM-28-278.PMC5034986.pdf
: http://www.education.nh.gov/instruction/school_health/ health_coord_education.htm .,Non-OADS,/arxiv_data1/oa_pdf/78/d9/MSM-28-278.PMC5034986.pdf
http://www.fmoh.gov.,Non-OADS,/arxiv_data1/oa_pdf/78/d9/MSM-28-278.PMC5034986.pdf
http://hr.wikipedia.org/wiki/Zdravst - veni_odgoj_u_Hrvatskoj [Accessed 16.12.2014.].,Non-OADS,/arxiv_data1/oa_pdf/78/d9/MSM-28-278.PMC5034986.pdf
http://www.roda.hr/article/print/po - drska-uvoenju-zdravstvenog-odgoja-u-osnovne-i-srednje-skole-kao-i-sadrzaju-kurikuluma .,Non-OADS,/arxiv_data1/oa_pdf/78/d9/MSM-28-278.PMC5034986.pdf
"The other method is reviving the length of affected limb and induced membrane technique is one of the latest methods for bones with defect due to infections.ORIGINAL PAPER © 2016 Ali Yeganeh, Mari Mahmodi,  Hosein Farahini, and Mehdi Moghtadaei This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.284-287 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/a8/86/MA-70-284.PMC5034987.pdf
"Eleva-tion and lowering of the patella have ORIGINAL PAPER © 2016 Mehdi Moghtadaei, Babak  Otoukesh, Bahram Bodduhi , Keyvan Ahmadi, and Ali Yeganeh This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.293-295 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/f6/95/MA-70-293.PMC5034988.pdf
"Most current is the clinical classification (Dana Point, Califor - nia, 2008), which classifies PH in six groups with different pathological, pathophysiological, prognostic and therapeutic properties:PROFESSIONAL PAPER © 2016 Senad Pesto, Zijo Begic, Sabina  Prevljak, Ehlimana Pecar, Nihad Kukavica and Edin Begic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.303-307 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/9b/10/MA-70-303.PMC5034989.pdf
"It represents PROFESSIONAL PAPER © 2016 Aziz Sukalo, Dervis Deljo, Amina  Krupalija, Nerma Zjajo, Sabina Kos, Amela Curic, Goran Divkovic, Sabina Hubjar, Mina Smailagic, Edina Hodzic, Danijela Marjanovic, and Senad MedjedovicThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.299-302 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/13/74/MA-70-299.PMC5034990.pdf
"CASE REPORT A 26-year-old male presented af - ter mild head injury sustained in a CASE REPORT © 2016 Bruno Splavski, Dario Muzevic,  Tatjana Ladenhauser-Palijan, and Brano Splavski Jr This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.311-313 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/23/19/MA-70-311.PMC5034991.pdf
"ORIGINAL PAPER © 2016 Leonardo S. Lino-Silva, Rosa A.  Salcedo-Hernández, Erika B. Ruiz-García, Leticia García-Pérez and Ángel Herrera-Gómez This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.256-260 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/25/54/MA-70-256.PMC5034992.pdf
"Coronary arteries clinical syn- dromes caused by chronic athero-ORIGINAL PAPER © 2016 Mohammad Manochehri and  Adel Johari Moghadam This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.261-264 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/a9/b2/MA-70-261.PMC5034993.pdf
"In the serum of healthy men in phys - iological conditions there is a very ORIGINAL PAPER © 2016 Alden Prcic, Edin Begic, and  Mustafa Hiros This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.288-292 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/09/1e/MA-70-288.PMC5034994.pdf
"A small purse-string suture with 4-0 CASE REPORT © 2016 Mingjia Ma, Mohamed  Abdulkadir, Yang Li, and Xiang Wei This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.321-323 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/83/0a/MA-70-321.PMC5034998.pdf
"Metaanalysis showed that progression of ASCUS can progress ORIGINAL PAPER © 2016 Mahira Jahic and Elmir Jahic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.296-298 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/18/f0/MA-70-296.PMC5035008.pdf
"Pathohistological analysis of the prostatic tissue sam-CASE REPORT © 2016 Zoran Campara, Dejan Simic,  Predrag Aleksic, Aleksandar Spasic, and Snjezana Milicevic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.318-320 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/f9/9c/MA-70-318.PMC5035009.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/9/e1600813/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/ae/50/1600813.PMC5035124.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/9/e1600292/DC1 fig.,Non-OADS,/arxiv_data1/oa_pdf/bb/a9/1600292.PMC5035125.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/9/e1600142/DC1 fig.,Non-OADS,/arxiv_data1/oa_pdf/09/84/1600142.PMC5035126.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/9/e1601014/DC1 Methods: FEA Methods: Electromagnetic simulations fig.,Non-OADS,/arxiv_data1/oa_pdf/09/fe/1601014.PMC5035128.pdf
The present study (NCT00154180; https://clinicaltrials.gov/ct2/show/NCT00154180) was approved by the Mayo Clinic institutional review board (no.,Non-OADS,/arxiv_data1/oa_pdf/9f/b1/NEUROLOGY2015674812.PMC5035155.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/jmedgenet-2016-103829).,Non-OADS,/arxiv_data1/oa_pdf/7c/f8/jmedgenet-2016-103829.PMC5035228.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Urbaniak JR, Jones JP, eds.",Non-OADS,/arxiv_data1/oa_pdf/7c/f8/jmedgenet-2016-103829.PMC5035228.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/03/7c/main.PMC5035238.pdf
http://dx.doi.org/10.1016/j.idcr.2016.09.004 2214-2509/ ã  2016  The  Authors.,OADS,/arxiv_data1/oa_pdf/03/7c/main.PMC5035238.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).IDCases  6  (2016)  26–28 Contents  lists  available  at  ScienceDirect IDCases journal  homepage:  www.elsevier.com/locat  e/idcr,Non-OADS,/arxiv_data1/oa_pdf/03/7c/main.PMC5035238.pdf
"Liver  Transplant  2005;11:1550 –5,  doi:http://dx.doi.org/ 10.1002/lt.20545 .",Non-OADS,/arxiv_data1/oa_pdf/03/7c/main.PMC5035238.pdf
"J  Clin  Pathol  2010;63:365 – 6,  doi:http://dx.doi.org/10.1136/jcp.2009.071787 .",Non-OADS,/arxiv_data1/oa_pdf/03/7c/main.PMC5035238.pdf
"J  Infect  Dis  2010;201(February  (4)):499 –504,  doi:http://dx.doi.org/ 10.1086/650302 .",OADS,/arxiv_data1/oa_pdf/03/7c/main.PMC5035238.pdf
"2)):773 –5,  doi:http://dx.doi.org/10.4103/0975-7406.163555 .",Non-OADS,/arxiv_data1/oa_pdf/03/7c/main.PMC5035238.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3d/19/main.PMC5035259.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.08.003,OADS,/arxiv_data1/oa_pdf/3d/19/main.PMC5035259.pdf
This  is  an  open  access  article under the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/37/b8/main.PMC5035330.pdf
The  ﬂap  was  anchored  to http://dx.doi.org/10.1016/j.ijscr.2016.05.035 2210-2612/© 2016  Published  by  Elsevier  Ltd  on  behalf  of  IJS  Publishing  Group  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/37/b8/main.PMC5035330.pdf
"(2015),  http://dx.doi.org/10.1111/ans.13397 .",Non-OADS,/arxiv_data1/oa_pdf/37/b8/main.PMC5035330.pdf
This  is  an  open  access  article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ce/ed/main.PMC5035331.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.05.023 2210-2612/© 2016  Published  by  Elsevier  Ltd  on  behalf  of  IJS  Publishing  Group  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/ce/ed/main.PMC5035331.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Microbacterium oleivoransDraft genomeDetailed annotation Student Initiated Microbial Discovery (SIMD) projectBioremediation potentialMetabolic versatility 1.,Non-OADS,/arxiv_data1/oa_pdf/d9/d3/main.PMC5035333.pdf
http://dx.doi.org/10.1016/j.gdata.2016.09.005 2213-5960/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d9/d3/main.PMC5035333.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d9/d3/main.PMC5035333.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Internet gaming disorderfMRICue reactivityCraving Intervention 1.,Non-OADS,/arxiv_data1/oa_pdf/73/c7/main.PMC5035334.pdf
http://dx.doi.org/10.1016/j.nicl.2016.09.004 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/73/c7/main.PMC5035334.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/73/c7/main.PMC5035334.pdf
"The results were visualized using BrainNet Viewer ( Xia et al., 2013 )a n dD P A B I( http://rfmri.org/dpabi ).",OADS,/arxiv_data1/oa_pdf/73/c7/main.PMC5035334.pdf
http://dx.doi.org/10.1111/adb.1233 .,Non-OADS,/arxiv_data1/oa_pdf/73/c7/main.PMC5035334.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7c/fa/main.PMC5035335.pdf
http://dx.doi.org/10.1016/j.idcr.2016.09.001 2214-2509/ ã  2016  The  Authors.,OADS,/arxiv_data1/oa_pdf/7c/fa/main.PMC5035335.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).IDCases  6  (2016)  23–25 Contents  lists  available  at  ScienceDirect IDCases journal  homepage:  www.elsevier.com/locate/idcr,Non-OADS,/arxiv_data1/oa_pdf/7c/fa/main.PMC5035335.pdf
MALDI-TOF MS spectrum accession number The MALDI-TOF MS spectrum of this strain is available at http://www.mediterranee-infection.com/article.php?laref= 256&titre=urms-database .,Non-OADS,/arxiv_data1/oa_pdf/63/2c/main.PMC5035336.pdf
New Microbe and New Infect 2016; 14:56–57 © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious DiseasesThis is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.07.015,Non-OADS,/arxiv_data1/oa_pdf/63/2c/main.PMC5035336.pdf
"“Anaerotruncus massiliensis ” 57 © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,14,5 6 –57 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/63/2c/main.PMC5035336.pdf
massiliensis ”is available at http://www.mediterraneeinfection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/62/9d/main.PMC5035340.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.07.005,Non-OADS,/arxiv_data1/oa_pdf/62/9d/main.PMC5035340.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,14,5 3 –55 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/62/9d/main.PMC5035340.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,14,5 3 –55 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/62/9d/main.PMC5035340.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a6/7a/main.PMC5035342.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.08.005,OADS,/arxiv_data1/oa_pdf/a6/7a/main.PMC5035342.pdf
MALDI-TOF MS spectrum The MALDI-TOF MS spectrum of “Lachnoclostridium touar- egense ”is available at http://www.mediterranee-infection.com/ article.php?laref=256&titre=urms-database .,OADS,/arxiv_data1/oa_pdf/69/63/main.PMC5035343.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.07.007,Non-OADS,/arxiv_data1/oa_pdf/69/63/main.PMC5035343.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,14,5 1 –52 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/69/63/main.PMC5035343.pdf
This is an openaccess article under the CC BY-NC-ND license ( http://creativecommons.or g/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/40/d0/main.PMC5035345.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.08.004,OADS,/arxiv_data1/oa_pdf/40/d0/main.PMC5035345.pdf
"Provision of clinical history improved inter-reader agreement, especially whenReceived: 4 July 2016 Revised: 15 August 2016 Accepted: 12 September 2016 Heliyon 2 (2016) e00162 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
Article No~e00162 2 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
Article No~e00162 3 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
"On post-contrast T1WI, Article No~e00162 4 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
Reader Sequence Without history With history 1 STIR 0.4 0.686 1 T1 0.261 0.686 2 STIR 0.424 0.442 2 T1 0.395 0.604 3 STIR 0.407 0.6423 T1 0.174 0.151 Overall STIR 0.411 0.577 Overall T1 0.255 0.459 Article No~e00162 5 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
Article No~e00162 6 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
They recommend indicating the clinical question being Article No~e00162 7 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
"Conclusions In summary, we assessed reader agreement before and after the provision of clinical history to determine its influence on MRI interpretation of optic Article No~e00162 8 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
Article No~e00162 9 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
Article No~e00162 10 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
Article No~e00162 11 http://dx.doi.org/10.1016/j.heliyon.2016.e00162 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d8/43/main.PMC5035347.pdf
http://dx.doi.org/10.1016/j.mmcr.2016.09.001 Received 16 July 2016; Received in revised form 17 August 2016; Accepted 13 September 2016⁎Corresponding author.Medical Mycology Case Reports 13 (2016) 12–16 2211-7539/ © 2016 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.,Non-OADS,/arxiv_data1/oa_pdf/6e/4e/main.PMC5035348.pdf
This is an open access article under the  CC BY-NC-ND license (http://creativecommons.org/licenses/by/4.0/).Available online 14 September 2016 crossmark,Non-OADS,/arxiv_data1/oa_pdf/6e/4e/main.PMC5035348.pdf
This  is  an  open  access  article under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ec/cd/main.PMC5035349.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.04.018 2210-2612/© 2016  Published  by  Elsevier  Ltd  on  behalf  of  IJS  Publishing  Group  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/ec/cd/main.PMC5035349.pdf
"Splenic  abscess  rupture postappendicectomy,  BMJ  Case  Rep.  (2012),  http://dx.doi.org/10.1136/bcr.01.",Non-OADS,/arxiv_data1/oa_pdf/ec/cd/main.PMC5035349.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/ef/35/main.PMC5035350.pdf
http://dx.doi.org/10.1016/j.jdcr.2016.08.007 363,OADS,/arxiv_data1/oa_pdf/ef/35/main.PMC5035350.pdf
CT http://dx.doi.org/10.1016/j.mmcr.2016.09.002 Received 17 June 2016; Received in revised form 18 August 2016; Accepted 13 September 2016⁎Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/40/9e/main.PMC5035351.pdf
This is an open access article under the  CC BY-NC-ND license (http://creativecommons.org/licenses/by/4.0/).Available online 14 September 2016 crossmark,Non-OADS,/arxiv_data1/oa_pdf/40/9e/main.PMC5035351.pdf
This  is  an  open  access  article under the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/60/d4/main.PMC5035352.pdf
Physical  examination  was http://dx.doi.org/10.1016/j.ijscr.2016.04.003 2210-2612/© 2016  Published  by  Elsevier  Ltd  on  behalf  of  IJS  Publishing  Group  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/60/d4/main.PMC5035352.pdf
"Rep. 10  (1)  (2009)  78–83,  http://dx.doi.org/10.1007/ s11934-009-0014-y  [PubMed][CrossRef].",Non-OADS,/arxiv_data1/oa_pdf/60/d4/main.PMC5035352.pdf
"[3] J. Ogino, J. Toda, S.  Onitsuka,  N.  Hashimoto,  Idiopathic  bilateral  adrenal haemorrhage  related  to  acute  adrenal  insufﬁciency,  BMJ  Case  Rep.  (2013), http://dx.doi.org/10.1136/bcr-2013-009626 [PMCfreearticle][PubMed][CrossRef].",OADS,/arxiv_data1/oa_pdf/60/d4/main.PMC5035352.pdf
"32  (2)  (2007) 167–169,  http://dx.doi.org/10.1016/j.jemermed.2006.05.046 [PubMed][CrossRef].",OADS,/arxiv_data1/oa_pdf/60/d4/main.PMC5035352.pdf
This  is  an  open access article under the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/f1/main.PMC5035353.pdf
The  CT  was  repeated  with  oral  and http://dx.doi.org/10.1016/j.ijscr.2016.07.026 2210-2612/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/64/f1/main.PMC5035353.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/be/75/main.PMC5035354.pdf
"At  present,  data  are  lacking  on the  treatment  of  solitary  pancreatic  metastases  of  RCC  with  novel targeted  agents  [6];  nevertheless,  it  may  be  reasonable  to  reserve http://dx.doi.org/10.1016/j.ijscr.2016.08.039 2210-2612/© 2016  The  Author(s).",Non-OADS,/arxiv_data1/oa_pdf/be/75/main.PMC5035354.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
1936-5233/16http://dx.doi.org/10.1016/j.tranon.2016.09.001,OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
"Front Endocrinol (Lausanne) 6, 176. http://dx.doi.org/10.3389/fendo.2015.00176 .",Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
F1000Res 4.http://dx.doi.org/10.12688/f1000research.7002.1 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
"Totowa, NJ: Humana Press; 2006 41 –53.http://dx.doi.org/ 10.1007/978 –1–59259-995-0_5 .",Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
"Front Endocrinol (Lausanne) 3, 83. http://dx.doi.org/10.3389/fendo.",Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/ 10.1371/journal.pone.0079008.s001 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1016/j.tranon.2015.11.012 .,OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1371/journal.pone.,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1097/RCT.,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1016/j.acra.2013.10.008 .,OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.3174/ajnr.A1338 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1002/mrm.22024 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.2353/ajpath.2010.090353 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1148/rg.273065038 [discussion 861 –5].,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1102/1470-7330.2005.0110 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1007/s00108 –005–1467-9 [quiz 1146].,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.2214/AJR.13.11673 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1210/jcem-63-4-960 .,OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1007/s00405-012-2205-2 .Translational Oncology Vol.,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
"BMC Medl Imaging 13,1 .http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1016/j.hoc.2015.07.011 .,OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1371/journal.pone.0161386 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1038/sj.bjc.6601453 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
"Cell 100, 57–70.http://dx.doi.org/10.1016/S0092-8674(00)81683-9 .",OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
"Transl Oncol 3,1–12.http://dx.doi.org/10.1593/tlo.09250 .",Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
http://dx.doi.org/10.1371/journal.pone.0040770 .,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
Mol Imaging Biol .http://dx.doi.org/10.1007/s11307-016-0978-1 .410 DWI in Thyroid Carcinoma Schob et al.,Non-OADS,/arxiv_data1/oa_pdf/13/dd/main.PMC5035355.pdf
"By Western blot analysis and mass spectrometry, Leukotoxin A was identified as a major component ofReceived: 19 August 2016 Accepted: 7 September 2016 Heliyon 2 (2016) e00158 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 2 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
The fermentation culture wasgrown at 37.0 ± 1.0 °C with dissolved oxygen set above 40% and variable Article No~e00158 3 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
The Article No~e00158 4 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Membranes were incubated for 1 h at room temperature with a 1:500 dilution of each serum andafterwards for 1 h at room temperature with a 1:5000 dilution of anti-bovine Article No~e00158 5 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This analysis showed that LKT expression Article No~e00158 6 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
"Subcellular in silico localization, predicted using free access PSORTb software (available at http://psort.hgc.jp/ ), indicated that most of the identified proteins are periplasmic (7/11), with others being extracellular (1/11) or located in the outer cell membrane (2/11).",OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 7 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 8 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 9 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
"multocida , both reported as Article No~e00158 10 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.",OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 11 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 12 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 13 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Serine/threonine protein Article No~e00158 14 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Effects of vaccination against respiratory Article No~e00158 15 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
Article No~e00158 16 http://dx.doi.org/10.1016/j.heliyon.2016.e00158 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/80/7a/main.PMC5035357.pdf
The results will be presented and a possible substitution of the materials to stabilize fly ash will be discussed.Received: 7 July 2016 Revised: 6 September 2016 Accepted: 14 September 2016 Heliyon 2 (2016) e00163 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Introduction Every year about 11 billion tons of solid waste are collected worldwide and the European Union alone generates about 3 billion tons of waste ( http://ec.europa.eu/ eurostat ).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
The corresponding quantity of landfilled and incinerated wastes are also shown (http://ec.europa.eu/eurostat ).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
The corresponding quantity of landfilled and incinerated wastes are also shown ( http://ec.europa.eu/Eurostat ).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 2 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
"With the Critical Raw Material initiative ( http://ec.europa.eu/growth/sectors/raw- materials/index_en.htm ), the European policy focus on the fundamental role of innovation to develop new materials, by optimizing the resource and minimizing the waste.",Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 3 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 4 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 5 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 6 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
"It was supposed that the active phase promoting metals stabilization is the portlandite, dueto the following reaction: Article No~e00163 7 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.",Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 8 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 9 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 10 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 11 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 12 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
"The main peak ofthis phase (at about 10,5° in 2Theta) appears also in the XRD pattern of sample S1, Article No~e00163 13 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.",Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 14 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 15 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 16 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 17 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 18 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
Article No~e00163 19 http://dx.doi.org/10.1016/j.heliyon.2016.e00163 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/69/main.PMC5035358.pdf
An increased PTB to TIAR binding ratio inReceived: 15 March 2016 Revised: 23 May 2016 Accepted: 9 September 2016 Heliyon 2 (2016) e00159 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is in line with the notion that the diverse and complex functions performed by the RBP Article No~e00159 2 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 3 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
"Theoligonucleotides used were: Rat5′short: 5 ′-Biotin-ACCAUCAGCAAGCAGGUCAUUGUUCCAAC-3 ′ 5’long:5 ′-GCUACAAUCAUAGACCAUCAGCAAGCAGGUCAUUGUUC- CAACAUGGCCCU-Biotin-3 ′ 3′short: 5 ′-Biotin-UCCACCACUCCCCGCCCACCCCUCU −3′ 3’long:5 ′-Biotin- CCACCACUCCCCGCCCACCCCUCUGCAAU- GAAUAAAGCCUUUGAAUGAGC-3 ′ Human 5′short: 5 ′-Biotin-GGCCAUCCAGCAGAUCACUGUCCUUCUGCC-3 ′ 5’long:5 ′-Biotin-AGAGGCCAUCAAGCAGAUCACUGUCCUUCUGC- CAUGGCCCU-3 ′ 3′short 1: 5 ′-Biotin-CGCAGCCCCCCACCCGCCGCCUCCU-3 ′ 3′short 2: 5 ′-AGGUGGGGCAGGUGGAGCUG-3 ′ For control, a scrambled non-specific oligonucleotide was used: Article No~e00159 4 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.",Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 5 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 6 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
The tubes were vortexed and then centrifuged for 2 min at 14000 x g. After removal of the Article No~e00159 7 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
HnRNP U is an 120 Article No~e00159 8 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 9 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 10 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Instead of a longer 3 ′-UTR oligonucleotide a non-biotinylated complementary oligonucleotide was used to mimic double stranded Article No~e00159 11 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 12 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
"The image is acquired after blotting forhnRNP U, hnRNP L, PTB and TIAR in sequence, thus showing the correlation from a single Article No~e00159 13 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.",Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 14 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
* denotes p <0.05 using Student ’s t-test when comparing HG to LG and IBMX and DNO to C. Article No~e00159 15 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 16 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 17 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 18 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Additional explanations may be that PTB becomes more actively recruited to the insulin Article No~e00159 19 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
"These elements confer mRNA instability and low translational rates, and hnRNP U was demonstrated to bind AREs as a multimeric Article No~e00159 20 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.",Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 21 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 22 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 23 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
"Steiner, Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN- Article No~e00159 24 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.",Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 25 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
Article No~e00159 26 http://dx.doi.org/10.1016/j.heliyon.2016.e00159 2405-8440/© 2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/03/b2/main.PMC5035359.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4a/20/main.PMC5035360.pdf
1936-5233/16http://dx.doi.org/10.1016/j.tranon.2016.08.006,OADS,/arxiv_data1/oa_pdf/4a/20/main.PMC5035360.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) whichpermits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.ANTIOXIDANTS & REDOX SIGNALING Volume 25, Number 9, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/ars.2016.6819 550",Non-OADS,/arxiv_data1/oa_pdf/20/a9/ars.2016.6819.PMC5035369.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncom-mercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 9, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/dia.2016.0128 574",Non-OADS,/arxiv_data1/oa_pdf/13/44/dia.2016.0128.PMC5035370.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.ANTIOXIDANTS & REDOX SIGNALING Volume 25, Number 9, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/ars.2016.6739 534",Non-OADS,/arxiv_data1/oa_pdf/fa/30/ars.2016.6739.PMC5035371.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 9, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/dia.2016.0156 525",Non-OADS,/arxiv_data1/oa_pdf/a9/0b/dia.2016.0156.PMC5035373.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 9, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/dia.2016.0171 532",Non-OADS,/arxiv_data1/oa_pdf/b6/a6/dia.2016.0171.PMC5035377.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b4/04/jjm-09-07-31824.PMC5035388.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/99/8b/jjm-09-07-31784.PMC5035389.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3a/e8/jjm-09-07-36582.PMC5035392.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e5/3b/jjm-09-07-33235.PMC5035393.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1d/01/jjm-09-07-30365.PMC5035394.pdf
"Gene Runner software (http://www .generunner.com), an Oligo analyzer (http://eu.idtdna.com), and Oligo6 (www .oligo.net) were used to design the primers.",OADS,/arxiv_data1/oa_pdf/1d/01/jjm-09-07-30365.PMC5035394.pdf
The ﬁnal primers that were selected were analyzed using BLAST software (ftp://ftp.ncbi.nlm.nih.gov/blast/db/).,OADS,/arxiv_data1/oa_pdf/1d/01/jjm-09-07-30365.PMC5035394.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/88/64/jjm-09-07-34373.PMC5035395.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e5/45/jjm-09-07-35685.PMC5035396.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b7/ca/jjm-09-07-34151.PMC5035436.pdf
"The obtained sequence data were adjusted us- ing SeqMan of the Lasergene software (DNAStar Inc., Madi- son, WI, USA) and compared with the GenBank database (http://blast.ncbi.nlm.nih.gov).",OADS,/arxiv_data1/oa_pdf/b7/ca/jjm-09-07-34151.PMC5035436.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/71/a1/jjm-09-07-34153.PMC5035437.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/34/d7/jjm-09-07-37329.PMC5035438.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/34/28/atr-05-02-29042.PMC5035439.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/39/51/atr-05-02-26892.PMC5035513.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/05/33/atr-05-02-25174.PMC5035514.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427",OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"InExtracellular vesicles in lymph Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427",OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"Scale bars: 100 nm.Extracellular vesicles in lymph Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427",OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"(*p B0.05, **p B0.01, ***p B0.001).Extracellular vesicles in lymph Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427",OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"2014;3:24641, doi: http://dx.doi.org/10.3402/jev.v3.24641Extracellular vesicles in lymph Citation: Journal of Extracellular Vesicles 2016, 5: 31427 - http://dx.doi.org/10.3402/jev.v5.31427 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/be/3f/JEV-5-31427.PMC5035515.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a3/be/atr-05-02-30610.PMC5035516.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3b/65/now182.PMC5035531.pdf
Retrieved from: http://www.phac-aspc.gc.ca/ aids-sida/publication/epi/2010/pdf/EN_Intro_Web.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/24/NUP-17-250.PMC5035547.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/3f/8a/40800_2016_Article_34.PMC5035647.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/7b/e0/40800_2016_Article_33.PMC5035648.pdf
Available at: https://www.farmacotherap eutischkompas.nl/bladeren- volgens-boek/preparaatteksten/l/lidocaine_prilocaine .,Non-OADS,/arxiv_data1/oa_pdf/7b/e0/40800_2016_Article_33.PMC5035648.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.994 E. A. Zimovetz et al.",Non-OADS,/arxiv_data1/oa_pdf/5a/67/40263_2016_Article_354.PMC5035654.pdf
"Manchester, UK: National Institute for Health and Care Excellence; 2008. http://www.nice.org.uk/guidance/cg72 .",Non-OADS,/arxiv_data1/oa_pdf/5a/67/40263_2016_Article_354.PMC5035654.pdf
"Manchester, UK: National Institute for Health and CareExcellence; 2013. http://publications.nice.org.uk/pmg9 .",Non-OADS,/arxiv_data1/oa_pdf/5a/67/40263_2016_Article_354.PMC5035654.pdf
London: Department of Health; 2012. http://www.dh.gov.uk/health/2012/ 11/2011-12-reference-costs/ .,Non-OADS,/arxiv_data1/oa_pdf/5a/67/40263_2016_Article_354.PMC5035654.pdf
London: British National Formulary; 2012. http://www.medicinescomplete.com/mc/bnf/ current/ .,Non-OADS,/arxiv_data1/oa_pdf/5a/67/40263_2016_Article_354.PMC5035654.pdf
"Leicester, UK: British Psychological Society, and London: Royal College of Psychiatrists; 2009. http://www.ncbi.nlm.nih.gov/books/ NBK53652/ .",Non-OADS,/arxiv_data1/oa_pdf/5a/67/40263_2016_Article_354.PMC5035654.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3b/64/atr-05-02-31380.PMC5035669.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d5/d9/atr-05-02-23198.PMC5035670.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/07/99/atr-05-02-31475.PMC5035671.pdf
Supplements Supplementary material(s) is available at below link: http://archtrauma.com/?page=download&ﬁle_id=58284 Acknowledgments This study was funded by the national institute on drug abuse (NIDA) (grant DA07484) to Marc Zimmerman.,Non-OADS,/arxiv_data1/oa_pdf/07/99/atr-05-02-31475.PMC5035671.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/55/cf/atr-05-02-29266.PMC5035672.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bb/03/ijem-14-02-28422.PMC5035673.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9d/21/ijem-14-02-36091.PMC5035675.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ef/17/ijem-14-02-34676.PMC5035676.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/03/2c/ijem-14-02-34312.PMC5035678.pdf
"- 147 -Imaging Science in Dentistry 2016; 46: 147-57 http://dx.doi.org/10.5624/isd.2016.46.3.147 Introduction One definition of an impacted tooth is a tooth that was  prevented from erupting into the correct position due to  lack of space, malposition, or other impediments.1 Sub- sequently, impacted teeth have been defined as those that have failed to erupt into the dental arch within the expect - ed time frame.",Non-OADS,/arxiv_data1/oa_pdf/d3/57/isd-46-147.PMC5035719.pdf
"(Imaging Sci Dent 2016; 46: 147-57) Key words :   Jaw; Tooth Diseases; Radiography; Diagnosis Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d3/57/isd-46-147.PMC5035719.pdf
"- 159 -Imaging Science in Dentistry 2016; 46: 159-65 http://dx.doi.org/10.5624/isd.2016.46.3.159 Introduction Increases in life expectancy worldwide have led to an  increased demand for oral rehabilitation surgical pro­ cedures, such as implant therapies and bone grafts.",Non-OADS,/arxiv_data1/oa_pdf/90/1e/isd-46-159.PMC5035720.pdf
"(Imaging Sci Dent 2016; 46: 159-65) Key words :   Radiography, Panoramic; Cone­Beam Computed Tomography; Mandible; Anatomic Variation Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non­Commercial License (http://creativecommons.org/licenses/by­nc/3.0)   which permits unrestricted non­commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/90/1e/isd-46-159.PMC5035720.pdf
- 167 -Imaging Science in Dentistry 2016; 46: 167-71 http://dx.doi.org/10.5624/isd.2016.46.3.167 Introduction The practice of dentistry has seen a paradigm shift not  only in the provision of quality dental care but also in  the diagnosis of diseases that adversely affect the general health of a patient.,Non-OADS,/arxiv_data1/oa_pdf/43/37/isd-46-167.PMC5035721.pdf
"(Imaging Sci Dent 2016; 46: 167-71) Key words :   Sleep Apnea, Obstructive; Cephalometry; Snoring; Obesity Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/43/37/isd-46-167.PMC5035721.pdf
- 173 -Imaging Science in Dentistry 2016; 46: 173-8 http://dx.doi.org/10.5624/isd.2016.46.3.173 Introduction Optical coherence tomography (OCT) is a diagnostic  imaging tool that uses low coherence interferometry to  determine the delay and magnitude of backscattered light  reflected from a biological structure (Fig.,Non-OADS,/arxiv_data1/oa_pdf/25/e6/isd-46-173.PMC5035722.pdf
"(Imaging Sci Dent 2016; 46: 173-8) Key words :   Dental Implants; Tomography, Optical Coherence; Peri-Implantitis Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/25/e6/isd-46-173.PMC5035722.pdf
- 179 -Imaging Science in Dentistry 2016; 46: 179-84 http://dx.doi.org/10.5624/isd.2016.46.3.179 Introduction Paranasal sinuses are air cavities that exist in some fa- cial bones.,Non-OADS,/arxiv_data1/oa_pdf/35/fa/isd-46-179.PMC5035723.pdf
"(Imaging Sci Dent 2016; 46: 179-84) Key words :   Maxillary Sinus; Tooth Root; Radiography, Dental, Digital; Prevalence Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/35/fa/isd-46-179.PMC5035723.pdf
"- 185 -Imaging Science in Dentistry 2016; 46: 185-202 http://dx.doi.org/10.5624/isd.2016.46.3.185 Introduction Osteoporosis is a skeletal disease characterized by low  bone mass, deterioration of the bone structure, and bone  fragility, leading to an increased risk of fracture;1 a less  substantial decrease in bone mass is termed osteopenia.2   Bone fragility is evaluated using dual-energy X-ray ab- sorptiometry (DXA), which measures bone mineral den- sity (BMD).",Non-OADS,/arxiv_data1/oa_pdf/eb/a9/isd-46-185.PMC5035724.pdf
"(Imaging Sci Dent 2016; 46: 185-202) Key wOrDS :   Radiography, Dental; Diagnosis; Absorptiometry, Photon; Osteoporosis Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/eb/a9/isd-46-185.PMC5035724.pdf
"- 203 -Imaging Science in Dentistry 2016; 46: 203-10 http://dx.doi.org/10.5624/isd.2016.46.3.203 Introduction Although the need for digital dental radiography quali - ty assurance (QA) testing is recognized, few studies have  been performed on the methods and best practices for  performing these tests.",Non-OADS,/arxiv_data1/oa_pdf/62/8e/isd-46-203.PMC5035725.pdf
"(Imaging Sci Dent 2016; 46: 203-10) Key words :   Radiography, Panoramic; Quality Assurance, Health Care; Phantoms, Imaging Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/62/8e/isd-46-203.PMC5035725.pdf
- 211 -Imaging Science in Dentistry 2016; 46: 211-6 http://dx.doi.org/10.5624/isd.2016.46.3.211 Introduction Evolving methods of student learning necessitate the  evolution of teaching methods.,Non-OADS,/arxiv_data1/oa_pdf/11/76/isd-46-211.PMC5035726.pdf
"(Imaging Sci Dent 2016; 46: 211-6) Key words :   Assessments, Educational; Education, Dental; Radiology; Computer-Assisted Instruction Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/11/76/isd-46-211.PMC5035726.pdf
Available from http://www.webarchive.org.uk/wayback/archive/2014   0615085433/http://www.jisc.ac.uk/media/documents/themes/elearning/effpraceassess.pdf 10.,Non-OADS,/arxiv_data1/oa_pdf/11/76/isd-46-211.PMC5035726.pdf
"- 217 -Imaging Science in Dentistry 2016; 46: 217-22 http://dx.doi.org/10.5624/isd.2016.46.3.217 The first case of a bifid mandibular condyle (BMC) was   presented by Hrdlička,1 who identified it in the skull spe­ cimen of a cadaver in 1941.",Non-OADS,/arxiv_data1/oa_pdf/de/11/isd-46-217.PMC5035727.pdf
"(Imaging  Sci Dent 2016; 46: 217-22) Key woRds :   Mandibular Condyle; Anatomic Variation; Congenital Abnormalities; Prevalence; Epidemiology Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non­Commercial License (http://creativecommons.org/licenses/by­nc/3.0)   which permits unrestricted non­commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/de/11/isd-46-217.PMC5035727.pdf
"- 223 -Imaging Science in Dentistry 2016; 46: 223-7 http://dx.doi.org/10.5624/isd.2016.46.3.223 Mandibular bone cavities, depressions, and defects have  often been described in connection to the development of  the salivary glands.",Non-OADS,/arxiv_data1/oa_pdf/88/fe/isd-46-223.PMC5035728.pdf
"(Imaging Sci Dent 2016; 46: 223-7) Key WoRDs : Cone-Beam Computed Tomography; Mandible; Parotid Gland; Salivary Glands Copyright ⓒ 2016 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/88/fe/isd-46-223.PMC5035728.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/91/af/ijem-14-02-33997.PMC5035773.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/76/9b/ijem-14-02-35424.PMC5035774.pdf
"http://data.world bank.org/country/malawi, Accessed 9 November 2015.",Non-OADS,/arxiv_data1/oa_pdf/65/2e/czw050.PMC5035778.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/07/8a/czw059.PMC5035781.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/78/92/rjw159.PMC5035782.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/73/10/mdw265.PMC5035785.pdf
"2013. http://www.euroqol.org/about-eq- 5d/publications/user-guide.html (10 November 2015, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/73/10/mdw265.PMC5035785.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0f/92/mdw282.PMC5035790.pdf
ClinicalTrials.gov: NCT00962611; https://clinicaltrials.gov/ct2/show/NCT00962611 .,Non-OADS,/arxiv_data1/oa_pdf/0f/92/mdw282.PMC5035790.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0f/92/mdw282.PMC5035790.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/83/7c/mdw288.PMC5035792.pdf
http://www.dako.com/download.pdf?,Non-OADS,/arxiv_data1/oa_pdf/83/7c/mdw288.PMC5035792.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e4/c8/mdw289.PMC5035793.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9b/a3/mdw291.PMC5035794.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ae/6b/iranjradiol-13-02-16705.PMC5035795.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/80/d0/iranjradiol-13-02-20919.PMC5035796.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.JOURNAL OF NEUROTRAUMA 33:1685–1695 (September 15, 2016) Mary Ann Liebert, Inc.DOI: 10.1089/neu.2015.4200 1685",Non-OADS,/arxiv_data1/oa_pdf/a8/ee/neu.2015.4200.PMC5035832.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribut ion, and reproduction in any medium, provided the original author(s) and the source are credited.JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY Volume 26, Number 7, 2016Mary Ann Liebert, Inc.Pp.",Non-OADS,/arxiv_data1/oa_pdf/78/be/cap.2015.0183.PMC5035833.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and re- production in any medium, provided the original author(s) and the source are credited.JOURNAL OF NEUROTRAUMA 33:1651–1657 (September 15, 2016) Mary Ann Liebert, Inc.DOI: 10.1089/neu.2015.4278 1651",Non-OADS,/arxiv_data1/oa_pdf/1e/97/neu.2015.4278.PMC5035837.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/83/c1/rjw162.PMC5035840.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.STEM CELLS AND DEVELOPMENT Volume 25, Number 20, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/scd.2016.0210 1483",Non-OADS,/arxiv_data1/oa_pdf/76/91/scd.2016.0210.PMC5035912.pdf
http://dx.doi.org/10.1101/049056 97.,Non-OADS,/arxiv_data1/oa_pdf/76/91/scd.2016.0210.PMC5035912.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e1/a3/iranjradiol-13-02-24350.PMC5035936.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and re- production in any medium, provided the original author(s) and the source are credited.JOURNAL OF NEUROTRAUMA 33:1667–1684 (September 15, 2016) Mary Ann Liebert, Inc.DOI: 10.1089/neu.2015.4218 1667",Non-OADS,/arxiv_data1/oa_pdf/4f/f1/neu.2015.4218.PMC5035937.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a5/c4/iranjradiol-13-02-21740.PMC5035938.pdf
"Key Words aaParkinson’s disease; risk factors; falls; Sub-Saharan Africa; Nigeria.ORIGINAL ARTICLEhttp://dx.doi.org/10.14802/jmd.16011  /  J Mov Disord  2016 ;9(3):160-165 pISSN 2005-940X / eISSN 2093-4939 Received:  February 29, 2016    Revised:  April 8, 2016    Accepted:  May 16, 2016 Corresponding author:  Adesola Ogunn iyi, MBChB , Department of Medicine, College of Medicine, University of Ibadan, University College Hospital,  PMB 5116, Ibadan 200001, Nageria / Tel: +234 8060 276274 / Fax: +234 8038 094173 / E-mail:  aogunniyi53@yahoo.com cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.JMD Falls are known to be frequent in patients with Parkinson’s  disease (PD) with a prevalence of approximately 13% weekly  and 70% annually.1 The risk increases exponentially with in - creasing age and disease severity.2 Although fall incidents are  said to be increasing among older adults living in senior com - munities, PD patients fell more when compared with healthy  adults of the same age.3  Studies have reported fall rates in PD patients who clearly  exceed those of community-dwelling healthy elderly persons.4,5  Falls are associated with considerable morbidity ranging from  minor bruises to major injuries, including fractures.6 Also note - worthy is the rapid progression of disease and poor overall sur - vival among patients who have fallen.7 Increased mortality and  morbidity occur as a result of lethal falls, reduced fitness, in -creased risk of cardiovascular disease, osteoporosis and social  isolation due to immobilization.8 Incapacitating fear of renewed  falls brought about by previous falls aggravates these problems.",Non-OADS,/arxiv_data1/oa_pdf/98/d1/jmd-16011.PMC5035939.pdf
Available from: http://www.who.int/media - centre/factsheets/fs344/en.,Non-OADS,/arxiv_data1/oa_pdf/98/d1/jmd-16011.PMC5035939.pdf
"Key Words aaParkinson’s disease; blood pressure; heart rate; variability; cognition.ORIGINAL ARTICLEhttp://dx.doi.org/10.14802/jmd.16012  /  J Mov Disord  2016 ;9(3):144-151 pISSN 2005-940X / eISSN 2093-4939 Received:  March 10, 2016    Revised:  June 30, 2016    Accepted:  August 3, 2016 Corresponding author:  Seong-Beom Koh, MD, PhD, Department of Neurology and Parkinson’s Disease Centre, Korea University Guro Hospital, Korea  University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea / Tel: +82-2-2626-3169 / Fax: +82-2-2626-1257 / E-mail:  parkin - son@korea.ac.kr cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.JMD Non-motor symptoms, including cognitive and cardiovascu - lar dysfunction, are commonly observed, even in the early stages  of Parkinson’s disease (PD).",Non-OADS,/arxiv_data1/oa_pdf/3b/de/jmd-16012.PMC5035940.pdf
Supplementary Materials The online-only Data Supplement is available with this arti - cle at http://dx.doi.org/10.14802/jmd.16012.,Non-OADS,/arxiv_data1/oa_pdf/3b/de/jmd-16012.PMC5035940.pdf
"Key Words aaMini-Mental State Examination; Montreal Cognitive Assessment; Parkinson’s disease; dementia; mild cognitive  impairment.ORIGINAL ARTICLEhttp://dx.doi.org/10.14802/jmd.16020  /  J Mov Disord  2016 ;9(3):152-159 pISSN 2005-940X / eISSN 2093-4939 Received:  April 21, 2016    Revised:  July 18, 2016    Accepted:  August 15, 2016 Corresponding author:  Jin Y .",Non-OADS,/arxiv_data1/oa_pdf/d1/32/jmd-16020.PMC5035941.pdf
"Hong, MD, Department of Neurology, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju 26426, Korea /  Tel: +82-33-741-0525 / Fax: +82-33-741-1365 / E-mail:  jinyhong@yonsei.ac.kr cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.JMD Cognitive impairment is common in patients with Parkin - son’s disease (PD), and its prevalence has been reported to be  up to 80%.1 Recently, diagnostic criteria for dementia or mild  cognitive impairment (MCI) were proposed by the Movement  Disorders Society Task Force and are widely used.2,3 The level II  assessments provide much more diagnostic accuracy and quan - titative information; however, the detailed neuropsychological  tests recommended by the level II assessments require consid -erable time and cost.",Non-OADS,/arxiv_data1/oa_pdf/d1/32/jmd-16020.PMC5035941.pdf
"Key Words aaHuntington’s disease; survival; CAG; Korea; Asia.ORIGINAL ARTICLEhttp://dx.doi.org/10.14802/jmd.16022  /  J Mov Disord  2016 ;9(3):166-170 pISSN 2005-940X / eISSN 2093-4939 Received:  May 15, 2016    Revised:  June 13, 2016    Accepted:  August 3, 2016 Corresponding author:  Beomseok Jeon, MD, PhD , Department of Neurology, College of Medicine, Seoul National University, 101 Daehak-ro, Jong - no-gu, Seoul 03080, Korea / Tel: +82-2-2072-2876 / Fax: +82-2-3672-7553 / E-mail:  brain@snu.ac.kr cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.JMD Huntington’s disease (HD) is an autosomal-dominant pro - gressive neurodegenerative disorder caused by CAG repeat ex - pansions in the huntingtin gene.",Non-OADS,/arxiv_data1/oa_pdf/0c/68/jmd-16022.PMC5035942.pdf
"Key Words Episodic ataxia; KCNA1 ; CACNA1A .http://dx.doi.org/10.14802/jmd.16028  /  J Mov Disord  2016 ;9(3):129-135 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/27/ef/jmd-16028.PMC5035943.pdf
"Key Words CRISPR/Cas9; gene editing; gene therapy;   hereditary movement disorders.http://dx.doi.org/10.14802/jmd.16029  /  J Mov Disord  2016 ;9(3):136-143 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/49/c0/jmd-16029.PMC5035944.pdf
Available at: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-424 8s2-2-QuantitativeSolutionsMandema.ppt.,Non-OADS,/arxiv_data1/oa_pdf/89/8a/NEUROLOGY2015642413.PMC5035985.pdf
Help Redesign Neurology ® Read the September 6 issue of Neurology®featuring new short-form articles and give us your feedback by September 27. http://tinyurl.com/Neurology2016.,Non-OADS,/arxiv_data1/oa_pdf/89/8a/NEUROLOGY2015642413.PMC5035985.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/26/9a/ipri-34-215.PMC5036010.pdf
"3, 215–223http://dx.doi.org/10.1080/02813432.2016.1207138",Non-OADS,/arxiv_data1/oa_pdf/26/9a/ipri-34-215.PMC5036010.pdf
Available from: 2010: http://kith.no/upload/1899/ICD10-2006_to_ICPC2_mapping%28RTV_240306%29.txt 2015: https://helsedirektoratet.,OADS,/arxiv_data1/oa_pdf/26/9a/ipri-34-215.PMC5036010.pdf
Available from: https://cran.r-project.org/web/packages/survival/vignett es/timedep.pdf .,Non-OADS,/arxiv_data1/oa_pdf/26/9a/ipri-34-215.PMC5036010.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/4a/ea/ipri-34-224.PMC5036011.pdf
"3, 224–231http://dx.doi.org/10.1080/02813432.2016.1207139",Non-OADS,/arxiv_data1/oa_pdf/4a/ea/ipri-34-224.PMC5036011.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/7e/09/ipri-34-232.PMC5036012.pdf
"3, 232–239http://dx.doi.org/10.1080/02813432.2016.1207140",Non-OADS,/arxiv_data1/oa_pdf/7e/09/ipri-34-232.PMC5036012.pdf
Available from: http://www.kith.no/upload/2705/ICPC-2-English.pdf 2015 [cited 2015 Jun 9].,Non-OADS,/arxiv_data1/oa_pdf/7e/09/ipri-34-232.PMC5036012.pdf
Available from: https://www.ssb.no/a/metadata/ conceptvariable/vardok/927/nb1994 [accessed 2016 Jan 19].,OADS,/arxiv_data1/oa_pdf/7e/09/ipri-34-232.PMC5036012.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/df/6a/ipri-34-240.PMC5036013.pdf
"3, 240–249http://dx.doi.org/10.1080/02813432.2016.1207141",Non-OADS,/arxiv_data1/oa_pdf/df/6a/ipri-34-240.PMC5036013.pdf
"Available from: http://www.sum.dk//C24/media/Filer-Publikationer_i_pdf/2013/Ulighed-i- sundhed-2013/Ulighed-i-sundhed-marts-2013.ashx [22] Rortveit G, Daltveit AK, Hannestad YS, et al.",OADS,/arxiv_data1/oa_pdf/df/6a/ipri-34-240.PMC5036013.pdf
Available from: https://www.cancer.dk/holdoejemandSCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE 249,Non-OADS,/arxiv_data1/oa_pdf/df/6a/ipri-34-240.PMC5036013.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/44/77/ipri-34-250.PMC5036014.pdf
"3, 250–257http://dx.doi.org/10.1080/02813432.2016.1207142",Non-OADS,/arxiv_data1/oa_pdf/44/77/ipri-34-250.PMC5036014.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
"3, 258–266http://dx.doi.org/10.1080/02813432.2016.1207143",Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
Available from: http://amr-review.org/ Publications .,Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
Available from: http://orbit.dtu.dk/en/ publications/danmap-2013(551c507b-7bbf-4d99-b3b8- 704bc5509db5).html .,Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
Available from: http://www.dak-e.dk/.,Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
Available from: http://vejledninger.dsam.,Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
"Available at: http://www.who.int/foodsafety/publica-tions/antibacterial-agent/en/ [23] Coenen S, Ferech M, Haaijer-Ruskamp FM, et al.",Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
Available at: http://ecdc.europa.eu/en/activities/surveillance/ESAC-Net/Pages/index.aspx .,Non-OADS,/arxiv_data1/oa_pdf/fd/35/ipri-34-258.PMC5036015.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/02/04/ipri-34-267.PMC5036016.pdf
"3, 267–273http://dx.doi.org/10.1080/02813432.2016.1207144",Non-OADS,/arxiv_data1/oa_pdf/02/04/ipri-34-267.PMC5036016.pdf
The dropouts were grouped into social classes according to a classification originally described by Statistics Finland (http://www.stat.fi/meta/luokitukset/ammatti/001-2010/index.html).,OADS,/arxiv_data1/oa_pdf/02/04/ipri-34-267.PMC5036016.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/cb/b9/ipri-34-274.PMC5036017.pdf
"3, 274–281http://dx.doi.org/10.1080/02813432.2016.1207145",Non-OADS,/arxiv_data1/oa_pdf/cb/b9/ipri-34-274.PMC5036017.pdf
Available from: http://apps.who.int/iris/ bitstream/10665/112642/1/9789241564748_eng.pdf .,OADS,/arxiv_data1/oa_pdf/cb/b9/ipri-34-274.PMC5036017.pdf
Available from: _http://ecdc.europa.eu/en/eaad/Documents/anti- biotic-consumptio-ESAC-Net-2014-EAAD.pdf .,Non-OADS,/arxiv_data1/oa_pdf/cb/b9/ipri-34-274.PMC5036017.pdf
Available from: http://www.folkhalsomyn digheten.se/documents/statistik-uppfoljning/antibiotika statistik/kvartalsrapporter/2013-antibiotikastatistik-kvartalsrapporter/Antibiotikastatistik-kvartalsrapport-4-2013.,OADS,/arxiv_data1/oa_pdf/cb/b9/ipri-34-274.PMC5036017.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/20/37/ipri-34-282.PMC5036018.pdf
"3, 282–285http://dx.doi.org/10.1080/02813432.2016.1207146",Non-OADS,/arxiv_data1/oa_pdf/20/37/ipri-34-282.PMC5036018.pdf
Available from:http://scott.fortmann-roe.com/docs/BiasVariance.html (accessed 8 Dec 2015).,Non-OADS,/arxiv_data1/oa_pdf/20/37/ipri-34-282.PMC5036018.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/6b/91/ipri-34-286.PMC5036019.pdf
"3, 286–294http://dx.doi.org/10.1080/02813432.2016.1207149",Non-OADS,/arxiv_data1/oa_pdf/6b/91/ipri-34-286.PMC5036019.pdf
"Method Design and setting This cross-sectional comparison database study waspart of a wider targeted melanoma screeningproject entitled ‘‘COhort of PAtient at elevated RIskof MElanoma’’ (COPARIME, http://clinicaltrials.govNCT01610531).",Non-OADS,/arxiv_data1/oa_pdf/6b/91/ipri-34-286.PMC5036019.pdf
SAMScore risk calculator on a server (http://www.dmg- nantes.fr/coparime/english) during the consultation and to enter each patient’s responses to seven ques-tions.,Non-OADS,/arxiv_data1/oa_pdf/6b/91/ipri-34-286.PMC5036019.pdf
[Internet]; [cited 2014 Nov 1] Available from: http://info.cancerre- searchuk.org/prod_consump/groups/cr_common/@nre/@hea/documents/generalcontent/cr_045568.pdf (accessed 1 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/6b/91/ipri-34-286.PMC5036019.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/81/bd/ipri-34-295.PMC5036020.pdf
"3, 295–303http://dx.doi.org/10.1080/02813432.2016.1207150",Non-OADS,/arxiv_data1/oa_pdf/81/bd/ipri-34-295.PMC5036020.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/90/73/ipri-34-304.PMC5036021.pdf
"3, 304–308http://dx.doi.org/10.1080/02813432.2016.1207151",Non-OADS,/arxiv_data1/oa_pdf/90/73/ipri-34-304.PMC5036021.pdf
Available from: http://sundhedsstyrelsen.dk/ /C24/media/ A7313BC72CC54058A1A660AAB8CCF465.ashx .,Non-OADS,/arxiv_data1/oa_pdf/90/73/ipri-34-304.PMC5036021.pdf
[Internet]; [cited 2015 Apr].Available from: http://dx.doi.org/10.1093/europace/ euu213 207-214 .,OADS,/arxiv_data1/oa_pdf/90/73/ipri-34-304.PMC5036021.pdf
[Internet]; [cited 2015 Apr].Available from: http://stard-statement.org/ .,OADS,/arxiv_data1/oa_pdf/90/73/ipri-34-304.PMC5036021.pdf
Available from: http://en.wikipedia.org/wiki/Sensitivity_ and_specificity .,Non-OADS,/arxiv_data1/oa_pdf/90/73/ipri-34-304.PMC5036021.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/5c/c6/ipri-34-309.PMC5036022.pdf
"3, 309–316http://dx.doi.org/10.1080/02813432.2016.1207152",Non-OADS,/arxiv_data1/oa_pdf/5c/c6/ipri-34-309.PMC5036022.pdf
Statistics Analyses were done in IBM SPSS version 21 (IBM Corp.)and in an online calculator from EpiTools epidemio-logical calculators (http://epitools.ausvet.com.au).,OADS,/arxiv_data1/oa_pdf/5c/c6/ipri-34-309.PMC5036022.pdf
Available from: http://www.ssb.no/ statistikkbanken .,OADS,/arxiv_data1/oa_pdf/5c/c6/ipri-34-309.PMC5036022.pdf
Available from: http://epitools.ausvet.com.au .,Non-OADS,/arxiv_data1/oa_pdf/5c/c6/ipri-34-309.PMC5036022.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/b0/10/ipri-34-317.PMC5036023.pdf
"3, 317 –324 http://dx.doi.org/10.1080/02813432.2016.1222200",Non-OADS,/arxiv_data1/oa_pdf/b0/10/ipri-34-317.PMC5036023.pdf
Available from: https://www.regjeringen.no/contentassets/f17befe0cb4c48d68c744bce3673413d/no/pdfs/stm201020110016000dddpdfs.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b0/10/ipri-34-317.PMC5036023.pdf
Available from: https://legeforeningen.no/ PageFiles/176624/140507%20KAD%20veileder.pdf [4] Sundlisæter Skinner SM.,Non-OADS,/arxiv_data1/oa_pdf/b0/10/ipri-34-317.PMC5036023.pdf
Available at: http://www.animalexperi- mentspictures.com/ Arluke A (1991) Going into the closest with science: Information control among animal experimenters.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.bbsrc.ac.uk/documents/animals-in-research-pdf/ Birchall C (2011) Introduction to ‘Secrecy and Transparency’: The politics of opacity and openness.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.publi- cations.parliament.uk/pa/cm201213/cmselect/cmjust/96/96we23.htm Cabinet Office (2010) The Coalition: Our Programme for Government.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
804 Public Understanding of Science 25(7) Declaration on Openness Coalition (2012) Available at: http://amrcpolicyblog.files.wordpress.com/2012/10/ declaration-on-openness-2012.pdf Etzioni A (2010) Is transparency the best disinfectant?,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.ncl.ac.uk/cre/publish/discussionpapers/ pdfs/dp24Hewitt.pdf HM Government (2006) Protecting people from animal rights extremists: A progress report.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at:  http://webarchive.nationalarchives.gov.uk/+/http://www.dti.gov.uk/files/file32673.pdf HM Government (2014) Working to reduce the use of animals in scientific research.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at:  http://www.theyworkforyou.com/wms/?id=2013-07-16a.72.0 Home Office (2014a) Consultation on the review of Section 24 of the Animals (Scientific Procedures)  Act 1986.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/ file/313410/Consultation_on_the_review_of_Section_24_of_ASPA.pdf Home Office (2014b) Project licence application.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: https://www.gov.uk/research-and-testing-using-animals#applying-for- licences Hood C (2006) Transparency in historical perspective.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.publications.parliament.uk/pa/ld199900/ldselect/ ldsctech/38/3807.htm House of Lords (2012) Justice committee.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.publications.parliament.uk/pa/cm201213/cmselect/cmjust/96/9602.htm Ipsos MORI (2012) Views on the use of animals in scientific research.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.ipsos-mori.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.express.co.uk/news/uk/425965/EXCLUSIVE-Outrage-as-major-UK-charity-uses-donations-to-fund-vivisection-tests-on-dogs Jump P (2014) ‘Why animal researchers are ending their silence.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.timeshighereducation.co.uk/features/feature-why-animal-researchers-are-end- ing-their-silence/2012957.fullarticle Levidow L and Marris C (2001) Science and governance in Europe: Lessons from the case of agbiotech.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available  at: http://blogs.independent.co.uk/2013/03/01/zero-dark-24-is-animal-testing-really-necessary/ Monaghan R (2000) Terrorism in the name of animal rights.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
"BBC News (Science/Nature), 19 April.Available at:  http://news.bbc.co.uk/1/hi/sci/tech/4923402.stm Murnaghan I (2010) Improving transparency in British animal testing.",Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.aboutanimal- testing.co.uk/improving-transparency-british-animal-testing.html Naturewatch Foundation (n.d.) Royal commission.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
"Available at: http://naturewatch.org/campaign/royal-com- mission National Anti-Vivisection Society (NAVS) (1997) Accountability, Animals Experiments & Freedom of  Information – A Parliamentary Briefing.",Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: https://navs.org.uk/about_vivisection/27/43/350/ National Anti-Vivisection Society (NAVS) (2013) End secret suffering in UK labs.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available  at: http://www.navs.org.uk/about_vivisection/27/43/3096/ Nerlich B (2013) Making the invisible visible: On the meanings of transparency.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: https://blogs.nottingham.ac.uk/makingsciencepub-lic/2012/10/12/making-the-invisible-visible-on-the-meanings-of-transparency/ Nuffield Council on Bioethics (2005) The Ethics of Research Involving Animals.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://issuu.com/icasonlinepublications/docs/jcas_vol_4_issue_1_2006/1?e=5211793/3279796 PETA (2013) It’s time to pull back the veil of secrecy surrounding animal testing.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
"Available at: http://blogs.nature.com/news/2012/10/researchers-issue-animal-research- transparency-declaration.html Phillips L, Bridgeman J and Ferguson-Smith M (2000) The BSE Inquiry: The Report.",Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.rspca.org.uk/servlet/Satellite?pagename=RSPCA/RSPCARedirect&pg=ResAnimalsReportsandResources Saumure K and Given LM (2008) Data saturation.,OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.sci- encemediacentre.org/wp-content/uploads/2013/02/SMC-Briefing-Notes-Animal-Research.pdf Shepherd J (2007) The mice that roared.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
"Available at: http://blog.universitiesuk.ac.uk/2012/01/11/foiexemption/ Stilgoe J, Locke SJ and Wilsdon J (2014) Why should we promote public engagement with science?",Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.timeshighereducation.co.uk/news/scientists-struggle-to-shake-off-secretivetag/157438.article University of Cardiff (2013) Animal experimentation at Cardiff University: FOI response to Dr Adrian  Stallwood.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
"Available at: https://www.whatdotheyknow.com/request/animal_experimentation_at_cardif Vincent B (2014) The politics of buzzwords at the interface of technoscience, market and society: The case of  ‘public engagement in science.",Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
Available at: http://www.wellcome.ac.uk/News/Media-office/Press-releases/2012/WTP040501.htm Wilson DC (2009) The Paradoxes of Transparency: Science and the Ecosystem Approach to Fisheries  Management in Europe.,Non-OADS,/arxiv_data1/oa_pdf/76/98/10.1177_0963662515586320.PMC5036072.pdf
"Preacher KJ (2001) Calculation for the chi-square test: an interactive cal- culation tool for chi-square tests of goodness of fit and independence [Computer software], http://quantpsy.org (accessed 12 October 2015).",Non-OADS,/arxiv_data1/oa_pdf/5c/c5/10.1177_0269881116652577.PMC5036078.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4a/0d/iranjradiol-13-02-21012.PMC5036116.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to:  Raffaele Girlanda, MD, Associate  Professor of Surgery, Transplant Institute, Georgetown  University Hospital, PHC Building, 2nd Floor, 3800 Reservoir  Road, NW, Washington, DC 20007,  United States.",Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
World J Transplant  2016;  6(3): 451-459  Available from: URL: http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
com/2220-3230/full/v6/i3/451.htm   DOI: http://dx.doi.org/ 10.55 00/wjt.v6.i3.451 INTRODUCTION Several obstacles have been overcome over the last few  decades to make organ transplantation an effective life- saving treatment for many patients.,Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
"Among them, the  refinement of surgical techniques and the availability of  effective immunosuppressive regimens against rejection FRONTIER 451 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comDeceased organ donation for transplantation: Challenges  and opportunitiesWorld J Transplant   2016 September 24; 6(3): 451-459 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.451World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
Available  from: URL: http://www.organdonor.gov/about/data.,OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
Available from: URL: http://www.aopo.org/related-links-data- on-donation-and-transplantation/ 10	 A	definition	of	irreversible 	coma.,Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
Available from: URL:  https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#na - meddest=Policy_01 15 U.S. Department of Health & Human Services .,OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
Available from: URL: https://optn.transplant.,Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
"Available from: URL:  https://optn.transplant.hrsa.gov/media/1161/ddps_03-2015.pdf 22 Roels L , Smits J, Cohen B.",OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
Available from: URL:  https://www.cihi.ca/web/resource/en/organdonorpotential_2014_en.,OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
Available from: URL: https://optn.transplant.,Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/d6/e0/WJT-6-451.PMC5036117.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Diana F Florescu, MD,  Transplant  Infectious Diseases Program, Division of Infectious Diseases,  Department of Internal Medicine, University of Nebraska  Medical Center, 985400 Nebraska Medical Center,Omaha, NE  68198-5400, United States.",Non-OADS,/arxiv_data1/oa_pdf/ba/4a/WJT-6-460.PMC5036118.pdf
"Electrolyte and fluid replacement,  reduction of immunosuppression and antiparasitic REVIEW 460 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comCryptosporidium  infection in solid organ transplantationWorld J Transplant   2016 September 24; 6(3): 460-471 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.460World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/ba/4a/WJT-6-460.PMC5036118.pdf
World J Transplant  2016; 6(3): 460-471   Available from: URL: http://www.wjgnet.com/2220-3230/full/ v6/i3/460.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v6.i3.460 INTRODUCTION Cryptosporidium  is a parasitic protozoan causing a  gastroenteritis syndrome[1].,Non-OADS,/arxiv_data1/oa_pdf/ba/4a/WJT-6-460.PMC5036118.pdf
"Available from: URL: http://www.cdc.gov/parasites/ crypto/gen_info/prevention-general-public.html 120 Okhuysen PC , Chappell CL, Crabb J, Valdez LM, Douglass ET,  DuPont HL.",OADS,/arxiv_data1/oa_pdf/ba/4a/WJT-6-460.PMC5036118.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/ba/4a/WJT-6-460.PMC5036118.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to:  Antonios H Tzamaloukas, MD, MACP,  Nephrology Section, Medicine Service, Raymond G. Murphy V A  Medical Center and Department of Medicine, University of New  Mexico School of Medicine, 1501 San Pedro, SE, Albuquerque,  NM 87108, United States.",Non-OADS,/arxiv_data1/oa_pdf/9a/10/WJT-6-472.PMC5036119.pdf
"Several compounds  have shown antiviral activity, but have not consistently REVIEW 472 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comBK nephropathy in the native kidneys of patients with  organ transplants: Clinical spectrum of BK infectionWorld J Transplant   2016 September 24; 6(3): 472-504 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.472World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/9a/10/WJT-6-472.PMC5036119.pdf
World J Transplant  2016;  6(3): 472-504  Available from: URL: http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/9a/10/WJT-6-472.PMC5036119.pdf
com/2220-3230/full/v6/i3/472.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9a/10/WJT-6-472.PMC5036119.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/9a/10/WJT-6-472.PMC5036119.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Thomas Tousseyn, MD, PhD, Depart - ment of Pathology, University Hospitals Leuven, Herestraat 49,  3000 Leuven, Belgium.",Non-OADS,/arxiv_data1/oa_pdf/c1/3b/WJT-6-505.PMC5036120.pdf
"However, increasing REVIEW 505 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comRecent insights in the pathogenesis of post-transplantation  lymphoproliferative disordersWorld J Transplant   2016 September 24; 6(3): 505-516 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.505World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/c1/3b/WJT-6-505.PMC5036120.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/c1/3b/WJT-6-505.PMC5036120.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source:  Invited manuscript Correspondence to:  Sunita Mathur, BScPT, MSc, PhD,  Department of Physical Therapy, University of Toronto, 160 ­500  University Ave, Toronto,  ON M5G 1V7,  Canada.",Non-OADS,/arxiv_data1/oa_pdf/06/b6/WJT-6-517.PMC5036121.pdf
"As medical and surgical  interventions in lung transplantation have evolved  over time, there has been a demographic shift of indivi - duals undergoing lung transplantation including older  individual s, those with multiple co-morbidites, and REVIEW 517 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comPhysical rehabilitation for lung transplant candidates and  recipients: An evidence-informed clinical approach World J Transplant   2016 September 24; 6(3): 517-531 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.517World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/06/b6/WJT-6-517.PMC5036121.pdf
"World J Transplant  2016; 6(3): 517­531   Available from: URL: http://www.wjgnet.com/2220 ­3230/full/ v6/i3/517.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v6.i3.517 INTRODUCTION Lung t ransplantation is performed for a variety of  advanced lung diseases, with primary indications inclu­ ding interstitial lung disease (ILD), chronic obstruc­ tive pulmonary disease (COPD), cystic fibrosis (CF) and  pulmonary vascular disease[1].",Non-OADS,/arxiv_data1/oa_pdf/06/b6/WJT-6-517.PMC5036121.pdf
"Available from: URL:  http://www.wtgf.org 95 Warburton DE , Sheel AW, Hodges AN, Stewart IB, Yoshida EM,  Levy RD, McKenzie DC.",Non-OADS,/arxiv_data1/oa_pdf/06/b6/WJT-6-517.PMC5036121.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/06/b6/WJT-6-517.PMC5036121.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Hisham A Edinur, PhD, Forensic  Science Programme, School of Health Sciences, Universiti Sains  Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan,  Malaysia.",Non-OADS,/arxiv_data1/oa_pdf/1b/75/WJT-6-532.PMC5036122.pdf
"Immunologically compatible donor REVIEW 532 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comGenetic barriers in transplantation medicineWorld J Transplant   2016 September 24; 6(3): 532-541 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.532World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/1b/75/WJT-6-532.PMC5036122.pdf
"World J Transplant  2016; 6(3): 532­541   Available from: URL: http://www.wjgnet.com/2220 ­3230/full/ v6/i3/532.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v6.i3.532 INTRODUCTION Transplantation is  a systematic medical procedure  for patients with organ failure and haematological  disorders[1,2].",Non-OADS,/arxiv_data1/oa_pdf/1b/75/WJT-6-532.PMC5036122.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/1b/75/WJT-6-532.PMC5036122.pdf
"See: http://creativecommons.org/licenses/by ­nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Amresh Raina, MD, FACC, Associate  Director  (Pulmonary Hypertension Program,  Section of  Heart Failure/Transplant/MCS and Pulmonary Hypertension),   Assistant Professor of Medicine  (Temple University School of  Medicine) , Cardiovascular Institute, Allegheny General Hospital,   320 East North Avenue,  Pittsburgh, PA 15212 ­4772,  United States.",Non-OADS,/arxiv_data1/oa_pdf/d5/fe/WJT-6-542.PMC5036123.pdf
"Clinicians MINIREVIEWS 542 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comHemodynamic monitoring in heart failure and pulmonary  hypertension: From analog tracings to the digital ageWorld J Transplant   2016 September 24; 6(3): 542-547 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.542World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/d5/fe/WJT-6-542.PMC5036123.pdf
"World J Transplant  2016; 6(3): 542­547  Available from: URL:  http://www.wjgnet.com/2220 ­3230/full/v6/i3/542.htm   DOI:  http://dx.doi.org/ 10.5500 /wjt.v6.i3.542 INTRODUCTION Heart failure (HF) is an increasingly prevalent disease  affecting, by  some estimates, over 23 million people  worldwide[1].",Non-OADS,/arxiv_data1/oa_pdf/d5/fe/WJT-6-542.PMC5036123.pdf
"Available from: URL: https:  //http://www.cms.gov/medicare/medicare ­fee­for­service ­payment/ acuteinpatientpps/readmissions ­reduction ­program.html 14 Abraham WT , Compton S, Haas G, Foreman B, Canby RC, Fishel  R, McRae S, Toledo GB, Sarkar S, Hettrick DA.",Non-OADS,/arxiv_data1/oa_pdf/d5/fe/WJT-6-542.PMC5036123.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/d5/fe/WJT-6-542.PMC5036123.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to:  Astrid Bauschke, MD, Department of  General, Visceral and Vascular Surgery, University Hospital Jena,  Erlanger Allee 101, 07740 Jena,  Germany.",Non-OADS,/arxiv_data1/oa_pdf/2e/bc/WJT-6-548.PMC5036124.pdf
"Until now, the best  improvement could be reached with the prophylactic MINIREVIEWS 548 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comCurrent techniques for AB0-incompatible living donor liver  transplantation World J Transplant   2016 September 24; 6(3): 548-555 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.548World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/2e/bc/WJT-6-548.PMC5036124.pdf
wjgnet.com/2220-3230/full/v6/i3/548.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/bc/WJT-6-548.PMC5036124.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/2e/bc/WJT-6-548.PMC5036124.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to:  Periklis Dousdampanis, MD, PhD,  Consultant Nephrologist,  Hemodialysis Unit, Kyanos Stavros,  Germanou 115, 26225 Patras, Greece.",Non-OADS,/arxiv_data1/oa_pdf/5f/32/WJT-6-556.PMC5036125.pdf
"World J Transplant   2016; 6(3): 556-563  Available from: URL: http://www.MINIREVIEWS 556 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comTregs and kidney: From diabetic nephropathy to renal  transplantationWorld J Transplant   2016 September 24; 6(3): 556-563 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.556World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/5f/32/WJT-6-556.PMC5036125.pdf
wjgnet.com/2220-3230/full/v6/i3/556.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5f/32/WJT-6-556.PMC5036125.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/5f/32/WJT-6-556.PMC5036125.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Guo-Sheng Wu, MD, PhD,  Division of  Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases,  the Fourth Military Medical University, #127 Changle West Rd,  Xi’an 710032, Shannxi Province,  China.",Non-OADS,/arxiv_data1/oa_pdf/bf/bf/WJT-6-564.PMC5036126.pdf
"World J Transplant  2016; 6(3): 564-572   Available from: URL: http://www.wjgnet.com/2220-3230/full/ v6/i3/564.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v6.i3.564 INTRODUCTION The intestine is often deemed one of the most difficult MINIREVIEWS 564 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comUpdates on antibody-mediated rejection in intestinal  transplantationWorld J Transplant   2016 September 24; 6(3): 564-572 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.564World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/bf/bf/WJT-6-564.PMC5036126.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/bf/bf/WJT-6-564.PMC5036126.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source: Invited manuscript Correspondence to:  Sascha David, MD,  Department of  Nephrology and Hypertension, Medical School Hannover, Carl Neuberg ­Straße 1, 30625 Hannover,  Germany.",Non-OADS,/arxiv_data1/oa_pdf/5b/1b/WJT-6-573.PMC5036127.pdf
"In this model, we analyzed: (1)  organ function; (2) Kaplan-Meier survival; (3) organ  damage (periodic acid Schiff staining) via semi-quantita - tive scoring [0-4 (0 = no injury/inflammation to 4 =  very severe injury/inflammation)]; (4) expression of  renal endothelial adhesion molecules (ICAM-1) via ORIGINAL ARTICLE 573 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comPharmacological Tie2 activation in kidney transplantationWorld J Transplant   2016 September 24; 6(3): 573-582 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.573World Journal of  Transplantation WJT Basic Study",Non-OADS,/arxiv_data1/oa_pdf/5b/1b/WJT-6-573.PMC5036127.pdf
World J Transplant  2016; 6(3): 573­582   Available from: URL: http://www.wjgnet.com/2220 ­3230/full/ v6/i3/573.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v6.i3.573 INTRODUCTION Graft failure and ultimately graft loss are still major problems in solid organ transplantation.,Non-OADS,/arxiv_data1/oa_pdf/5b/1b/WJT-6-573.PMC5036127.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/5b/1b/WJT-6-573.PMC5036127.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to:  Lesley De Pietri,  MD, Division of Anaes - thesiology and Intensive Care Unit, Department of Cardiology,  Thoracic and V ascular Surgery, Critical Care Medicine, Arcispedale  Santa Maria Nuova, IRCCS, Viale Risorgimento 80, 42123 Reggio  Emilia, Italy.",Non-OADS,/arxiv_data1/oa_pdf/ea/5b/WJT-6-583.PMC5036128.pdf
"In particular the adult  patients (aged 18-70 years) underwent to a first LT with  a MELD score between 15 an d 40 were included, while ORIGINAL ARTICLE 583 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comThromboelastographic reference ranges for a cirrhotic  patient population undergoing liver transplantationWorld J Transplant   2016 September 24; 6(3): 583-593 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.583World Journal of  Transplantation WJT Retrospective Cohort Study",Non-OADS,/arxiv_data1/oa_pdf/ea/5b/WJT-6-583.PMC5036128.pdf
wjgnet.com/2220-3230/full/v6/i3/583.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/5b/WJT-6-583.PMC5036128.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/ea/5b/WJT-6-583.PMC5036128.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Jennifer C Lai, MD, MBA,  Division of  Gastroenterology and Hepatology, UCSF, 513 Parnassus Avenue,  UCSF Box 0538, San Francisco, CA 94143,  United States.",Non-OADS,/arxiv_data1/oa_pdf/0f/1a/WJT-6-594.PMC5036129.pdf
"We encourage early integration of these ser -ORIGINAL ARTICLE 594 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comUnderutilization of palliative care services in the liver  transplant populationWorld J Transplant   2016 September 24; 6(3): 594-598 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.594World Journal of  Transplantation WJT Retrospective Study",Non-OADS,/arxiv_data1/oa_pdf/0f/1a/WJT-6-594.PMC5036129.pdf
wjgnet.com/2220-3230/full/v6/i3/594.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0f/1a/WJT-6-594.PMC5036129.pdf
"Available from: URL: http://www.who.int/cancer/palliative/ definition/en/ 8 Walling AM , Schreibeis-Baum H, Pimstone N, Asch SM, Robinson  L, Korlekar S, Lorenz K, Nwajuaku T, Rosenfeld K. Proactive  case finding to improve concurrently curative and palliative care  in patients with end-stage liver disease.",Non-OADS,/arxiv_data1/oa_pdf/0f/1a/WJT-6-594.PMC5036129.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/0f/1a/WJT-6-594.PMC5036129.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to:  Dr. Wenzel Schoening, Depar tment  of General, Visceral and Transplantation Surgery, Unive rsity  Hospital, Universitätsklinikum der RWTH Aachen, 52074  Aachen, Germany.",Non-OADS,/arxiv_data1/oa_pdf/35/82/WJT-6-599.PMC5036130.pdf
"Particular  attention was paid to the Model for End-Stage Liver  Disease (labMELD)-score and the Eurotransplant Donor  Risk Index (ET-DRI) to unravel their impact on 20-year  survival after LT.ORIGINAL ARTICLE 599 September 24, 2016 |Volume 6 |Issue 3| WJT|www.wjgnet.comEvaluating twenty-years of follow-up after orthotopic liver  transplantation, best practice for donor-recipient matching:  What can we learn from the past era?World J Transplant   2016 September 24; 6(3): 599-607 ISSN 2220-3230 (online) © 2016 Baishideng Publishing Group Inc. All rights reserved.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5500/wjt.v6.i3.599World Journal of  Transplantation WJT Retrospective Study",Non-OADS,/arxiv_data1/oa_pdf/35/82/WJT-6-599.PMC5036130.pdf
"World J Transplant  2016; 6(3): 599­607  Available from: URL:  http://www.wjgnet.com/2220 ­3230/full/v6/i3/599.htm   DOI:  http://dx.doi.org/ 10.5500 /wjt.v6.i3.599 INTRODUCTION Over the last three decades, liver transplantation (LT)  has become the standard therapeutic treatment for patients with terminal liver failure[1-4].",Non-OADS,/arxiv_data1/oa_pdf/35/82/WJT-6-599.PMC5036130.pdf
"Available from: URL: http://www.eurotransplant.org/cms/mediao­ bject.php?file=ar_2011.pdf 10 Ioannou GN , Perkins JD, Carithers RL.",Non-OADS,/arxiv_data1/oa_pdf/35/82/WJT-6-599.PMC5036130.pdf
"© 2016 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/35/82/WJT-6-599.PMC5036130.pdf
[http://dx.doi.org/10.1111/1475-6773.12135 ] [PMID: 24359580 ] [2] Verdon DR. EHRs: the real story.,Non-OADS,/arxiv_data1/oa_pdf/ab/49/TOMINFOJ-10-1.PMC5036150.pdf
"Feb 26 eCollection 2014 [http://dx.doi.org/10.4338/ACI-2013-10-RA-0081 ] [4] Lin CT, McKenzie M, Pell J, Caplan L. Health care provider satisfaction with a new electronic progress note format: SOAP vs. APSO format.",Non-OADS,/arxiv_data1/oa_pdf/ab/49/TOMINFOJ-10-1.PMC5036150.pdf
"[http://dx.doi.org/10.1001/2013.jamainternmed.474 ] [PMID: 23403939 ] [5] Shoolin J, Ozeran L, Hamann C, Bria W II.",OADS,/arxiv_data1/oa_pdf/ab/49/TOMINFOJ-10-1.PMC5036150.pdf
"[http://dx.doi.org/10.4338/ACI-2013-02-R-0012 ] [PMID: 23874365 ] [6] Jablecki CK, Busis NA, Brandstater MA, Krivickas LS, Miller RG, Robinton JE.",OADS,/arxiv_data1/oa_pdf/ab/49/TOMINFOJ-10-1.PMC5036150.pdf
"[http://dx.doi.org/10.1002/mus.20422 ] [PMID: 16116647 ] [7] Moacdieh N, Sarter N. Clutter in electronic medical records: examining its performance and attentional costs using eye tracking.",Non-OADS,/arxiv_data1/oa_pdf/ab/49/TOMINFOJ-10-1.PMC5036150.pdf
[http://dx.doi.org/10.1177/0018720814564594 ] [PMID: 25850110 ] © Shenoy et al.,Non-OADS,/arxiv_data1/oa_pdf/ab/49/TOMINFOJ-10-1.PMC5036150.pdf
"; Licensee Bentham Open This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ab/49/TOMINFOJ-10-1.PMC5036150.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)RBM47 inhibits Nrf2 activity in lung cancer cells T Sakurai et al 5009 © 2016 Macmillan Publishers Limited, part of Springer Nature.",Non-OADS,/arxiv_data1/oa_pdf/ef/7f/onc201635a.PMC5036161.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)TopoII αmediates TCF-dependent EMT in colon cancer Q Zhou et al 4999 © 2016 Macmillan Publishers Limited, part of Springer Nature.",Non-OADS,/arxiv_data1/oa_pdf/c6/08/onc201629a.PMC5036162.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/95/b7/iranjradiol-13-02-20963.PMC5036190.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Hendrikse J, Petersen ET, van Laar PJ, et al.",Non-OADS,/arxiv_data1/oa_pdf/52/ae/jnnp-2015-312906.PMC5036207.pdf
To view please visit the journal online (http://dx.doi.org/10.1136/jech-2015-206870).,Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
"6 T o advance international comparability, the European Joint Action on Healthy Life Y ears ( JA:EHLEIS, http://www.eurohex.eu) set up a workinggroup composed of experts from the EU, Japan,the USA, the Organisation for EconomicCo-operation and Development (OECD) and theWHO.",Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
"Yes —some dif ﬁculty C. Yes —a lot of dif ﬁculty D. Cannot do at all *http://www.cdc.gov/nchs/data/washington_group/WG_Short_Measure_on_Disability.pdf Berger N, et al.J Epidemiol Community Health 2016; 70:1039 –1044.",Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Murray CJ, Salomon JA, Mathers CD, et al .Summary measures of population health: concepts, ethics, measurement and applications .",Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
2011. http://healthypeople.gov/2020/ about/GenHealthAbout.aspx#healthy (accessed 19 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
2014. http://www.eurohex.eu/pdf/Reports_2014/2014_TR7204_A20blueprint.pdf (accessed 19 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
http://www.cdc.gov/nchs/data/washington_group/WG_purpose_paper.pdf(accessed 19 Feb 2016).,OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
2001. http://www.who.int/classi ﬁcations/icf/en/ (accessed 19 Feb 2016).,OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
2002. http://www.who.int/classi ﬁcations/icf/training/icfbeginnersguide.pdf (accessed 19 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
2013. http://www.unece.org/ ﬁleadmin/DAM/stats/publications/BI_ Report_to_CES_2012_-_BI-M2_Final_Version__10_with_cover.pdf (accessed 19 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
2005. http://www.share-project.org/uploads/ tx_sharepublications/SHARE_BOOK_METHODOLOGY_Wave1.pdf (accessed 19 Feb2016).,Non-OADS,/arxiv_data1/oa_pdf/77/30/jech-2015-206870.PMC5036208.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/REFERENCES 1 Buse DC, Manack A, Serrano D, et al.",Non-OADS,/arxiv_data1/oa_pdf/b2/42/jnnp-2016-313458.PMC5036209.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ flgastro-2016-100727).,OADS,/arxiv_data1/oa_pdf/65/2a/flgastro-2016-100727.PMC5036211.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Soubieres A, Wilson P , Poullis A, et al.",Non-OADS,/arxiv_data1/oa_pdf/65/2a/flgastro-2016-100727.PMC5036211.pdf
2014. http://www.bsg.org.uk/clinical/commissioning-report/ibs/functional-symptoms.html 5 National Institute for Health and Care Excellence.,Non-OADS,/arxiv_data1/oa_pdf/65/2a/flgastro-2016-100727.PMC5036211.pdf
"CG61 Manchester: NICE, 2008. https://www.nice.org.uk/guidance/cg61/resources/costing-report-196660189 6 Bellini M, T osetti C, Costa F , et al.",Non-OADS,/arxiv_data1/oa_pdf/65/2a/flgastro-2016-100727.PMC5036211.pdf
"Manchester: NICE, 2013. https://www.nice.org.",Non-OADS,/arxiv_data1/oa_pdf/65/2a/flgastro-2016-100727.PMC5036211.pdf
"British Dietetic Association, 2016. https://www.bda.uk.com/foodfacts/ IBSfoodfacts.pdfSMALL BOWEL AND NUTRITION 330 Williams M, et al.Frontline Gastroenterology 2016; 7:323 –330.",Non-OADS,/arxiv_data1/oa_pdf/65/2a/flgastro-2016-100727.PMC5036211.pdf
To view please visit the journal online (http://dx.doi.org/10.1136/annrheumdis-2015-208121).,Non-OADS,/arxiv_data1/oa_pdf/2f/e8/annrheumdis-2015-208121.PMC5036212.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Hinchcliff M, Varga J.",Non-OADS,/arxiv_data1/oa_pdf/2f/e8/annrheumdis-2015-208121.PMC5036212.pdf
To view please visit the journal online (http://dx.doi.org/10.1136/annrheumdis-2015-207872).,Non-OADS,/arxiv_data1/oa_pdf/34/98/annrheumdis-2015-207872.PMC5036214.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Solomon DH, Goodson NJ, Katz JN, et al.",Non-OADS,/arxiv_data1/oa_pdf/34/98/annrheumdis-2015-207872.PMC5036214.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/jclinpath-2015-203403).,Non-OADS,/arxiv_data1/oa_pdf/19/24/jclinpath-2015-203403.PMC5036215.pdf
"by criteria listed above, were further assessed by the ClinV ar Database (http://www.ncbi.nlm.nih.gov/clinvar/, last accessed 30 November 2015) for classifying a genetic alteration as germlineor somatic.",OADS,/arxiv_data1/oa_pdf/19/24/jclinpath-2015-203403.PMC5036215.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Malapelle U, Carlomagno C, de Luca C, et al.",Non-OADS,/arxiv_data1/oa_pdf/19/24/jclinpath-2015-203403.PMC5036215.pdf
To viewplease visit the journal online(http://dx.doi.org/10.1136/ annrheumdis-2015-207709).,OADS,/arxiv_data1/oa_pdf/c4/a4/annrheumdis-2015-207709.PMC5036216.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Conaghan PG, O ’Connor P, McGonagle D, et al.",Non-OADS,/arxiv_data1/oa_pdf/c4/a4/annrheumdis-2015-207709.PMC5036216.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2015-311004).,OADS,/arxiv_data1/oa_pdf/b2/49/gutjnl-2015-311004.PMC5036217.pdf
"1Translational Research Center for Gastrointestinal Disorders(TARGID), University of Leuven,Leuven, Belgium 2Department of Microbiology and Immunology, Laboratory ofMolecular Bacteriology, KULeuven —University of Leuven, Rega Institute for Medical Research, Leuven, Belgium 3Center for the Biology of Disease, VIB, Leuven, Belgium 4Department of Microbiology, VUB, Brussels, Belgium 5Department of Microbiology and Immunology, Center for the Biology of Disease, REGA institute, KU Leuven —VIB, Leuven, Belgium 6Department of Hepatology, KU Leuven, Leuven, Belgium Correspondence to Jeroen Raes, LaboratoriumMoleculaire Bacteriologie (Rega Instituut), O&N I Herestraat 49 —bus 1028, Leuven 3000, Belgium;jeroen.raes@vib-kuleuven.be JS, SV-S Joint ﬁrst co-authorship SV, JR Joint last co-authorshipReceived 30 October 2015 Revised 18 April 2016Accepted 19 April 2016 Published Online First 20 May 2016 ▸http://dx.doi.org/10.1136/ gutjnl-2016-312137 To cite: Sabino J, Vieira- Silva S, Machiels K, et al.",Non-OADS,/arxiv_data1/oa_pdf/b2/49/gutjnl-2015-311004.PMC5036217.pdf
Combined reads quality threshold was set at minimum 30quality score over 90% of read length (Fastx tool kit; http://hannonlab.cshl.edu/fastx_toolkit/) and chimeric sequences wereﬁltered out (UCHIME 17).,OADS,/arxiv_data1/oa_pdf/b2/49/gutjnl-2015-311004.PMC5036217.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Hirsch ﬁeld GM, Karlsen TH, Lindor KD, et al.",Non-OADS,/arxiv_data1/oa_pdf/b2/49/gutjnl-2015-311004.PMC5036217.pdf
To view please visit the journal online (http://dx.doi.org/10.1136/ flgastro-2015-100651).,Non-OADS,/arxiv_data1/oa_pdf/88/c3/flgastro-2015-100651.PMC5036220.pdf
"See: http://creativecommons.org/licenses/by- nc/4.0/ REFERENCES 1 Hungin AP , Molloy-Bland M, Claes R, et al.",Non-OADS,/arxiv_data1/oa_pdf/88/c3/flgastro-2015-100651.PMC5036220.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 International Organization for Standardization.,Non-OADS,/arxiv_data1/oa_pdf/85/d0/oemed-2016-103688.PMC5036229.pdf
"See: http://creativecommons.org/licenses/ by-nc/4.0/ To cite Krustrup P, Dvorak J, Bangsbo J. Br J Sports Med 2016; 50:1166 –1167.",Non-OADS,/arxiv_data1/oa_pdf/88/3e/bjsports-2016-096266.PMC5036233.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2015-310022).,OADS,/arxiv_data1/oa_pdf/19/d3/gutjnl-2015-310022.PMC5036234.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ Figure 7 Vedolizumab treatment of patients with UC results in increased numbers of regulatory T (Treg) cells in the peripheral blood.,Non-OADS,/arxiv_data1/oa_pdf/19/d3/gutjnl-2015-310022.PMC5036234.pdf
"Gut Published Online First: 24 Feb 2015. http://dx.doi.org/10.1136/gutjnl-2014-306919 51 Fantini MC, Becker C, Tubbe I, et al.",OADS,/arxiv_data1/oa_pdf/19/d3/gutjnl-2015-310022.PMC5036234.pdf
To view please visit the journal online (http://dx.doi.org/10.1136/thoraxjnl-2016-208501).,Non-OADS,/arxiv_data1/oa_pdf/6d/d0/thoraxjnl-2016-208501.PMC5036235.pdf
"Correspondence to Dr Juan F Masa, C/Rafael Alberti 12, Cáceres 10005,Spain; fmasa@separ.es Received 25 February 2016 Revised 16 May 2016 Accepted 17 June 2016Published Online First12 July 2016 ▸http://dx.doi.org/10.1136/ thoraxjnl-2016-208986 To cite: Masa JF, Corral J, Caballero C, et al.Thorax 2016; 71:899 –906.ABSTRACT Background Non-invasive ventilation (NIV) is an effective form of treatment in patients with obesityhypoventilation syndrome (OHS) who have concomitantsevere obstructive sleep apnoea (OSA).",Non-OADS,/arxiv_data1/oa_pdf/6d/d0/thoraxjnl-2016-208501.PMC5036235.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Mokhlesi B, Kryger MH, Grunstein RR.",Non-OADS,/arxiv_data1/oa_pdf/6d/d0/thoraxjnl-2016-208501.PMC5036235.pdf
To view please visit the journal online (http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/94/0d/gutjnl-2016-311937.PMC5036237.pdf
"See: http://creativecommons.org/licenses/ by-nc/4.0/ To cite Nishimoto Y, Mizutani S, Nakajima T, et al .",Non-OADS,/arxiv_data1/oa_pdf/94/0d/gutjnl-2016-311937.PMC5036237.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/gutjnl-2015-311000).,Non-OADS,/arxiv_data1/oa_pdf/4b/48/gutjnl-2015-311000.PMC5036239.pdf
"Received 30 October 2015 Revised 24 March 2016 Accepted 10 April 2016Published Online First24 May 2016 ▸http://dx.doi.org/10.1136/ gutjnl-2016-312040 To cite: Todt D, Gisa A, Radonic A, et al.Gut 2016; 65:1733 –1743.ABSTRACT Objective Hepatitis E virus (HEV) infection can take chronic courses in immunocompromised patientspotentially leading to liver cirrhosis and liver failure.Ribavirin (RBV) is currently the only treatment option formany patients, but treatment failure can occur which has been associated with the appearance of a distinct HEV polymerase mutant (G1634R).",Non-OADS,/arxiv_data1/oa_pdf/4b/48/gutjnl-2015-311000.PMC5036239.pdf
To viewplease visit the journal online(http://dx.doi.org/10.1136/ gutjnl-2014-307856).,OADS,/arxiv_data1/oa_pdf/1d/fd/gutjnl-2014-307856.PMC5036242.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Shepard CW, Finelli L, Alter MJ.",Non-OADS,/arxiv_data1/oa_pdf/1d/fd/gutjnl-2014-307856.PMC5036242.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/gutjnl-2014-308876).,Non-OADS,/arxiv_data1/oa_pdf/50/ea/gutjnl-2014-308876.PMC5036244.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 He R, Geha RS.",Non-OADS,/arxiv_data1/oa_pdf/50/ea/gutjnl-2014-308876.PMC5036244.pdf
"Center for Health Care Strategies, Inc., 2009,  http://www.chcs.org/resource/the-faces-of-medicaid-iii-refin- ing-the-portrait-of-people-with-multiple-chronic-conditions/  16.",Non-OADS,/arxiv_data1/oa_pdf/05/e9/10.1177_2050312116670928.PMC5036246.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/gutjnl-2014-308614).,Non-OADS,/arxiv_data1/oa_pdf/6c/c1/gutjnl-2014-308614.PMC5036249.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Grady WM, Carethers JM.",Non-OADS,/arxiv_data1/oa_pdf/6c/c1/gutjnl-2014-308614.PMC5036249.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/thoraxjnl-2015-208273).,Non-OADS,/arxiv_data1/oa_pdf/6d/c1/thoraxjnl-2015-208273.PMC5036250.pdf
"METHODS Protocol and registration The protocol for this overview, modelled on the Cochrane Collaboration approach14and written using the Preferred Reporting Items for Systematic review and Meta-AnalysisProcotol (PRISMA-P) guidelines, 15has been registered (National Institute of Health Research International Prospective Register of Systematic Reviews (PROSPERO) CRD42015001068, avail-able at http://www.crd.york.ac.uk/PROSPERO/prospero.asp) andpublished previously .",OADS,/arxiv_data1/oa_pdf/6d/c1/thoraxjnl-2015-208273.PMC5036250.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Puthucheary ZA, Rawal J, McPhail M, et al.",Non-OADS,/arxiv_data1/oa_pdf/6d/c1/thoraxjnl-2015-208273.PMC5036250.pdf
"London, UK: National Institute for Health and Care Excellence, 2009; http://www.nice.org.uk/guidance/cg83 (accessed 1 May 2015).",Non-OADS,/arxiv_data1/oa_pdf/6d/c1/thoraxjnl-2015-208273.PMC5036250.pdf
Development of a core outcomes set for trials of rehabilitation following critical illness Core Outcome Measures inEffectiveness Trials Initiative 2013. http://www.comet-initiative.org/studies/details/288?result=true 46 Developing and evaluating complex interventions: new guidance.,Non-OADS,/arxiv_data1/oa_pdf/6d/c1/thoraxjnl-2015-208273.PMC5036250.pdf
"2008. http://www.mrc.ac.uk/complexinterventionsguidance 890 Connolly B, et al.Thorax 2016; 71:881–890.",Non-OADS,/arxiv_data1/oa_pdf/6d/c1/thoraxjnl-2015-208273.PMC5036250.pdf
Acknowledgements Iain McElarney of MAST Group (http://www.mastgrp.com) helped in the design and production of the patient information sheets.,Non-OADS,/arxiv_data1/oa_pdf/e1/b8/gutjnl-2015-309579.PMC5036251.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 NICE clinical guideline 27; Referral guidelines for suspected cancer.,Non-OADS,/arxiv_data1/oa_pdf/e1/b8/gutjnl-2015-309579.PMC5036251.pdf
http://www.nice.,Non-OADS,/arxiv_data1/oa_pdf/e1/b8/gutjnl-2015-309579.PMC5036251.pdf
http://www.nice.org.uk/guidance/ indevelopment/gid-cgwave0618 (accessed May 2015).,Non-OADS,/arxiv_data1/oa_pdf/e1/b8/gutjnl-2015-309579.PMC5036251.pdf
https://www.nice.org.uk/guidance/dg11 (accessed Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/e1/b8/gutjnl-2015-309579.PMC5036251.pdf
"http://www.stard- statement.org/ (last accessed December 2014) 20 Fraser CG, Allison JE, Halloran SP, et al.",Non-OADS,/arxiv_data1/oa_pdf/e1/b8/gutjnl-2015-309579.PMC5036251.pdf
https://weatherspark.com/#!,Non-OADS,/arxiv_data1/oa_pdf/e1/b8/gutjnl-2015-309579.PMC5036251.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/gutjnl-2015-311304).,Non-OADS,/arxiv_data1/oa_pdf/48/20/gutjnl-2015-311304.PMC5036253.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Suerbaum S, Michetti P. Helicobacter pylori infection.",Non-OADS,/arxiv_data1/oa_pdf/48/20/gutjnl-2015-311304.PMC5036253.pdf
"8), 2014. http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php (accessed 19 Oct 2015).",Non-OADS,/arxiv_data1/oa_pdf/48/20/gutjnl-2015-311304.PMC5036253.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-BMIsage).",Non-OADS,/arxiv_data1/oa_pdf/de/92/10.1177_2048004016669645.PMC5036254.pdf
"Geneva: WHO, http://www.who.int/mediacen- tre/factsheets/fs311/en/ (2016, accessed 7 September 2016).",Non-OADS,/arxiv_data1/oa_pdf/de/92/10.1177_2048004016669645.PMC5036254.pdf
To view please visit the journal online (http://dx.doi.org/10.1136/gutjnl-2015-310625).,Non-OADS,/arxiv_data1/oa_pdf/28/48/gutjnl-2015-310625.PMC5036256.pdf
"Correspondence to Professor Kam M Hui, Divisionof Cellular and MolecularResearch, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore;cmrhkm@nccs.com.sg Received 25 August 2015 Revised 11 February 2016 Accepted 12 February 2016Published Online First3 March 2016 ▸http://dx.doi.org/10.1136/ gutjnl-2016-311637 To cite: Chen J, Rajasekaran M, Xia H, et al.",Non-OADS,/arxiv_data1/oa_pdf/28/48/gutjnl-2015-310625.PMC5036256.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2014-308932).,OADS,/arxiv_data1/oa_pdf/99/01/gutjnl-2014-308932.PMC5036257.pdf
"POU2F2 may affect GC metastasis by the positive regulation of ROBO1 T o uncover the mechanism of POU2F2 in GC, the target genes that may be regulated by POU2F2 were analysedusing TRANSFAC (http://www.gene-regulation.com/index2.html).",Non-OADS,/arxiv_data1/oa_pdf/99/01/gutjnl-2014-308932.PMC5036257.pdf
NF- κB was predicted to have four potential binding sites in the POU2F2 promoter region based on the TRANSFACdata and Promoter 2.0 (http://www.cbs.dtu.dk/services/Promoter/).,Non-OADS,/arxiv_data1/oa_pdf/99/01/gutjnl-2014-308932.PMC5036257.pdf
"T argetScanHuman 6.2 (http://www.targetscan.org/) analysis indicated that the POU2F2 3 0-UTR region contained miR-218-binding sites, suggesting thatPOU2F2 might be the target gene of miR-218.",Non-OADS,/arxiv_data1/oa_pdf/99/01/gutjnl-2014-308932.PMC5036257.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Friedl EM, Matthias P. Transcriptional activation and repression, two properties of the lymphoid-speci ﬁc transcription factor Oct-2a.",Non-OADS,/arxiv_data1/oa_pdf/99/01/gutjnl-2014-308932.PMC5036257.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Malone RE.,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2014. http://www.cancerresearchuk.org/sites/default/ ﬁles/policy_july2014_fullendgame_report.pdf (accessed 11 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2015. http://www.euromonitor.com/ tobacco-in-brazil/report (accessed 3 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
http://europa.eu/rapid/press-release_MEMO-14-134_ en.htm.,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2015. http://www.fctc.org/fca-news/opinion-pieces/1328-canadian- provinces- ﬁrst-to-ban-menthol- ﬂavouring (accessed 10 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
http://www.azdhs.gov/medicalmarijuana/ 46 Pidd H. Doctors to prescribe cigarettes under plan.,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2011. http://www.ashaust.org.au/pdfs/DutyFreeASHandHFpos1109.pdf (accessed 22 Jul 2013).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2007. http://www.enzi.senate.gov/public/index.cfm/news-releases?ContentRecord_ id=e04eb904-802a-23ad-4157-dd5d44e9d647 (accessed 10 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2015. http://www.clivebates.com/documents/endgame.pdf (accessed 10 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2014. http://www.hurriyetdailynews.com/uruguay-marijuana-sales-delayed-until- 2015-president.aspx?pageID=238&nID=68922&NewsCatID=358 (accessed 20 Jul2015).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2015. http://www.ash.org.uk/ ﬁles/documents/ASH_963.pdf (accessed 15 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
2010. http://www.publicintegrity.org/ 2010/11/15/4036/part-iii-uruguay-vs-philip-morris (accessed 2015 15 July).,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/tobaccocontrol-2015-052356.PMC5036259.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).T rends in Hearing 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/93/58/10.1177_2331216516665608.PMC5036260.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2015-309276).,OADS,/arxiv_data1/oa_pdf/23/95/gutjnl-2015-309276.PMC5036270.pdf
"Data in the HumanProtein Altas show high or medium protein expression ofMDGA2 in some normal human tissues including the stomach(http://www.proteinatlas.org/ENSG00000139915/tissue), but itwas not detected in all 12 tested stomach cancer tissues accord-ing to data in the Human Protein Altas (http://www.proteinatlas.org/ENSG00000139915/cancer).",Non-OADS,/arxiv_data1/oa_pdf/23/95/gutjnl-2015-309276.PMC5036270.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Camargo MC, Kim WH, Chiaravalli AM, et al.",Non-OADS,/arxiv_data1/oa_pdf/23/95/gutjnl-2015-309276.PMC5036270.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/oemed-2016-103775).,Non-OADS,/arxiv_data1/oa_pdf/fb/27/oemed-2016-103775.PMC5036271.pdf
See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 International Atomic Energy Agency.,Non-OADS,/arxiv_data1/oa_pdf/fb/27/oemed-2016-103775.PMC5036271.pdf
To viewplease visit the journal online(http://dx.doi.org/10.1136/ tobaccocontrol-2015-052582).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Institute for Health Metrics and Evaluation.,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
"Seattle, USA, 2013. http://www.healthmetricsandevaluation.org/gbd (accessed 8 May 2014).",Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
Geneva: 2003 http://apps.who.int/iris/bitstream/10665/42811/1/9241591013.pdf(accessed 21 Sept 2015) 5 Ustawa z dnia 9 listopada 1995 r. o ochronie zdrowia przed nast ępstwami używania tytoniu i wyrobów tytoniowych.,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
1995. http://isap.sejm.gov.pl/ DetailsServlet?id=WDU19960100055 (accessed 23 Apr 2015).,OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
Brussels: 2001. http://ec.europa.eu/health/tobacco/docs/dir200137ec_tobaccoproducts_en.pdf (accessed 21 Sept 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2012. http://seatca.org/dmdocuments/Art%205.3% 20Toolkit%202012.pdf (accessed 23 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2012. http://www.who.int/tobacco/wntd/2012/industry_interference.pdf(accessed 1 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
"Krakow: 2013. http://ash.org/wp-content/uploads/2013/08/PR-and-CSR-practices-of-the-Tobacco-Industry-in-Poland_MANKO-Association.pdf(accessed 23 Apr 2015).21 Stoklosa M, Ross H. Contrasting academic and tobacco industry estimates of illicit cigarette trade: evidence from Warsaw, Poland.",Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
"Gda ńsk, Poland: Polskie Towarzystwo Programów Zdrowotnych, 2013. http://ptpz.pl/images/publikacjePTPZ/analiza%20dzialan% 20przemyslu%20tytoniowego%202006%202012.pdf (accessed 23 Apr 2015).",Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2015. http://www.bcc.org.pl/ Czlonkowie-BCC.297.0.html (accessed 27 Aug 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2015. http://www.tobaccoatlas.org/topic/ growing-tobacco/ (accessed 30 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
"Pracuj ący w gospodarce narodowej w 2012 r. 2013. http://stat.gov.pl/obszary-tematyczne/rynek-pracy/pracujacy-zatrudnieni-wynagrodzenia-koszty-pracy/ pracujacy-w-gospodarce-narodowej-w-2012-r-,7,9.html (accessed 1 May 2015).",Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2014. http://www.pmi.com/eng/media_center/media_kit/documents/sun%20report%202013.pdf (accessed 9 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
"Atlanta, GA: The American Cancer Society, Inc., 2015. http://tobaccoatlas.org/ (accessed 9 Apr 2015).",Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2013. http://www.mf.gov.pl/documents/764034/6107396/Opracowanie +tytoniowe+2011 –2012-biuletyn+zatwierdzony.pdf (accessed 30 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2013. http://www.tobaccofreekids.org/research/factsheets/pdf/0325.pdf (accessed 30 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2009. http://stopcontrabandtobacco.ca/wp-content/themes/ stopcontrabandtobacco/pdf/timeforaction2009.pdf (accessed 3 May 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
http://www.pmi.,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2014. http://info.worldbank.org/governance/wgi/index.aspx#home (accessed 29 Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2015. http://comtrade.un.org/data/ (accessed 24 Apr 2015).,OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
2014.http://curia.europa.eu/juris/document/document.jsf?text=&docid=156981&pageIndex=0&doclang=EN&mode=lst&dir=&occ= ﬁrst&part=1&cid=191696 (accessed 6 May 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
Bloomberg Published Online First: 2014. http://www.ekonomia.rp.pl/artykul/1163808.html?print=tak&p=0(accessed 6 May 2015).,Non-OADS,/arxiv_data1/oa_pdf/83/cc/tobaccocontrol-2015-052582.PMC5036272.pdf
"International Journal of Preventive Medicine 2016, 7:108 http://www.ijpvmjournal.net/content/7/1/108the MuPINSC.",Non-OADS,/arxiv_data1/oa_pdf/a1/52/IJPVM-7-108.PMC5036276.pdf
"International Journal of Preventive Medicine 2016, 7:108 http://www.ijpvmjournal.net/content/7/1/108of the study.",Non-OADS,/arxiv_data1/oa_pdf/a1/52/IJPVM-7-108.PMC5036276.pdf
"International Journal of Preventive Medicine 2016, 7:108 http://www.ijpvmjournal.net/content/7/1/108When the household and demographic characteristics  were taken into account in the ordinal logistic regression  analysis [ Table  3], for each person increase in family  size, the odds of having worse food insecurity, increased  by 38% (odds ratio [OR] =1.38, 95% confidence  interval [CI]: 1.1–1.73).",Non-OADS,/arxiv_data1/oa_pdf/a1/52/IJPVM-7-108.PMC5036276.pdf
"International Journal of Preventive Medicine 2016, 7:108 http://www.ijpvmjournal.net/content/7/1/108indirectly influence the household food security status  or food access.",Non-OADS,/arxiv_data1/oa_pdf/a1/52/IJPVM-7-108.PMC5036276.pdf
"International Journal of Preventive Medicine 2016, 7:108 http://www.ijpvmjournal.net/content/7/1/108their report, BMI was not associated with household  food insecurity as measured by HFIAS.",Non-OADS,/arxiv_data1/oa_pdf/a1/52/IJPVM-7-108.PMC5036276.pdf
"International Journal of Preventive Medicine 2016, 7:109 http://www.ijpvmjournal.net/content/7/1/109antibodies at the same time can help to understand the  relationship between these two diseases.",Non-OADS,/arxiv_data1/oa_pdf/13/58/IJPVM-7-109.PMC5036277.pdf
"International Journal of Preventive Medicine 2016, 7:109 http://www.ijpvmjournal.net/content/7/1/109this antibody in normal people.",Non-OADS,/arxiv_data1/oa_pdf/13/58/IJPVM-7-109.PMC5036277.pdf
"International Journal of Preventive Medicine 2016, 7:109 http://www.ijpvmjournal.net/content/7/1/10917.1% of the cases had a positive familial history, which  was in the range of other studies.",Non-OADS,/arxiv_data1/oa_pdf/13/58/IJPVM-7-109.PMC5036277.pdf
Available from: http://www.consensus.nih.gov/.,Non-OADS,/arxiv_data1/oa_pdf/13/58/IJPVM-7-109.PMC5036277.pdf
"International Journal of Preventive Medicine 2016, 7:107 http://www.ijpvmjournal.net/content/7/1/107fitness.",Non-OADS,/arxiv_data1/oa_pdf/7d/a0/IJPVM-7-107.PMC5036278.pdf
The number of shuttles and  laps completed were then recorded and subsequently  converted to estimated VO2 max values via the calculator  provided in a website (http://www.topendsports.com/ testing/beepcalc.htm).,Non-OADS,/arxiv_data1/oa_pdf/7d/a0/IJPVM-7-107.PMC5036278.pdf
"International Journal of Preventive Medicine 2016, 7:107 http://www.ijpvmjournal.net/content/7/1/107and fungal immunomodulatory proteins.",Non-OADS,/arxiv_data1/oa_pdf/7d/a0/IJPVM-7-107.PMC5036278.pdf
"International Journal of Preventive Medicine 2016, 7:107 http://www.ijpvmjournal.net/content/7/1/107Wingate anaerobic power and capacity At pre‑ and post‑tests, anaerobic power of the RT group  was significantly lower ( P < 0.05) compared to the C  group [ Table  4].",Non-OADS,/arxiv_data1/oa_pdf/7d/a0/IJPVM-7-107.PMC5036278.pdf
"International Journal of Preventive Medicine 2016, 7:107 http://www.ijpvmjournal.net/content/7/1/107there was no significant difference in any of the groups.",Non-OADS,/arxiv_data1/oa_pdf/7d/a0/IJPVM-7-107.PMC5036278.pdf
"International Journal of Preventive Medicine 2016, 7:107 http://www.ijpvmjournal.net/content/7/1/107power of shoulder extension and flexion at 300°/s, peak  torque of knee flexion at 60°/s, and average power of  knee extension and flexion at 300°/s.",Non-OADS,/arxiv_data1/oa_pdf/7d/a0/IJPVM-7-107.PMC5036278.pdf
"International Journal of Preventive Medicine 2016, 7:107 http://www.ijpvmjournal.net/content/7/1/107Mdm.",Non-OADS,/arxiv_data1/oa_pdf/7d/a0/IJPVM-7-107.PMC5036278.pdf
"International Journal of Preventive Medicine 2016, 7:111 http://www.ijpvmjournal.net/content/7/1/111F344 rats was selected, given its recognized capabilities  of being a model organism.",Non-OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
"International Journal of Preventive Medicine 2016, 7:111 http://www.ijpvmjournal.net/content/7/1/111a count of true positives ( Tp) and false negatives (FN), as  shown in Eq.",Non-OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
"International Journal of Preventive Medicine 2016, 7:111 http://www.ijpvmjournal.net/content/7/1/111is more likely to suffer alterations in pituitary gland with  low exposure times (3–6 months), without taking into  account the dosage level.",Non-OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
"International Journal of Preventive Medicine 2016, 7:111 http://www.ijpvmjournal.net/content/7/1/111combinations can be omitted for the prediction of effects  on the endocrine system, the average magnitude of error  is considered feasible or appropriate for this study.",Non-OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
"International Journal of Preventive Medicine 2016, 7:111 http://www.ijpvmjournal.net/content/7/1/111rat‑human mathematical model for the endocrine system,  will be useful to improve and explore more prediction  tasks in discovering alterations in glands, with the  advantage of decrease test in animals.",Non-OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
"International Journal of Preventive Medicine 2016, 7:111 http://www.ijpvmjournal.net/content/7/1/111Epidemiological Monitoring System ‑ Sivigila.",Non-OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
Available from: http://www.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
Available from: http://www.epa.,OADS,/arxiv_data1/oa_pdf/5c/93/IJPVM-7-111.PMC5036280.pdf
"International Journal of Preventive Medicine 2016, 7:106 http://www.ijpvmjournal.net/content/7/1/106“self‑rated stress” (SRS) instrument in relation with  coronary artery calcification in 325 patients undergoing a  comprehensive health assessment.",Non-OADS,/arxiv_data1/oa_pdf/f0/9d/IJPVM-7-106.PMC5036281.pdf
"International Journal of Preventive Medicine 2016, 7:106 http://www.ijpvmjournal.net/content/7/1/106social problems.",Non-OADS,/arxiv_data1/oa_pdf/f0/9d/IJPVM-7-106.PMC5036281.pdf
"International Journal of Preventive Medicine 2016, 7:106 http://www.ijpvmjournal.net/content/7/1/106TPSS [ Figure  2].",Non-OADS,/arxiv_data1/oa_pdf/f0/9d/IJPVM-7-106.PMC5036281.pdf
"International Journal of Preventive Medicine 2016, 7:106 http://www.ijpvmjournal.net/content/7/1/106so that it has not recognized as an independent risk  factor for CAD.",Non-OADS,/arxiv_data1/oa_pdf/f0/9d/IJPVM-7-106.PMC5036281.pdf
"International Journal of Preventive Medicine 2016, 7:106 http://www.ijpvmjournal.net/content/7/1/1069.",Non-OADS,/arxiv_data1/oa_pdf/f0/9d/IJPVM-7-106.PMC5036281.pdf
"International Journal of Preventive Medicine 2016, 7:110 http://www.ijpvmjournal.net/content/7/1/110enrolled in the project.",Non-OADS,/arxiv_data1/oa_pdf/18/be/IJPVM-7-110.PMC5036282.pdf
"International Journal of Preventive Medicine 2016, 7:110 http://www.ijpvmjournal.net/content/7/1/110RESULTS Fifty‑six individuals were registered in the study; however,  the trial was completed only by fifty participants.",Non-OADS,/arxiv_data1/oa_pdf/18/be/IJPVM-7-110.PMC5036282.pdf
"International Journal of Preventive Medicine 2016, 7:110 http://www.ijpvmjournal.net/content/7/1/110Nuclear factor‑ κβ modulates expression of inflammatory  cytokines, including tumor necrosis factor alpha (TNF‑α).",Non-OADS,/arxiv_data1/oa_pdf/18/be/IJPVM-7-110.PMC5036282.pdf
"International Journal of Preventive Medicine 2016, 7:110 http://www.ijpvmjournal.net/content/7/1/110attributed to greater reduction in adiposity and body  weight [Table 2].",Non-OADS,/arxiv_data1/oa_pdf/18/be/IJPVM-7-110.PMC5036282.pdf
"International Journal of Preventive Medicine 2016, 7:110 http://www.ijpvmjournal.net/content/7/1/110randomized controlled trials of low‑carbohydrate vs. low‑fat/low‑calorie diets  in the management of obesity and its comorbidities.",Non-OADS,/arxiv_data1/oa_pdf/18/be/IJPVM-7-110.PMC5036282.pdf
"1 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by- nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited.",Non-OADS,/arxiv_data1/oa_pdf/86/f4/iew066.PMC5036285.pdf
This trial was registered with  http://www.irct.ir (no.,Non-OADS,/arxiv_data1/oa_pdf/6f/6e/NMJ-57-253.PMC5036295.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.MICROBIAL DRUG RESISTANCE Volume 22, Number 6, 2016Mary Ann Liebert, Inc.DOI: 10.1089/mdr.2016.0070 477",Non-OADS,/arxiv_data1/oa_pdf/43/64/mdr.2016.0070.PMC5036311.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.MICROBIAL DRUG RESISTANCE Volume 22, Number 6, 2016Mary Ann Liebert, Inc.DOI: 10.1089/mdr.2016.0053 461",Non-OADS,/arxiv_data1/oa_pdf/9a/00/mdr.2016.0053.PMC5036312.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.MICROBIAL DRUG RESISTANCE Volume 22, Number 6, 2016Mary Ann Liebert, Inc.DOI: 10.1089/mdr.2016.0128 499",Non-OADS,/arxiv_data1/oa_pdf/43/de/mdr.2016.0128.PMC5036315.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.MICROBIAL DRUG RESISTANCE Volume 22, Number 6, 2016Mary Ann Liebert, Inc.DOI: 10.1089/mdr.2016.0084 487",Non-OADS,/arxiv_data1/oa_pdf/8e/04/mdr.2016.0084.PMC5036317.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.MICROBIAL DRUG RESISTANCE Volume 22, Number 6, 2016Mary Ann Liebert, Inc.DOI: 10.1089/mdr.2016.0083 470",Non-OADS,/arxiv_data1/oa_pdf/d2/b3/mdr.2016.0083.PMC5036320.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.POPULATION HEALTH MANAGEMENT Volume 19, Number 5, 2016Mary Ann Liebert, Inc.DOI: 10.1089/pop.2015.0108 357",Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
Available at: http://www.myhealthycommunities.g ov.au/Content/publications/downloads/NHPA_ HC_Report_Avoidable_deaths_life_expectan cy_ December_2013.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
2015. http://commonwealth.communitycarenc.org/about/evol ution.aspx.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
May 2012. https://cco.health.o regon.gov/RFA/Documents/ CCO_RFA_without_separate_documents_Final_3-18-12.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
https://http://www.communitycarenc.org/about-us/history-ccnc-rev/.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
January 2012. https://cco.health.oregon.gov/ Documents/cco-implementation-proposal.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://www.myhealthycommunities.gov.au/Cont ent/publications/downloads/NHPA_HC_Report_ Avoidable_deaths_life_expectancy_December_2013.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
April 2015. https://www.colorado.gov /paciﬁc/sites/default/ﬁles/ KPI%20Incentive%20Fact%20Sheet.pdf.,OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
January 2015. http://www.oregon.gov/oha /Metrics/Documents/2014%20Mid- Year%20Report%20-%20Jan%202015.pdf.,OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://www.chcs.org/media/ACO-Governance-Matrix_Final_ 072415.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
"Updated January 6, 2015. https://www.cms.gov/Medicare/Medicare-Fee-for-Service- Payment/ACO/index.html.",Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://pcmh.ahrq.gov/page/deﬁning-pcmh.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://www.nashp.org/sites/default/ﬁles/The_Essential_Role_ of_States_in_Financing_ﬁnal.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://www.federalﬁnancialrelations.gov .au/content/npa/health_reform/national-agreement.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
https://www.colorado .gov/paciﬁc/sites/default/ﬁles/Overview of the ACC Pro- gram.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
"New York Times; April 12, 2013. http://www.nytimes .com/2013/04/13/us/oregon-expe riments-with-localized- medicaid.html?_r=0.",Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
https://ic.n3cn.org/.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://www.orhealthleadershipcouncil.org/our-current-initiatives/emergency-department-information- exchange-edie.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://www.myhealthycommunities.gov.au/.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
June 2014. http://www.statesmanjournal.com/story/news/ politics/state-workers/2014/06/17/state-worker-insurance- premiums-cheaper-next-year/10714099/.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
Septe mber 2011. http://www.amednews .com/article/20110912/government/309129956/6/.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
https://www.colorado.gov/ paciﬁc/sites/default/ﬁles/Accountable Care Collaborative 2014 Annual Report.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
Last updated April 2015. http://www.health.gov.au/ internet/ministers/publishing.nsf/Content/health-mediarel- yr2015-ley036.htm.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
2014. http://www.health.gov.au/internet/main/publishing.nsf/Content/ 53A642596DABB8BFCA257DDD00106EAD/$File/guide lines.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
http://www.humanservices .gov.au/customer/services/medicare/healthcare-identiﬁers- service.,Non-OADS,/arxiv_data1/oa_pdf/2c/3f/pop.2015.0108.PMC5036321.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncom-mercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.THYROID Volume 26, Number 9, 2016Mary Ann Liebert, Inc.DOI: 10.1089/thy.2016.0016 1215",Non-OADS,/arxiv_data1/oa_pdf/0a/74/thy.2016.0016.PMC5036323.pdf
Data analysis and ﬁltering An in-house developed analysis pipeline was used for the evaluation of raw fastq ﬁles generated by the MiSeq-sequencer.Cutadapt (https://code.google.com/p/cutadapt/) software served for adapter removal and read trimming.,OADS,/arxiv_data1/oa_pdf/0a/74/thy.2016.0016.PMC5036323.pdf
The remaining reads were mapped to thehuman reference genome hg19 using a BWA-MEM algorithm (http://bio-bwa.sourceforge.net/).,OADS,/arxiv_data1/oa_pdf/0a/74/thy.2016.0016.PMC5036323.pdf
"Variant calling (SNVs and indels) was performed using four different variant callertools: GATK HaplotypeCaller (www.broadinstitute.org/gatk/),SAMTools mpileup (http://samtools.sourceforge.net/), At- las2 (http://sourceforge.net/projects/atlas2/), and Platypus (www .well.ox.ac.uk/platypus).",OADS,/arxiv_data1/oa_pdf/0a/74/thy.2016.0016.PMC5036323.pdf
"All called variants were annotatedusing SnpEff (http://snpeff.sourceforge.net/), ANNOVAR (http:// annovar.openbioinformatics.org/), and multiple different public databases (e.g., ExAC, 1000 Genomes, dbSNP, and ClinVar).Variants met the following inclusion criteria for the downstream analysis: located within the exon or splicing regions, a high or moderate effect on gene function, and an unknown or variantallele frequency <1% in the 1000 genomes variant database.Table 1.List and the Coverage of the Genes Included in the NGS Panel Used for the Genetic CH Screening Target ID Regions CoverageHigh coverage (‡90%)Low coverage (<90%) DUOX1a33 95.83% 31 2 DUOX2 32 95.82% 31 2 IYD 8 100.00% 8 0 NKX2-5 4 100.00% 4 0 PAX8 11 100.00% 11 0 SLC26A4 21 99.71% 21 0 SLC5A5 15 99.85% 15 0 TG 50 100.00% 50 0 TPO 18 100.00% 18 0 TRHa2 100.00% 2 0 TRHRb2 100.00% 2 0 TSHBb2 100.00% 2 0 TSHR 11 100.00% 11 0 Three other known CH genes ( DUOXA2 ,FOXE1 , and IGSF1 ) were not included in the screening panel.",OADS,/arxiv_data1/oa_pdf/0a/74/thy.2016.0016.PMC5036323.pdf
Variants that met these conditions and passed visual inspection were annotated using Condel (http://bg.upf.edu/fannsdb/).,Non-OADS,/arxiv_data1/oa_pdf/0a/74/thy.2016.0016.PMC5036323.pdf
Available: http://ofbindia.gov.in/download/ rti_man/rti_am/OFB%20guideline%20on%20PME.pdf [May 2006].,OADS,/arxiv_data1/oa_pdf/44/a2/IJRI-26-402.PMC5036342.pdf
Available: https://www.iocl.,Non-OADS,/arxiv_data1/oa_pdf/44/a2/IJRI-26-402.PMC5036342.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/ef/rjw164.PMC5036355.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/30/dd/iranjradiol-13-02-20143.PMC5036402.pdf
"19-21The number of CTCs CONTACT Tongjun Liu tongjunliu@163.com ,383888697@qq.com Department of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China; Lizhi Niu fudaclab@gmail.com Fuda Cancer Hospital, Jinan University School of Medicine; Guangzhou Fuda Cancer Insititute, Guangzhou, Guangdong, China Published with license by Taylor & Francis Group, LLC © Jian Shi, Yuan Li, Shuzhen Liang, Jianying Zeng, Guifeng Liu, Feng Mu, Haibo Li, Jibing Chen, Ton gjun Liu, and Lizhi Niu This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
"9, 935 –942 http://dx.doi.org/10.1080/15384047.2016.1210731",Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cell 2011; 147:275-92; PMID:22000009; http://dx.doi.org/10.1016/j.cell.2011.09.024 2.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
World J Surg 1995; 19:59-71; PMID:7740812; http://dx.doi.org/10.1007/BF00316981 3.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cancer Epidemiol Bio-markers Prev 2010; 19:1893-907; PMID:20647400; http://dx.doi.org/ 10.1158/1055-9965.EPI-10-0437 4.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
J Gastrointest Surg 2013; 17:195-201; quiz p.201-2; PMID:23054896; http://dx.doi.org/ 10.1007/s11605-012-2022-3 5.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Ann Surg 1999; 230:309-18; discussion 318-21; PMID:10493478; http://dx.doi.org/ 10.1097/00000658-199909000-00004 6.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Br Med Bull 2011; 99:107-24; PMID:21813558; http://dx.doi.org/10.1093/bmb/ ldr034 7.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cancer 2001; 91:1121-8; PMID:11267957;http://dx.doi.org/10.1002/1097-0142(20010315)91:6%3c1121::AID-CNCR1108%3e3.0.CO;2-2 8.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
CA Cancer J Clin 2009; 59:145-70; PMID:19364702; http://dx.doi.org/10.3322/caac.20013 10.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Surgery 2004; 136:770-9; PMID:15467661; http://dx.doi.org/10.1016/j.surg.2004.07.001 11.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Case Rep Med 2011; 2011:243243; PMID:21629795; http://dx.doi.org/10.1155/2011/243243 12.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Tech Cancer ResTreat 2004; 3:151-63; PMID:15059021; http://dx.doi.org/10.1177/ 153303460400300208 13.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Eur J Surg 2001; 167:610-7; PMID:11716448; http://dx.doi.org/10.1080/110241501753171227 14.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
J Surg Oncol 2010; 102:413-8; PMID:20544718; http://dx.doi.org/10.1002/ jso.21618 17.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Clin Chem 2013; 59:110-8; PMID:23014601; http://dx.doi.org/ 10.1373/clinchem.2012.194258 18.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Nat Rev Cancer 2009; 9:274-84; PMID:19308067; http://dx.doi.org/10.1038/nrc2622CANCER BIOLOGY & THERAPY 941,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cancer Cell 2013;23:573-81; PMID:23680145; http://dx.doi.org/10.1016/j.ccr.2013.04.017 20.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cancer Immunol Immunother 2013; 62:931- 9; PMID:23314304; http://dx.doi.org/10.1007/s00262-012-1387-1 21.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cancer Metastasis Rev 2012; 31:663-71;PMID:22692478; http://dx.doi.org/10.1007/s10555-012-9366-8 22.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Am J Pathol 2009; 175:808-16;PMID:19628770; http://dx.doi.org/10.2353/ajpath.2009.090078 23.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
J Clin Oncol 2011; 29:1556-63; PMID:21422424; http://dx.doi.org/10.1200/JCO.2010.28.7045 24.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
N Engl J Med 2004; 351:781-91; PMID:15317891; http://dx.doi.org/10.1056/NEJMoa040766 25.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
ClinCancer Res 2006; 12:4218-24; PMID:16857794; http://dx.doi.org/ 10.1158/1078-0432.CCR-05-2821 26.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
"J ClinOncol 2008; 26:3213-21; PMID:18591556; http://dx.doi.org/10.1200/JCO.2007.15.8923 27. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulatingtumor cells predict survival bene ﬁt from treatment in metastatic cas- tration-resistant prostate cancer.",Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Clin Cancer Res 2008; 14:6302-9; PMID:18829513; http://dx.doi.org/10.1158/1078-0432.CCR-08-0872 28.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Nat Rev Cancer 2008; 8:329-40; PMID:18404148; http://dx.doi.org/10.1038/ nrc2375 29.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Semin Oncol 2006; 33:S9-14; PMID:16797376; http://dx.doi.org/10.1053/j.seminoncol.2006.03.016 30.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
World J Gastroenterol2008; 14:1430-6; PMID:18322961; http://dx.doi.org/10.3748/wjg.14.1430 31.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
J Clin Transl Hepatol 2014; 2:182-8; PMID:26355719; http://dx.doi.org/10.14218/JCTH.2014.00017 32.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cytometry A 2010; 77:213-9; PMID:20169594; http://dx.doi.org/10.1002/cyto.a.20838 33.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Ann Surg 2002; 235:499-506; PMID:11923605; http://dx.doi.org/10.1097/00000658-200204000-00007 34.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
"Isolation, culture and phenotypic characterization of human sweat gland epithelial cells.Int J Mol Med 2014; 34:997-1003; PMID:25187692; http://dx.doi.org/ 10.3892/ijmm.2014.1851 35.",Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
World J Surg 2006; 30:1007- 13; PMID:16736329; http://dx.doi.org/10.1007/s00268-005-0485-z 36.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Lancet Oncol 2004; 5:79-88; PMID:14761811; http://dx.doi.org/ 10.1016/S1470-2045(04)01381-6 37.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
JJ Cell Biol 1979; 81:570-80; PMID:379021; http://dx.doi.org/10.1083/jcb.81.3.570 38.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Clin Chem Lab Med 2001; 39:811-7; PMID:11601678; http://dx.doi.org/10.1515/CCLM.2001.134 40.,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Med Oncol 2014; 31:343; PMID:25412938; http://dx.doi.org/10.1007/s12032-014-0343-7 41.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Br J Cancer 2006; 95:896-905; PMID:16953240; http://dx.doi.org/ 10.1038/sj.bjc.6603341 42.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Cryobiology 2009; 58:1-11; PMID:19007768; http://dx.doi.org/ 10.1016/j.cryobiol.2008.10.126 43.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
"Semin Cancer Biol 2012; 22:327-34; PMID:22465232; http://dx.doi.org/10.1016/j.semcancer.2012.03.004 44. de Wit S, van Dalum G, Lenferink AT, Tibbe AG, Hiltermann TJ, Groen HJ, van Rijn CJ, Terstappen LW.",OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Sci Rep 2015; 5:12270; PMID:26184843; http://dx.doi.org/10.1038/srep12270 4 5 .,OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
Pancreas 2013; 42:1143-9; PMID:23899940; http://dx.doi.org/10.1097/MPA.,Non-OADS,/arxiv_data1/oa_pdf/f9/b5/kcbt-17-09-1210731.PMC5036405.pdf
"9, 943 –954 http://dx.doi.org/10.1080/15384047.2016.1210734",Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
"the cytoskeleton, microtubule organizing center, centrosome, nucleus and cell membrane, according to the UniProtKB/Swiss-Prot data for the NDRG1 gene (http://www.genecards.org/).",OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther 2013; 14:164-74;PMID:23192272; http://dx.doi.org/10.4161/cbt.22956 2.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther 2010; 10:172-9; PMID:20543560; http://dx.doi.org/10.4161/cbt.10.2.12166 3.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther 2010; 10:617-24; PMID:20603606; http://dx.doi.org/10.4161/cbt.10.6.12609 4.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther2007; 6:1553-8; PMID:17912028; http://dx.doi.org/10.4161/cbt.6.10.4709 5.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Carci-nogenesis 2013; 34:1943-54; PMID:23671130; http://dx.doi.org/ 10.1093/carcin/bgt163 6.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther 2006; 5:380-5; PMID:16481741; http://dx.doi.org/10.4161/cbt.5.4.2477 8.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther 2007; 6:534-40; PMID:17457048;http://dx.doi.org/10.4161/cbt.6.4.3832 9.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther 2005; 4:974-8;PMID:16082195; http://dx.doi.org/10.4161/cbt.4.9.1914 10.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Can-cer Biol Ther 2005; 4:1216-21; PMID:16357509; http://dx.doi.org/10.4161/cbt.4.11.2090 11.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Biochim Biophys Acta 2014; 1845:1-19; PMID:24269900; http://dx.doi.org/10.1016/j.bbagrm.2013.11.001 1 2 .,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Mol Biol Rep2014; 41:6215-23; PMID:24985974; http://dx.doi.org/10.1007/s11033-014-3501-2 13.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Sci 2008; 99:706-10; PMID:18377423; http://dx.doi.org/10.1111/j.1349-7006.2008.00749.x 14.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
PLoS One 2013; 8:e68206;PMID:23874544; http://dx.doi.org/10.1371/journal.pone.0068206 15.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Ann Surg Oncol 2009; 16:1287-94; PMID:19259744;http://dx.doi.org/10.1245/s10434-009-0381-0 17.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
CancerLett 2014; 355:242-52; PMID:25218595; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
MolBiol Rep 2012; 39:10157-65; PMID:22972152; http://dx.doi.org/10.1007/s11033-012-1889-0 20.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Lett 2008; 264:36-43; PMID:18281151; http://dx.doi.org/10.1016/j.canlet.2008.01.020 21.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
FEBS Lett 2007; 581:989-94;PMID:17316623; http://dx.doi.org/10.1016/j.febslet.2007.01.080 22.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
DisEsophagus 2006; 19:454-8; PMID:17069588; http://dx.doi.org/ 10.1111/j.1442-2050.2006.00618.x 23.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
PLoS One 2013; 8:e84295; PMID:24386364; http://dx.doi.org/10.1371/journal.pone.0084295 24.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
J Cancer Res Clin Oncol 2012; 138:1813-20; PMID:22722710; http://dx.doi.org/10.1007/s00432-012-1236-9 25.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
PLoS One 2012; 7:e41312; PMID:22844455; http://dx.doi.org/10.1371/ journal.pone.0041312 27.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer 1992; 69:277-84; PMID:1728357; http://dx.doi.org/10.1002/1097-0142 (19920115)69:2%3c277::AID-CNCR2820690202%3e3.0.CO;2-C 28.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Clin Cancer Res 2011; 17:5412-22;PMID:21676925; http://dx.doi.org/10.1158/1078-0432.CCR-11-0426 29.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cell 2009; 137:1100-11; PMID:19524512; http://dx.doi.org/ 10.1016/j.cell.2009.05.021 30.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Mol Cancer Res 2012; 10:25-33; PMID:22086908; http://dx.doi.org/10.1158/1541-7786.MCR-11-0456 32.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
PLoS One 2014 Jun 24; 9(6):e100127; PMID:24959694; http://dx.doi.org/10.1371/journal.pone.0100127 33.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
PLoS One 2014; 9:e107204; PMID:25232961; http://dx.doi.org/10.1371/journal.pone.0107204 34.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cancer Biol Ther 2013; 14:401-10; PMID:23377825; http://dx.doi.org/10.4161/cbt.23759 35.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Cell 2012; 149:1192-205; PMID:22682243; http://dx.doi.org/10.1016/j.cell.2012.05.012 36.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
J Biol Chem 2012; 287:17016-28;PMID:22453918; http://dx.doi.org/10.1074/jbc.M112.350470 38.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
J Biol Chem 2011; 286:18949-59; PMID:21454613; http://dx.doi.org/ 10.1074/jbc.M111.232637 39.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Dev Cell 2009; 17:9-26; PMID:19619488; http://dx.doi.org/10.1016/j.devcel.2009.06.016 41.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
EMBO Mol Med 2012; 4:93-108; PMID:22246988; http://dx.doi.org/10.1002/emmm.201100190 42.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
J Cell Sci 2014; 127:3116-30;PMID:24829151; http://dx.doi.org/10.1242/jcs.147835 4 3 .,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
FASEB J 2010; 24:4153-66; PMID:20667976; http://dx.doi.org/10.1096/fj.09-151464 44.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Mol Cell 2012; 45:619-28; PMID:22304967; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
"B u s c a r l e tM ,P e r i nA ,L a i n gA ,B r i c k m a nJ M ,S t i f a n iS .I n h i b i t i o n of cortical neuron differentiation by Groucho/TLE1 requires inter-a c t i o nw i t hW R P W ,b u tn o tE h 1 ,r e p r e s s o rp e p t i d e s .JB i o lC h e m 2008; 283:24881-8; PMID:18611861; http://dx.doi.org/10.1074/jbc.",Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
Development 2010; 137:1553-62; PMID:20356955; http://dx.doi.org/10.1242/dev.044909 47.,Non-OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
J Virol 2010; 84:2047-62; PMID:19939918;http://dx.doi.org/10.1128/JVI.01984-09954 R. AI ET AL.,OADS,/arxiv_data1/oa_pdf/8e/67/kcbt-17-09-1210734.PMC5036407.pdf
"Several well-known PKPD soft- ware applications have their own coding language using named blocks of code which are selected and executed as determined by the software, for examples DIFF or $DES respectively for differential equations in PKPD softwareWinNonlin (http://www.certara.com) or NONMEM (http:// www.iconplc.com).",Non-OADS,/arxiv_data1/oa_pdf/cd/d8/PSP4-5-455.PMC5036420.pdf
A chapter on Custom PD Unit is provided in the Sim-cyp help file facility and is freely accessible from the Members’ area(https://members.simcyp.com/) to the Simcyp consortium members.,OADS,/arxiv_data1/oa_pdf/cd/d8/PSP4-5-455.PMC5036420.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Pharmacodynamic Scripting Facility in Simcyp Abduljalil et al.,Non-OADS,/arxiv_data1/oa_pdf/cd/d8/PSP4-5-455.PMC5036420.pdf
<http://www.r-project.org >.,Non-OADS,/arxiv_data1/oa_pdf/cc/50/PSP4-5-466.PMC5036421.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Time of Day Affects Drug-Induced QTc Prolongation Kervezee et al.,Non-OADS,/arxiv_data1/oa_pdf/cc/50/PSP4-5-466.PMC5036421.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)PBPK and PopPK Pediatric Modeling Zhou et al.,Non-OADS,/arxiv_data1/oa_pdf/8a/dc/PSP4-5-475.PMC5036422.pdf
<http://www.page-meeting.org/default.,Non-OADS,/arxiv_data1/oa_pdf/8a/c2/PSP4-5-484.PMC5036423.pdf
<http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm413614.htm >.,Non-OADS,/arxiv_data1/oa_pdf/8a/c2/PSP4-5-484.PMC5036423.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)Population PK and PD Analysis of Etecalcetide Chen et al .,OADS,/arxiv_data1/oa_pdf/8a/c2/PSP4-5-484.PMC5036423.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)A Population Pharmacokinetic Model for Vancomycin Moore et al.,OADS,/arxiv_data1/oa_pdf/8e/6b/PSP4-5-495.PMC5036424.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8b/a7/iranjradiol-13-02-18480.PMC5036456.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5f/65/iranjradiol-13-02-20004.PMC5036457.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a0/59/iranjradiol-13-02-19814.PMC5036458.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/19/76/iranjradiol-13-02-20102.PMC5036459.pdf
Available from: http://searchhealthit.techtarget.com/blog/Health- IT-Pulse/Global-PACS-market-to-double-by-2017-report-says .,Non-OADS,/arxiv_data1/oa_pdf/19/76/iranjradiol-13-02-20102.PMC5036459.pdf
Avail- able from: http://www.hospitaliteurope.com/article/26388/Middle_ East_PACS_%26_RIS_market_heats_up .,Non-OADS,/arxiv_data1/oa_pdf/19/76/iranjradiol-13-02-20102.PMC5036459.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d5/4b/ndt-12-2343.PMC5036510.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2343–2347Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2343OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10248 5splitting, impulsivity, and intimate partnerships  in young obese women seeking bariatric  treatment Jana Zmolikova1,2 Dita Pichlerova3 Petr Bob1,4 Denisa schückova5 Jitka herlesova3 Petr Weiss6 1Department of Psychiatry, First  Faculty of Medicine, center for  Neuropsychiatric research of  Traumatic stress, charles University,   2Department of clinical Psychology,   Na homolce hospital, 3OB clinic,   Prague, 4Faculty of Medicine, central  european institute of T echnology,   Masaryk University, Brno, 5iscare  clinical centre, 6institute of sexology,   First Faculty of Medicine, charles  University, Prague, czech republicBackground:  Splitting represents a defense mechanism that describes fragmentation of  conscious experience that may occur in various psychopathological conditions.",Non-OADS,/arxiv_data1/oa_pdf/d5/4b/ndt-12-2343.PMC5036510.pdf
"Keywords:  splitting, impulsivity, obesity, bulimia nervosa, bariatric treatment Introduction According to recent findings, disturbed intimate relationships, sexual dysfunctions,  and other mental health problems have high prevalence in obese women and are par - ticularly significant in patients seeking bariatric surgery.1–8 For example, the results  of one study show that ~60% of the patients seeking bariatric surgery report sexual  dysfunctions and other difficulties in sexual satisfaction and intimate relationships.2  On the other hand, several studies indicate that bariatric treatment may significantly  improve these dysfunctions, quality of life, and decrease depressive symptoms.9–14 Recent studies indicate that obese women have higher impulsivity,15–18 and this  impulsive behavior mainly increases in binge eating patients.19,20 On the other hand,  some data show decreased nonfood-related impulsivity in patients who achieved a  substantial weight loss after bariatric surgery.21 According to the current findings, there is no evidence how increased impulsivity  and disturbed intimate partnerships are related to conflicting and unstable perceptual  and emotional patterns represented by unexpected shifts between idealization and  devaluation of other persons and the self, and this condition is described in the objective correspondence: Petr Bob Department of Psychiatry, First Faculty  of Medicine, center for Neuropsychiatric  research of Traumatic stress, charles  University, Ke Karlovu 11, 12000  Prague 2, czech republic email petrbob@netscape.ne t Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Zmolikova et al Running head recto: Splitting, impulsivity, and intimate partnerships in young obese women DOI: http://dx.doi.org/10.2147/NDT.S102485",Non-OADS,/arxiv_data1/oa_pdf/d5/4b/ndt-12-2343.PMC5036510.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/d5/4b/ndt-12-2343.PMC5036510.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d5/4b/ndt-12-2343.PMC5036510.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: ctDNA cfDNA Small-cell lung cancerTP53 mutations Early detectionScreening 1.,Non-OADS,/arxiv_data1/oa_pdf/eb/65/main.PMC5036515.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.06.032 2352-3964/© 2016 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/eb/65/main.PMC5036515.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/65/main.PMC5036515.pdf
"For the calling of variants we used Needlestack , a recently developed ultra-sensitive variant caller, which estimates the distribution of se- quencing errors across multiple samples to reliably identify variants present in very low proportion ( https://github.com/IARCbioinfo/ needlestack ) (unpublished data; Delhomme et al.).",OADS,/arxiv_data1/oa_pdf/eb/65/main.PMC5036515.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Mucopolysaccharidosis type BBone mineral density Dual-energy X-ray absorptiometry L a t e r a ld i s t a lf e m u rd u a l - e n e r g yX - r a yabsorptiometry 1.,Non-OADS,/arxiv_data1/oa_pdf/a3/25/main.PMC5036531.pdf
http://dx.doi.org/10.1016/j.ymgmr.2016.08.0012214-4269/© 2016 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/a3/25/main.PMC5036531.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/25/main.PMC5036531.pdf
[7] HGMD-The Human Gene Mutation DatabaseAvailable at: http://www.hgmd.cf.ac.,Non-OADS,/arxiv_data1/oa_pdf/a3/25/main.PMC5036531.pdf
"57 (11) (Nov 2015) 1064 –1069, http://dx.doi.org/10.1111/dmcn.12790 (Epub 2015 May 6.",Non-OADS,/arxiv_data1/oa_pdf/a3/25/main.PMC5036531.pdf
"[25] Centers for Disease Control and Prevention, National Center for Health Statistics LMS Parameters for Girls & Boys: Height for Age, National Health and Nutrition Sur-vey (NHANES), Atlanta, 2000 http://www.cdc.gov/growthcharts/zscore.htm Accessed 15 Sept 2015.",Non-OADS,/arxiv_data1/oa_pdf/a3/25/main.PMC5036531.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/29/9b/jpr-9-689.PMC5036542.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/29/9b/jpr-9-689.PMC5036542.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 689–692Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  689 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S109616Effectiveness of low-dose intravenous ketamine to  attenuate stress response in patients undergoing  emergency cesarean section with spinal anesthesia Tjokorda Gde Agung  Senapathi I Made Gede Widnyana Made WiryanaI Gusti Ngurah Mahaalit Aribawa I Wayan Aryabiantara I Gusti Agung Gede Utara HartawanI Ketut Sinardja I Putu Pramana Suarjaya I Ketut Wibawa NadaAA Gde Putra Semara Jaya Department of Anesthesiology and  Intensive Care, Faculty of Medicine,  Udayana University, Sanglah Hospital,  Bali, IndonesiaPurpose: Cesarean section is a surgical procedure.",Non-OADS,/arxiv_data1/oa_pdf/29/9b/jpr-9-689.PMC5036542.pdf
"5,9–11Correspondence: Tjokorda Gde Agung  Senapathi Department of Anesthesiology and Intensive Care, Faculty of Medicine, Udayana University, Sanglah Hospital, Diponegoro Street, Denpasar 80114,   Bali, IndonesiaTel +62 36 1257 361Fax +62 36 1235 980Email tjoksenapathi@unud.ac.idJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Senapathi et alRunning head recto: Effectiveness of ketamine to attenuate stress response on cesarean sectionDOI: http://dx.doi.org/10.2147/JPR.S109616",Non-OADS,/arxiv_data1/oa_pdf/29/9b/jpr-9-689.PMC5036542.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/29/9b/jpr-9-689.PMC5036542.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 692 Senapathi et al a review of ketamine and peripheral inflammation, De Kock  et al summarized that ketamine acts as a homeostatic regulator of acute inflammatory reactions and stress-induced immune disturbances.",Non-OADS,/arxiv_data1/oa_pdf/29/9b/jpr-9-689.PMC5036542.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/f7/7e/jhc-3-031.PMC5036543.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/f7/7e/jhc-3-031.PMC5036543.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Hepatocellular Carcinoma 2016:3 31–36Journal of Hepatocellular Carcinoma Dovepress submit your manuscript | www.dovepress.com Dovepress 31 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S112537 Role of regorafenib as second-line therapy and  landscape of investigational treatment options in  advanced hepatocellular carcinoma Jörg Trojan   Oliver Waidmann Medizinische Klinik 1,   Universitätsklinikum Frankfurt,  GermanyAbstract:  Sorafenib is still the only systemic drug approved for the treatment of advanced  hepatocellular carcinoma (HCC).",Non-OADS,/arxiv_data1/oa_pdf/f7/7e/jhc-3-031.PMC5036543.pdf
"In this review, recent data on antiangio-genic agents including the multikinase inhibitors sorafenib and regorafenib, inhibitors of the MET pathway, and immunotherapeutics will be discussed.Correspondence: Jörg Trojan   Medizinische Klinik 1,  Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, GermanyTel +49 69 6301 7860Fax +49 69 6301 83776Email trojan@em.uni-frankfurt.deJournal name: Journal of Hepatocellular Carcinoma Article Designation: REVIEWY ear: 2016V olume: 3Running head verso: Trojan and WaidmannRunning head recto: Role of regorafenib as second-line therapyDOI: http://dx.doi.org/10.2147/JHC.S112537",Non-OADS,/arxiv_data1/oa_pdf/f7/7e/jhc-3-031.PMC5036543.pdf
"Journal of Hepatocellular Carcinoma 2016:3submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journalThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina-tion and study of clinical, translational and basic research findings in this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/f7/7e/jhc-3-031.PMC5036543.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 36 Trojan and Waidmann  19.,Non-OADS,/arxiv_data1/oa_pdf/f7/7e/jhc-3-031.PMC5036543.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1433–1444Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1433Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S10901 1 Long-term safety of tiotropium delivered by  Respimat® SoftMist™ inhaler: patient selection  and special considerations Ching Kuo Tan Gui Quan Say James B Geake Department of Respiratory Medicine,   Lyell Mcewin Hospital, elizabeth vale,   SA, AustraliaAbstract:  Tiotropium bromide is a long-acting inhaled muscarinic antagonist used in patients  with chronic respiratory disease.",Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
"There is convincing evidence that this treatment results in improved lung function and  quality of life and reduced breathlessness and exacerbations in patients with COPD.3–6  It has also been trialed in other obstructive lung diseases, and in particular there is  now also increasing evidence that it has favorable effects on chronic suboptimally  controlled asthma.7–9 The HandiHaler DPI device delivers tiotropium via an inhaled  dry powder mechanism, using lactose powder as a carrier.10 This mechanism relies Correspondence: Ching Kuo Tan Department of Respiratory Medicine,  Lyell Mcewin Hospital, Haydown Road,  elizabeth vale, SA 5112, Australia email chingkuo.tan@sa.gov.a u Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Tan et al Running head recto: Tiotropium safety delivered via novel mechanical metered-dose inhaler DOI: http://dx.doi.org/10.2147/TCRM.S109011",Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
"Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcod e.21 Abbreviations:  DPI, dry powder inhaler; max, maximum; min, minimum; P10, 10th percentile; Q1, first quartile; Gmean, geometric mean; Q3, third quartile; P90, 90th percentile,  of the tiotropium plasma steady state concentration in the group; SMi, SoftMist™ inhaler.",Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
Available from: http://www.accessdata.,OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
Avail - able from: https://www.spiriva.com/pdf/SPIRIVA_HandiHaler_Instruc - tions.pd f  11.,Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
Available from: http://www.mimsonline.com.au/Search/FullPI.,Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
"Available from:  http://docs.boehringer-ingelheim.com/Prescribing%20Information/ PIs/Spiriva%20Respimat/spirivarespimat.pd f. Accessed Feberuary 29,  2016.",Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT01172808?ter m=NCT01172808&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
Available from: https://clinicaltrials.gov/ct2/show/ NCT01257230?term=NCT+01257230&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c2/97/tcrm-12-1433.PMC5036544.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/60/23/jbm-7-199.PMC5036545.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/60/23/jbm-7-199.PMC5036545.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Blood Medicine 2016:7 199–204Journal of Blood Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress  199 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JBM.S105063Body surface area: a predictor of response to red  blood cell transfusion Louise Man1 H Raymond Tahhan1–3 1Department of Internal Medicine,   Eastern Virginia Medical School,   2Department of Pathology, Eastern  Virginia Medical School, 3Department  of Pathology, Sentara Norfolk General  Hospital, Norfolk, VA, USAAbstract: A current focus of transfusion medicine is a judicious strategy in transfusion of blood  products.",Non-OADS,/arxiv_data1/oa_pdf/60/23/jbm-7-199.PMC5036545.pdf
"3–5 The purpose of this study was twofold: 1) to determine Correspondence: Louise Man Division of Hematology/Oncology, University of Virginia, PO Box 800716, Charlottesville, VA 22908-0716, USATel +1 434 9826 517Fax +1 434 2435 956Email LMM3R@hscmail.mcc.virginia.eduJournal name: Journal of Blood Medicine Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 7Running head verso: Man and TahhanRunning head recto: Body surface areaDOI: http://dx.doi.org/10.2147/JBM.S105063",Non-OADS,/arxiv_data1/oa_pdf/60/23/jbm-7-199.PMC5036545.pdf
"Journal of Blood Medicine 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Blood Medicine Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/journal-of-blood-medicine-journalThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects   of all aspect pertaining to blood based medicine including but not limited to:   Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,   and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspec-tives.",Non-OADS,/arxiv_data1/oa_pdf/60/23/jbm-7-199.PMC5036545.pdf
Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dovepress 204 Man and Tahhan believe that the derived model is notable in an area that  could benefit from more precise prediction tools.,Non-OADS,/arxiv_data1/oa_pdf/60/23/jbm-7-199.PMC5036545.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2016:8 505–517International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  505RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S9897 3 epilepsy during pregnancy: focus on management  strategies Laura M Borgelt1 Felecia M Hart2 Jacquelyn L Bainbridge2 1Departments of Clinical Pharmacy  and Family Medicine, 2Departments  of Clinical Pharmacy and Neurology,   University of Colorado Anschutz  Medical Campus, Skaggs School  of Pharmacy and Pharmaceutical  Sciences, Aurora, CO, USAAbstract:  In the US, more than one million women with epilepsy are of childbearing age and  have over 20,000 babies each year.",Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
"Risks and complications in pregnant WWE Although a majority of WWE (54%–80%) will not experience a change in seizure  frequency during pregnancy, seizure frequency and severity may increase in 15%–32% Correspondence: Jacquelyn L Bainbridge Departments of Clinical Pharmacy and  Neurology, University of Colorado  Anschutz Medical Campus, Skaggs School  of Pharmacy and Pharmaceutical Sciences,  Aurora, CO, USA Tel +1 303 724 9892 email jacci.bainbridge@ucdenver.ed uJournal name: International Journal of Women’s Health Article Designation: Review Y ear: 2016 Volume: 8 Running head verso: Borgelt et al Running head recto: Epilepsy during pregnancy DOI: http://dx.doi.org/10.2147/IJWH.S98973",Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
"Available from:  http://www.epilepsy.com/learn/impact/reproductive-risks/risks-during- pregnanc y. Accessed June 19, 2016.",Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
"Available from:  http://www.epilepsy.com/information/women/epilepsy-and-pregnanc y.  Accessed June 19, 2016.",Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
"Available from: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess /DevelopmentResources/Labeling/ ucm093307.ht m. Accessed June 19, 2016.",Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
Available from: https://www.nice.org.uk/ guidance/cg13 7.,Non-OADS,/arxiv_data1/oa_pdf/36/6b/ijwh-8-505.PMC5036546.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/21/29/ott-9-5797.PMC5036547.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 5797–5802OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  5797Case repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10329 1 a clear cell adenocarcinoma of the gallbladder  with hepatoid differentiation: case report and  review of literature Chengsheng Zhang1,2 Wei Zhang1,2 Dianbin Mu1 Xuetao shi1 Lei Zhao1,2 1Department of Hepatobiliary surgery,   shandong Cancer Hospital affiliated  to shandong University, shandong  academy of Medical science, 2school  of Medicine and Life sciences,   University of Jinan- shandong academy  of Medical sciences, Jinan, shandong  province, people’s republic of ChinaAbstract:  An 80-year-old male was referred to our department for a gallbladder mass.",Non-OADS,/arxiv_data1/oa_pdf/21/29/ott-9-5797.PMC5036547.pdf
"Written informed consent was obtained from the patient for publication of this case  report and accompanying images.Correspondence: Lei Zhao Department of Hepatobiliary surgery,  Shandong Cancer Hospital affiliated to  shandong University, shandong academy  of Medical science, No 440 Jiyan road,  Jinan City, shandong province 250117,  people's republic of China Tel +86 531 6762 6368 email drzhaolei@hotmail.co m Journal name: OncoTargets and Therapy Article Designation: Case report Y ear: 2016 Volume: 9 Running head verso: Zhang et al Running head recto: CCG with hepatoid differentiation DOI: http://dx.doi.org/10.2147/OTT.S103291",Non-OADS,/arxiv_data1/oa_pdf/21/29/ott-9-5797.PMC5036547.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/21/29/ott-9-5797.PMC5036547.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/21/29/ott-9-5797.PMC5036547.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/21/ca/ijn-11-4819.PMC5036548.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 4819–4834International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4819RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S10884 7 TiO2 nanotube platforms for smart drug delivery:  a review Qun wang1,2,* Jian-Ying Huang1,* Hua-Qiong Li3 Zhong Chen4 Allan Zi-Jian Zhao3 Yi wang3 Ke-Qin Zhang1 Hong-Tao Sun2 Salem S Al-Deyab5 Yue-Kun Lai1 1National engineering Laboratory  for Modern Silk, College of Textile  and Clothing engineering, Soochow  University, Suzhou, 2College of  Chemistry, Chemical engineering  and Materials Science, Soochow  University, Suzhou, People’s Republic  of China; 3wenzhou Institute of  Biomaterials and engineering, Chinese  Academy of Sciences, wenzhou,   People’s Republic of China; 4School  of Materials Science and engineering,   Nanyang T echnological University,   Singapore, Singapore; 5Department of  Chemistry, College of Science, King  Saud University, Riyadh, Saudi Arabia *These authors contributed equally  to this workAbstract:  Titania nanotube (TNT) arrays are recognized as promising materials for localized  drug delivery implants because of their excellent properties and facile preparation process.",Non-OADS,/arxiv_data1/oa_pdf/21/ca/ijn-11-4819.PMC5036548.pdf
"The TiO2 material possesses excellent biocompatibility and has demonstrated tunable Correspondence: Yue-Kun Lai National engineering Laboratory for  Modern Silk, College of Textile and  Clothing engineering, Soochow University,  No 199, Renai Road, Suzhou 215123,  People’s Republic of China Tel +86 512 6706 1169 email yklai@suda.edu.c n Journal name: International Journal of Nanomedicine Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Wang et al Running head recto: TiO2 nanotube platforms for smart drug delivery DOI: http://dx.doi.org/10.2147/IJN.S108847",Non-OADS,/arxiv_data1/oa_pdf/21/ca/ijn-11-4819.PMC5036548.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/21/ca/ijn-11-4819.PMC5036548.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/21/ca/ijn-11-4819.PMC5036548.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/85/a2/copd-11-2321.PMC5036550.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2321–2327International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2321OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11370 7 Chronic Pseudomonas aeruginosa  infection-induced  chronic bronchitis and emphysematous changes   in CCSP-deficient mice Takemasa Matsumoto1 Masaki Fujita1 ryosuke hirano1 Junji Uchino1 Yukari Tajiri2 satoru Fukuyama2 Yasuo Morimoto3 Kentaro Watanabe1 1Department of respiratory Medicine,   Faculty of Medicine, Fukuoka  University, 2research Institute for  Diseases of the Chest, graduate  school of Medical sciences, Kyushu  University, Fukuoka, 3Department  of Occupational Pneumology,   Institute of Industrial and ecological  sciences, University of Occupational  and environmental health,   Kitakyushu, JapanAbstract:  The club cell secretory protein (CCSP) is a regulator of lung inflammation following  acute respiratory infection or lung injury.",Non-OADS,/arxiv_data1/oa_pdf/85/a2/copd-11-2321.PMC5036550.pdf
"Correspondence: Masaki Fujita Department of respiratory Medicine,  Faculty of Medicine, Fukuoka University,  7-45-1 nanakuma, Jonan-ku, Fukuoka  814-0180, Japan Tel +81 92 801 1011 Fax +81 92 865 6220 email mfujita@fukuoka-u.ac.j p Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Matsumoto et al Running head recto: CCSP deficiency and chronic infection DOI: http://dx.doi.org/10.2147/COPD.S113707",Non-OADS,/arxiv_data1/oa_pdf/85/a2/copd-11-2321.PMC5036550.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/85/a2/copd-11-2321.PMC5036550.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/85/a2/copd-11-2321.PMC5036550.pdf
"Available from: http://www.goldcopd.or g. Accessed  March 1, 2016.",OADS,/arxiv_data1/oa_pdf/85/a2/copd-11-2321.PMC5036550.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/06/3d/ndt-12-2387.PMC5036551.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2387–2402Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2387Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S11456 0 Nine traditional Chinese herbal formulas for the  treatment of depression: an ethnopharmacology,  phytochemistry, and pharmacology review Dan-dan Feng Tao Tang Xiang-ping Lin Zhao-yu Yang Shu Yang Zi-an Xia Yun wang Piao Zheng Yang wang Chun-hu Zhang Laboratory of ethnopharmacology,   institute of integrated Traditional  Chinese and western Medicine,   Xiangya Hospital, Central South  University, Changsha, People’s  Republic of ChinaAbstract:  Depression is a major mental disorder, and is currently recognized as the  second-leading cause of disability worldwide.",Non-OADS,/arxiv_data1/oa_pdf/06/3d/ndt-12-2387.PMC5036551.pdf
"According to the Global  Burden of Disease Study 2013, major depressive disorder (MDD) is the second-leading  global cause of years lived with disability.5 The population-attributable risk for depres - sion and all-cause death is 12.7%, and for depression and suicide it is 11.2%.6 The  economic burden of individuals with MDD in the US increased by 21.5% between  2005 and 2010 (from $173.2 billion to $210.5 billion, inflation-adjusted).7 A recent  meta-analysis of the prevalence of depressive symptoms in older Chinese adults from  1987 to 2012 reported an overall prevalence of 23.6%.8–10 Conventional antidepressants, such as selective reuptake inhibitors of serotonin  (5-HT) or norepinephrine (NE), monoamine oxidase inhibitors, tricyclic antidepressants, Correspondence: Yang wang;   Chun-hu Zhang Laboratory of ethnopharmacology,  institute of integrated Traditional Chinese  and western Medicine, Xiangya Hospital,  Central South University, 87 Xiangya  Road, Changsha, Hunan 410008,  People’s Republic of China Tel +86 731 8432 7122 Fax +86 731 8432 8386 email wangyang_xy87@163.co m;  zchu77@yeah.ne tJournal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Feng et al Running head recto: Chinese herbal formulas as antidepressants DOI: http://dx.doi.org/10.2147/NDT.S114560",Non-OADS,/arxiv_data1/oa_pdf/06/3d/ndt-12-2387.PMC5036551.pdf
Relevant TCM  information was from http://www.tcmwiki.com/w/TCM_ Wiki and the Pharmacopoeia of the People’s Republic of  China  (2015).,OADS,/arxiv_data1/oa_pdf/06/3d/ndt-12-2387.PMC5036551.pdf
"Third, only four trials have registered online at  https://ClinicalTrials.go v (for wuling capsules, XYS, and two  for shuganjieyu capsules), and only two multicenter RCTs  were identified (for shuganjieyu and wuling capsules).72,87  No large-scale RCTs have been performed.",Non-OADS,/arxiv_data1/oa_pdf/06/3d/ndt-12-2387.PMC5036551.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/06/3d/ndt-12-2387.PMC5036551.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/06/3d/ndt-12-2387.PMC5036551.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/73/71/jaa-9-171.PMC5036552.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/73/71/jaa-9-171.PMC5036552.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Journal of Asthma and Allergy 2016:9 171–181Journal of Asthma and Allergy Dove press submit your manuscript | www.dovepress.co m Dove press  171Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JAA.S8154 0Chronic hypersensitivity pneumonitis Carlos AC Pereira1 Andréa Gimenez2 Lilian Kuranishi2  Karin Storrer2 1interstitial Lung Diseases Program,   2Pulmonology Postgraduate, Federal  University of São Paulo, São Paulo,   Brazil Correspondence: Carlos AC Pereira   Department of Pulmonology, Paulista  School of Medicine, Federal University  of São Paulo, Av iraí, 393, conj 34,  CeP 04082-001   São Paulo, SP , Brazil   email pereirac@uol.com.b rAbstract:  Hypersensitivity pneumonitis (HSP) is a common interstitial lung disease resulting  from inhalation of a large variety of antigens by susceptible individuals.",Non-OADS,/arxiv_data1/oa_pdf/73/71/jaa-9-171.PMC5036552.pdf
"Journal of Asthma and Allergy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-asthma-and-allergy-journa lThe Journal of Asthma and Allergy is an international, peer-reviewed  open-access journal publishing original research, reports, editorials  and commentaries on the following topics: Asthma; Pulmonary physi - ology; Asthma related clinical health; Clinical immunology and the  immunological basis of disease; Pharmacological interventions and new therapies.",Non-OADS,/arxiv_data1/oa_pdf/73/71/jaa-9-171.PMC5036552.pdf
Visit http://www.dovepress.com/testimonials.ph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/73/71/jaa-9-171.PMC5036552.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/af/65/ott-9-5781.PMC5036553.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 5781–5789OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  5781Case repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11247 2 a case report and literature review of primary  resistant Hodgkin lymphoma: a response to  anti-pD-1 after failure of autologous stem cell  transplantation and brentuximab vedotin peipei Xu Fan Wang Chaoyang Guan Jian Ouyang Xiaoyan shao Bing Chen Department of Hematology, The  affiliated Drum T ower Hospital of  Nanjing University Medical school,   Nanjing, people’s republic of ChinaAbstract:  Hodgkin lymphoma (HL) is a highly curable hematologic malignancy, and ~70%  of cases can be cured with combination chemotherapy with or without radiation.",Non-OADS,/arxiv_data1/oa_pdf/af/65/ott-9-5781.PMC5036553.pdf
"Based on its  promising results (75% response rate and 34% complete remission [CR]) from a phase II   open-label study,5 brentuximab vedotin has been approved by the US Food and Drug Correspondence: Bing Chen;  Xiaoyan shao Department of Hematology, The Affiliated  Drum Tower Hospital of Nanjing  University Medical school, Nanjing 210008,  people’s republic of China Tel +86 258 310 5211 email chenb211@163.co m;  15358184562@163.co m Journal name: OncoTargets and Therapy Article Designation: Case report Y ear: 2016 Volume: 9 Running head verso: Xu et al Running head recto: A case report of primary resistant Hodgkin lymphoma DOI: http://dx.doi.org/10.2147/OTT.S112472",Non-OADS,/arxiv_data1/oa_pdf/af/65/ott-9-5781.PMC5036553.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/af/65/ott-9-5781.PMC5036553.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/af/65/ott-9-5781.PMC5036553.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/71/11/tcrm-12-1425.PMC5036554.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1425–1432Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1425ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S11072 7 in vitro and in vivo postmarketing surveillance  of valsartan, alone or in combination with  amlodipine or hydrochlorothiazide, among  Palestinian hypertensive patients abdel naser Zaid1 Masshour ghanem2 Dua’a shweiki1 hala shtewi1 Raja’ shaheen1 sondos al helaly1 Zeina Khayyat1 Rowa’a al Ramahi1 sa’ed h Zyoud1 1Department of Pharmacy, Faculty  of Medicine & health sciences,   an-n ajah national University, nablus,   2Pharmacare ltd, Ramallah, PalestineObjectives:  The objectives of this study were to evaluate the general quality of the most  prescribed products of valsartan (VL; alone or in combination) and to evaluate their efficacy  and safety among Palestinian population through in vivo postmarketing surveillance.",Non-OADS,/arxiv_data1/oa_pdf/71/11/tcrm-12-1425.PMC5036554.pdf
"These  two strengths are available as monotherapy or in combination therapy with other Correspondence: abdel naser Zaid Department of Pharmacy, Faculty of  Medicine & health sciences, an-najah  national University, PO Box 7, nablus,  Palestine Tel +970 9 72 9234 5113 Fax +970 9 72 9234 5982 email anzaid@najah.ed u Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Zaid et al Running head recto: Efficacy and safety of valsartan among Palestinian population DOI: http://dx.doi.org/10.2147/TCRM.S110727",Non-OADS,/arxiv_data1/oa_pdf/71/11/tcrm-12-1425.PMC5036554.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/71/11/tcrm-12-1425.PMC5036554.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/71/11/tcrm-12-1425.PMC5036554.pdf
"Available from:  http://www.drugs.com/dosage/valsartan.htm l. Accessed April 10, 2016.",Non-OADS,/arxiv_data1/oa_pdf/71/11/tcrm-12-1425.PMC5036554.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e1/e0/ppa-10-1847.PMC5036555.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1847–1852Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1847OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S11576 7 satisfaction and associated factors of outpatient  psychiatric service consumers in ethiopia solomon Yimer1 Zegeye Y ohannis2 Wondale getinet3 T esfa Mekonen4 Wubalem Fekadu4 habte Belete4 Melak Menberu5 Asmamaw getnet6 Amsalu Belete7 1Psychiatry Department, college of  health sciences and Medicine, Dilla  University, Dilla, 2Amanuel Mental  specialized hospital, Addis Ababa,   3Psychiatry Department, college  of health science and Medicine,   University of gondar, gondar,   4Psychiatry Department, college  of Medicine and health sciences,   Bahir Dar University, Bahir Dar,   5Department of nursing, college  of health sciences, Mizan-Tepi  University, Mizan, 6Finote selam  hospital, Finote selam, 7Department  of nursing, college of health sciences  and Medicine, Debre Tabor University,   Debre Tabor, ethiopiaPurpose:  The purpose of this study was to assess the level of patient satisfaction and associated  factors with psychiatric outpatient services in Ethiopia.",Non-OADS,/arxiv_data1/oa_pdf/e1/e0/ppa-10-1847.PMC5036555.pdf
"Keywords:  patient satisfaction, mental illness, social functioning Introduction Satisfaction is a general psychological condition that results from emotional  surrounding expectations coupled with the prior feeling of consumers toward the  consumption experience.1 Even though it is difficult to find an agreed-upon definition,  patient satisfaction is “health care recipient’s reaction to salient aspects of his or her  experience, expectation and preference of a service” met by health care service and  provider.2 Patient satisfaction is one desired outcome of mental health care service  and core parameter for the positive evaluation of a mental health care system.3–5 For  consumers of mental health services, satisfaction has become a significant contributing  outcome in the assessment and improvement of quality of care, including adherence to  treatment, intent to return for care and follow-up, and continuity of outpatient care.6 Different studies showed that the global level of patient satisfaction to psychiatric  services ranges from 39.3% to 91.9%, with 39.3% in London,7 44.8% in the university  hospitals of Canada and USA,8 57% in India,9 90% in Ireland,10 and 91.9% in South  Africa.11 A range of factors can affect patient satisfaction, including unpleasantly built  environments, staff being too busy, failure to obtain prescribed medications from the  hospital pharmacies, the stigma of a psychiatric treatment service, long waiting hours, correspondence: Tesfa Mekonen Psychiatry Department, college  of Medicine and health sciences,  Bahir Dar University, Bahir Dar,  PO Box 79, ethiopia Tel +251 9 1264 0412 Fax +251 58 220 5932 email smarthope1@gmail.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Yimer et al Running head recto: Satisfaction of outpatient psychiatric service consumers DOI: http://dx.doi.org/10.2147/PPA.S115767",Non-OADS,/arxiv_data1/oa_pdf/e1/e0/ppa-10-1847.PMC5036555.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/e1/e0/ppa-10-1847.PMC5036555.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 3021–3028Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3021Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S11389 1 comparisons of the pharmacokinetics and  tolerability of fixed-dose combinations of  amlodipine besylate/losartan and amlodipine  camsylate/losartan in healthy subjects:  a randomized, open-label, single-dose, two-period,  two-sequence crossover study Y oonJung choi1 seung hwan lee2 Sang-Min Cho3 Won-Ho Kang3 Kyu-Yeol Nam4 In-Jin Jang1 Kyung-Sang Yu1 1Department of clinical Pharmacology  and Therapeutics, seoul national  University College of Medicine,   2clinical Trials center, seoul national  University hospital, 3research  institute, 4Global R&D, Korea United  Pharm Inc., Seoul, Republic of KoreaBackground:  A fixed-dose combination (FDC) of amlodipine and losartan has been used to  reduce blood pressure in patients whose hypertension is not sufficiently controlled with either  drug alone.",Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
"The main  objective  of hypertension treatment is to normalize BP to prevent complications such as stroke Correspondence: Kyung-Sang Yu Department of clinical Pharmacology  and Therapeutics, seoul national  University College of Medicine, Seoul  national University hospital, 101  Daehak-ro, Jongno-gu, Seoul 110-744,  Republic of Korea Tel +82 2 2072 1920 Fax +82 2 742 9252 email ksyu@snu.ac.k r Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Choi et al Running head recto: Pharmacokinetic comparison of two amlodipine/losartan combination tablets DOI: http://dx.doi.org/10.2147/DDDT.S113891",Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
Available from: https://www.nice.,Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
Available from: http://www.accessdata.,OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
"Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances /ucm088645.pd f. Accessed January 25, 2016.",Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
Available from: http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/70/33/dddt-10-3021.PMC5036556.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9e/90/ndt-12-2373.PMC5036557.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2373–2380Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2373Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S10983 5 Noradrenaline plays a critical role in the  switch to a manic episode and treatment of a  depressive episode Masatake Kurita1–3 1Koutokukai wakamiya Hospital,   Y oshihara, Yamagata, 2Department of  Cellular Signaling, Graduate School  of Pharmaceutical Sciences, Tohoku  University, Sendai, 3Department of  Psychiatry and Behavioral Science,   Graduate School of Medicine, Nippon  Medical School, T okyo, JapanAbstract:  Although antidepressants may increase the risk of switching to mania in bipolar  disorder (BD), clinicians have been using antidepressants to treat patients with bipolar depres - sion.",Non-OADS,/arxiv_data1/oa_pdf/9e/90/ndt-12-2373.PMC5036557.pdf
"In particular, the longitudinal symptomatic course of BD is chronic and dominated  by depressive symptoms, rather than the characteristic manic symptoms of BD, and –  surprisingly – the depressive state can be dominant for as much as $50% during the  course of BD.7–9 These longitudinal depressive symptoms lead to loss of social benefits Correspondence: Masatake Kurita Koutokukai wakamiya Hospital,  2-15-3 Y oshihara, Yamagata 990-2451,   Japan Tel +81 23 643 8222 email kurita@koutoku.or.j p Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Kurita Running head recto: Noradrenaline plays a role in switching in BD DOI: http://dx.doi.org/10.2147/NDT.S109835 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/9e/90/ndt-12-2373.PMC5036557.pdf
Or use: http://youtu.be/AKxJ5enJCr Ivideo abstract,Non-OADS,/arxiv_data1/oa_pdf/9e/90/ndt-12-2373.PMC5036557.pdf
http://www.sciencedirect.com/science/journal/0014299 9.,Non-OADS,/arxiv_data1/oa_pdf/9e/90/ndt-12-2373.PMC5036557.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/9e/90/ndt-12-2373.PMC5036557.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9e/90/ndt-12-2373.PMC5036557.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4a/16/ndt-12-2425.PMC5036558.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2425–2434Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2425OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11580 0 Delirium as a complication of the surgical  intensive care rostislav horacek1 Barbora Krnacova2 Jan Prasko2 Klara latalova2 1Department of central intensive  care Unit for surgery, 2Department  of Psychiatry, Faculty of Medicine  and Dentistry, University hospital  Olomouc, Palacky University  Olomouc, czech republicBackground:  The aim of this study was to examine the impact of somatic illnesses, electrolyte  imbalance, red blood cell count, hypotension, and antipsychotic and opioid treatment on the  duration of delirium in Central Intensive Care Unit for Surgery.",Non-OADS,/arxiv_data1/oa_pdf/4a/16/ndt-12-2425.PMC5036558.pdf
"Keywords:  delirium, care duration, intensive care, risk factors, treatment, antipsychoticscorrespondence: Jan Prasko Department of Psychiatry, Faculty  of Medicine and Dentistry,  University hospital Olomouc, Palacky  University Olomouc, iP Pavlova 6,  Olomouc 775 20, czech republic Tel +420 588 443 519 email praskojan@seznam.c z Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Horacek et al Running head recto: Delirium as a complication of the surgical intensive care DOI: http://dx.doi.org/10.2147/NDT.S115800",Non-OADS,/arxiv_data1/oa_pdf/4a/16/ndt-12-2425.PMC5036558.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/4a/16/ndt-12-2425.PMC5036558.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4a/16/ndt-12-2425.PMC5036558.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2016:7 527–531Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 527 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S116147 Job satisfaction among community pharmacy  professionals in Mekelle city, Northern Ethiopia Yared Belete Belay Pharmacoepidemiology and Social  Pharmacy Course and Research T eam,  Department of Pharmacy, Mekelle University, Mekelle, EthiopiaIntroduction: Job satisfaction is a multidimensional, enduring, important, and much-researched  concept in the field of organizational behavior and has been identified as recognition in one’ s  field of work, level of salary, opportunities for promotion, and achievement of personal goals.",Non-OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
"A study conducted in Ireland reported that Correspondence: Yared Belete Belay Pharmacoepidemiology and Social Pharmacy Course and Research Team, Department of Pharmacy, Mekelle University, PO Box 1871, Mekelle, EthiopiaTel +251 91 285 4443Email yaredbeleteb@gmail.comJournal name: Advances in Medical Education and Practice Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 7Running head verso: BelayRunning head recto: Satisfaction level of pharmacy professionals in Mekelle cityDOI: http://dx.doi.org/10.2147/AMEP .S116147 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
Or use: http://youtu.be/FBSDGm3V3bk,Non-OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
Available from: http://www.fmhaca.gov.et/documents/SCOPE%20OF%20PRACTICE%20FOR%20HEALTH%20PROFESSIONALS%20IN%20ETHIOPIA.pdf.,Non-OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 531 Satisfaction level of pharmacy professionals in Mekelle city,Non-OADS,/arxiv_data1/oa_pdf/05/70/amep-7-527.PMC5036559.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f0/09/ndt-12-2403.PMC5036560.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2403–2410Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2403OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11622 3 Distinctive Rorschach profiles of young adults  with schizophrenia and autism spectrum disorder Naoko Kishimoto1 Kazuhiko Yamamuro1 Junzo iida2 T oyosaku Ota1 shohei Tanaka1 Masanori Kyo3 sohei Kimoto1 T oshifumi Kishimoto1 1Department of Psychiatry, 2Faculty  of Nursing, Nara Medical University  School of Medicine, 3Department  of Psychiatry, Kyo Mental Clinic,   Nara, JapanObjective:  The differential diagnosis of schizophrenia (SZ) versus autism spectrum disorder  (ASD) can be clinically challenging because accumulating evidence suggests both clinical and  biological overlaps between them.",Non-OADS,/arxiv_data1/oa_pdf/f0/09/ndt-12-2403.PMC5036560.pdf
"In the late 1970s, one innovation separated SZ from ASD  into different diagnostic categories using the diagnostic and statistical manual of mental  disorders III (DSM-III).4 While such approaches based on DSM criteria truly offer  many practical advantages to psychiatry, the results of previous studies have suggested  the potential mechanisms underlying the neurobiological overlap between SZ and  ASD.5–7 Consistent with these findings, several lines of epidemiological study have  revealed that 30%–50% of patients have comorbid pervasive development disorder  preceding the psychotic symptoms of childhood-onset SZ.7 Even among adults with correspondence: sohei Kimoto Department of Psychiatry, Nara  Medical University School of Medicine,  840 Shijyou-cho, Kashihara, Nara  634-8521, Japan Tel +81 744 22 3051 Fax +81 744 22 3854 email sohei@naramed-u.ac.j p Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Kishimoto et al Running head recto: Rorschach profiles of young adults DOI: http://dx.doi.org/10.2147/NDT.S116223",Non-OADS,/arxiv_data1/oa_pdf/f0/09/ndt-12-2403.PMC5036560.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/f0/09/ndt-12-2403.PMC5036560.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f0/09/ndt-12-2403.PMC5036560.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/2f/84/btt-10-139.PMC5036561.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/2f/84/btt-10-139.PMC5036561.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Biologics: Targets and Therapy 2016:10 139–148Biologics: Targets and Therapy Dovepress submit your manuscript | www.dovepress.com Dovepress  139 Review open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/BTT .S87402eag1 channels as potential early-stage biomarkers  of hepatocellular carcinoma María de Guadalupe  Chávez-López1 violeta Zúñiga-García1 Julio isael Pérez-Carreón2 Arturo Avalos-Fuentes3 Yesenia escobar4 Javier Camacho1 1Department of Pharmacology,   Centro de investigación y de  estudios Avanzados del instituto  Politécnico Nacional, 2instituto  Nacional de Medicina Genómica,   3Department of Physiology, Biophysics  and Neuroscience, Centro de  investigación y de estudios Avanzados  del instituto Politécnico Nacional,   4Centro de investigación Clínica  Acelerada Sc, Mexico City, MexicoAbstract:  Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide.",Non-OADS,/arxiv_data1/oa_pdf/2f/84/btt-10-139.PMC5036561.pdf
"Other well-defined risk factors comprise viral infections (chronic hepatitis B and C), toxics (alcohol and aflatoxin B1), and altered Correspondence: Javier Camacho Department of Pharmacology, Centro de investigación y de estudios Avanzados del instituto Politécnico Nacional, Avenida instituto Politécnico Nacional 2508, CP 07360, Mexico City, MexicoTel +52 55 5747 3800 ext 5416 Fax +52 55 5343 0106 email fcamacho@cinvestav.mxJournal name: Biologics: Targets and Therapy Article Designation: REvIEwY ear: 2016volume: 10 Running head verso: Chávez-López et alRunning head recto: Eag1 channels in HCCDOI: http://dx.doi.org/10.2147/BTT.S87402",Non-OADS,/arxiv_data1/oa_pdf/2f/84/btt-10-139.PMC5036561.pdf
"Biologics: Targets and Therapy 2016:10submit your manuscript | www.dovepress.com Dovepress Dovepress Biologics: Targets and Therapy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/biologics-targets-and-therapy-journalBiologics: Targets and Therapy is an international, peer-reviewed journal  focusing on the patho-physiological rationale for and clinical applica-tion of Biologic agents in the management of autoimmune diseases, cancers or other pathologies where a molecular target can be identified.",Non-OADS,/arxiv_data1/oa_pdf/2f/84/btt-10-139.PMC5036561.pdf
visit http://www.dovepress.com/testimonials.php to read real quotes  from published authors.Dovepress 148 Chávez-López et al,Non-OADS,/arxiv_data1/oa_pdf/2f/84/btt-10-139.PMC5036561.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/16/7c/ott-9-5771.PMC5036562.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 5771–5779OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  5771Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11235 8 Prognostic value of decreased microrna-133a  in solid cancers: a meta-analysis Jian Xiao Y ong Zou Xiaoxiao lu Bin Xie Qiao Yu Baimei he Bixiu he Qiong chen Department of geriatrics, respiratory  Medicine, Xiangya hospital of central  south University, changsha, People’s  republic of chinaObjective:  Increasing evidence indicates that the decreased expression of microRNA-133a  (miR-133a) may be correlated with poor survival for cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/16/7c/ott-9-5771.PMC5036562.pdf
"Studies showed that miR-133a is a tumor suppressor.22,23 Conse - quently, decreased expression of miR-133a in cancer patients correlates with poor  survival and prognosis.24–27 However, the results from some studies find that lower  expression of miR-133a functioned as a favorable outcome factor.28,29 Thus, as these correspondence: Qiong chen Department of geriatrics, respiratory  Medicine, Xiangya hospital of central  south University, 87 Xiangya rd,  changsha 410008, hunan Province,  People’s republic of china Tel +86 731 8975 3756 email qiongch@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Xiao et al Running head recto: microRNA-133a in solid cancers DOI: http://dx.doi.org/10.2147/OTT.S112358",Non-OADS,/arxiv_data1/oa_pdf/16/7c/ott-9-5771.PMC5036562.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/16/7c/ott-9-5771.PMC5036562.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/16/7c/ott-9-5771.PMC5036562.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/76/31/ppa-10-1903.PMC5036564.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1903–1911Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1903OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S11117 8 evaluation of factors associated with psychiatric  patient dropout at a university outpatient clinic  in Japan Atsumi Minamisawa1 Jin narumoto1 isao Y okota2 Kenji Fukui1 1Department of Psychiatry,   2Department of Biostatistics,   graduate school of Medical science,   Kyoto Prefectural University of  Medicine, Kyoto, JapanBackground:  Patient dropout from treatment can lead to a deterioration in clinical condition,  thereby increasing the need for more intensive therapy that incurs substantial social and economic  losses.",Non-OADS,/arxiv_data1/oa_pdf/76/31/ppa-10-1903.PMC5036564.pdf
"Keywords:  patient dropout, psychiatry, outpatient care, mood disorders, anxiety disorders Introduction Patient dropout from treatment can cause a deterioration in clinical condition, result - ing in the need for more intensive therapy that incurs higher social and economic  losses.1–3 Previously reported dropout rates in patients with mental disorders have  ranged from 20% to 82%, and many risk factors have been identified (including patient  age, socioeconomic status, educational level, and treating physician characteristics)  for various definitions of dropout and clinical settings in different countries.2–10 Among the mental disorders, patient dropout in individuals with mood and anxiety  disorders has drawn special attention due to the relatively high disease prevalence and  impact on patient function.11–14 The dropout rates in patients with mood disorders have correspondence: Atsumi Minamisawa Department of Psychiatry, graduate  school of Medical science, Kyoto  Prefectural University of Medicine,  465 Kajii-cho, Kawaramachi  hirokoji Kamigyo-ku, Kyoto city,  Kyoto 602-8566, Japan Tel +81 75 251 5612 Fax +81 75 251 5839 email aminami@koto.kpu-m.ac.j pJournal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Minamisawa et al Running head recto: Patient dropout at a psychiatric outpatient clinic DOI: http://dx.doi.org/10.2147/PPA.S111178",Non-OADS,/arxiv_data1/oa_pdf/76/31/ppa-10-1903.PMC5036564.pdf
Available from: http://www.mhlw.go.jp/ stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/iryouhoken11 /.,OADS,/arxiv_data1/oa_pdf/76/31/ppa-10-1903.PMC5036564.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/76/31/ppa-10-1903.PMC5036564.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/9c/8d/jpr-9-693.PMC5036565.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/9c/8d/jpr-9-693.PMC5036565.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 693–700Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  693 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S113216Survey of pain specialists regarding conversion of  high-dose intravenous to neuraxial opioids Andrew W Gorlin David M Rosenfeld Jillian Maloney Christopher S WieJohnathan McGarveyT errence L Trentman Department of Anesthesiology, Mayo  Clinic Arizona, Phoenix, AZ, USAAbstract:  The conversion of high-dose intravenous (IV) opioids to an equianalgesic epidural  (EP) or intrathecal (IT) dose is a common clinical dilemma for which there is little evidence  to guide practice.",Non-OADS,/arxiv_data1/oa_pdf/9c/8d/jpr-9-693.PMC5036565.pdf
"Although there are well-established  guidelines for Correspondence: Andrew W Gorlin Department of Anesthesiology, Mayo Clinic Arizona, 5777 West Mayo Boulevard, Phoenix, AZ 85054, USATel +1 480 342 2446Fax: +1 480 342 2319Email gorlin.andrew@mayo.eduJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Gorlin et alRunning head recto: Survey of pain specialistsDOI: http://dx.doi.org/10.2147/JPR.S113216",Non-OADS,/arxiv_data1/oa_pdf/9c/8d/jpr-9-693.PMC5036565.pdf
Available from: http://www.medscape.org/viewarticle/466349.,Non-OADS,/arxiv_data1/oa_pdf/9c/8d/jpr-9-693.PMC5036565.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/9c/8d/jpr-9-693.PMC5036565.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 700 Gorlin et al  15.,Non-OADS,/arxiv_data1/oa_pdf/9c/8d/jpr-9-693.PMC5036565.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/da/c2/opth-10-1837.PMC5036566.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1837–1846Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1837CliniC al Trial repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10615 9 preservative-free bimatoprost 0.03%/timolol 0.5%  fixed combination in patients with glaucoma in  clinical practice Stefan pfennigsdorf1 peter eschstruth2 Stefan Häsemeyer3 Cord Feuerhake4 Gerrett Brief5 ioana Grobeiu6 andrew Shirlaw6 1polch Ophthalmology practice,   polch, 2Ophthalmology practice, Kiel,   3Ophthalmology practice,   Wiesloch, 4Ophthalmology  practice, lehrte, 5Ophthalmology  practice, Dortmund, Germany;   6allergan Holdings ltd., Marlow, UKPurpose:  The aim of this study was to evaluate the efficacy and tolerability of, and compliance  to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients  with primary open-angle glaucoma or ocular hypertension in a clinical practice setting.",Non-OADS,/arxiv_data1/oa_pdf/da/c2/opth-10-1837.PMC5036566.pdf
"Keywords:  bimatoprost 0.03%/timolol 0.5%, intraocular pressure, prostaglandin, preservative  free, glaucoma, fixed combination Introduction Glaucoma is a leading cause of blindness, accounting for ~12% of cases globally  and 18%–20% of all cases in Europe.1 Primary open-angle glaucoma (POAG) is the  most common form of this disease, with prevalence ranging from 0.03% to 20%, as  determined by an epidemiological analysis of studies spanning 42 years on glaucoma  prevalence.2 Visual impairment due to glaucoma significantly reduces patients’ quality  of life; individuals with glaucoma are three times more likely to report difficulty with Correspondence: Stefan pfennigsdorf Ophthalmology practice, Marktplatz 13,  56751 polch, Germany Tel +49 2654 964 515 email dr_pfennigsdorf@icloud.co m Journal name: Clinical Ophthalmology Article Designation: Clinical Trial Report Y ear: 2016 Volume: 10 Running head verso: Pfennigsdorf et al Running head recto: Efficacy and tolerability of PF FC bimatoprost 0.03%/timolol 0.5% DOI: http://dx.doi.org/10.2147/OPTH.S106159",Non-OADS,/arxiv_data1/oa_pdf/da/c2/opth-10-1837.PMC5036566.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/da/c2/opth-10-1837.PMC5036566.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/da/c2/opth-10-1837.PMC5036566.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/da/84/dddt-10-3043.PMC5036568.pdf
